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ADAMTS4 (A Disintegrin-like And Metalloprotease with 
ThromboSpondin motifs 4) is an 837 amino acid secreted protein in human 
belonging to the ADAMTS family of zinc metalloproteases. It is also named 
aggrecanase-1 and has been previously characterized as an aggrecanase 
responsible for osteoarthritis and rheumatoid arthritis. Abundant expression of 
ADAMTS4 has been reported in several human cancers, however, its role in 
cancer remains unknown. In this study, I aimed to characterize the role of 
ADAMTS4 in cancer and angiogenesis. 
Mouse tumorigenesis studies revealed that the full-length ADAMTS4 
or its catalytically more active N-terminal 53 kDa autocatalytic fragment both 
promote B16 melanoma growth and angiogenesis in mice. In contrast, 
overexpression of its catalytically-inactive E362A mutant or truncated 
fragments containing only the C-terminal ancillary domains suppress 
melanoma growth and angiogenesis under similar conditions. 
Structure-function mapping revealed that the single TSR domain is 
essential and sufficient for the anti-tumorigenic activity displayed by the 
catalytically inactive ADAMTS4 isoforms. Suppression of tumor growth and 
angiogenesis in mice is accompanied by a significant increase in tumor cell 
apoptosis while tumor cell proliferation is not affected. 
Importantly, I identified and demonstrated the presence of novel 
proteolytic fragments of ADAMTS4 containing essentially only the C-
xviii 
 
terminal ancillary domains in cultured cells, and also in human cancer tissues, 
co-existing with full-length and catalytically active N-terminal fragments.  
To reveal the possible mechanism behind the contrasting functions of 
full-length ADAMTS4 and its enzyme inactive mutant in angiogenesis and 
tumorigenesis, a mouse angiogenesis antibody array approach was adopted. 
Results showed that the full-length wildtype ADAMTS4 protein and its 
catalytically inactive mutant E362A influenced the angiogenesis signaling 
pathway molecules in B16 melanoma in mice in a contrasting manner. Pro-
angiogenic molecules such as IGFBP-1, IL-1α and PlGF-2 were found to be 
upregulated only in tumors transfected with wildtype ADAMTS4, with 
corresponding downregulation in tumors transfected with inactive ADAMTS4 
mutant. In contrast, anti-angiogenic molecules such as DPPIV and IL-10 were 
found to upregulated in the tumors transfected with inactive ADAMTS4 
mutant with no change or downregulation in the corresponding tumors 
transfected with wildtype ADAMTS4. 
ADAMTS4 also exerted similar effects on tumor progression in other 
cancer models such as 4T1 mouse breast cancer and A549 human lung cancer 
model. ADAMTS4 full-length protein promoted tumor growth and 
angiogenesis in the 4T1 breast cancer model while the catalytically inactive 
suppressed tumor growth and angiogenesis in both models under similar 
experimental conditions. 
I further investigated the influence of ADAMTS4 on B16 mouse 
melanoma metastasis. ADAMTS4 promoted B16 melanoma lung metastasis in 
an enzyme-dependent manner. The loss of enzymatic activity in the 
xix 
 
ADAMTS4 active site mutant resulted in its acquirement of anti-metastatic 
properties. 
Therefore, my results demonstrate for the first time that ADAMTS4 
plays a role in cancer and tumor angiogenesis. This work has helped to 
elucidate a heretofore uncharacterized function of ADAMTS4 and provides 
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1.1 Angiogenesis in physiology and pathology 
 Angiogenesis is the process of new blood vessel formation from the 
existing vasculature. It is a complex and intricate process involving a diverse 
array of molecules. Angiogenesis occurs both under physiological and 
pathological conditions. In physiology, angiogenesis is central to processes 
such as embryonic development (Reynolds, Killilea et al. 1992; Fraser and 
Lunn 2000; Shimizu, Hoshino et al. 2012), wound healing (Tonnesen, Feng et 
al. 2000; Eming, Brachvogel et al. 2007) and ovulation (Plendl 2000; 
Robinson, Woad et al. 2009). However, when there is excessive or insufficient 
angiogenesis, diseases arise. Excessive and abnormal vessel growth are 
involved in pathological conditions such as cancer, inflammatory disorders, 
hypertension or blinding eye diseases such as age-related macular eye 
degeneration (AMD), diabetic retinopathy (DPR) and corneal 
neovascularization, while insufficient angiogenesis can lead to stroke, 
myocardial infarction and neurodegenerative disorders (Carmeliet 2003). 
Thus, angiogenesis is an important drug target which has been widely 
explored for the past decade with many angiogenesis-targeting drugs reaching 
clinical trials (Folkman 2007; Cook and Figg 2010). 
1.2 Angiogenic switch and tumor development 
 Cancerous transformation of normal cells occurs via the accumulation 
of genetic and epigenetic changes. In addition to these, another discrete step is 
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required for tumor progression – the development of a vasculature. This 
process is termed the “Angiogenic switch” (Fig 1.1). Like normal tissues, 
tumors require an adequate supply of oxygen, metabolites and an effective 
way to remove waste products (Papetti and Herman 2002). Gaining access to 
the host vascular system and the generation of a tumor blood supply are thus 
rate-limiting steps in tumor progression.  
 
Fig 1.1 - Angiogenic switch - Angiogenic switch is the rate limiting step in 
tumor progression. A small avascular tumor requires a continuous supply of 
nutrients and oxygen and the removal of waste products to increase in size 
and eventually metastasize. This occurs via the shift of the angiogenic balance 
towards pro-angiogenesis. (Adapted from 
http://www.angioworld.com/DominiqueGarrel.html).  
 
 Induction of the angiogenic switch depends on the extent of shift 
towards pro-angiogenesis (Baeriswyl and Christofori 2009). This is a tightly 
regulated process and is disrupted during tumor progression. Maintaining the 
angiogenic balance has been discussed in more detail in section 1.3. The onset 
of angiogenesis, or the ‘angiogenic switch’, is a discrete step that can occur at 
any stage of tumor progression. It depends on the type of tumor and its 
microenvironment (Bergers and Benjamin 2003). 
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 There are several different mechanisms through which tumors can 
establish their own blood supply. One is the classical method, similar to 
normal angiogenesis; tumors may elicit new blood vessel formation from pre-
existing capillaries in the surrounding tissues through angiogenesis. Another is 
through vasculogenesis by circulating endothelial precursor cells (EPCs), 
angioblast-like cells derived from bone marrow. Circulating EPCs have been 
shown to contribute to tumor-derived blood vessels (Rafii 2000). The third 
means for tumor vascularization is for tumor cells to grow around an existing 
vessel and hence, at least initially, do not need to induce angiogenesis for 
adequate vascularization in a process known as “vessel cooption” (Holash, 
Maisonpierre et al. 1999; Vajkoczy, Farhadi et al. 2002). 
 Tumor-induced blood vessels, although they provide the necessary 
nutrients to the growing tumor, are ultrastructurally abnormal. Many lack 
functional pericytes, they are dilated and convoluted, and not organized into 
definite venules or capillaries (Benjamin, Golijanin et al. 1999; Morikawa, 
Baluk et al. 2002). They are exceptionally leaky due to the presence of 
fenestrae and transcellular holes and lack of a complete basement membrane 
and the overproduction of vascular endothelial growth factor (VEGF). 
Furthermore, tumor vessel walls may be made up of both endothelial cells and 
tumor cells (Folberg, Hendrix et al. 2000). Blood flows irregularly and leads 
to dysfunctional capillaries. Tumors are heterogeneous in their vascular 
patterns and control over vessel density is lost (Bergers and Benjamin 2003). 
These structural abnormalities in tumor vessels reflect the pathological nature 
of their induction, yet their ability to support cell growth also underlies the use 
4 
 
of physiological mechanisms of angiogenesis that tumors commandeer for 
their propagation (Papetti and Herman 2002). 
1.3 Maintaining the angiogenic balance 
 Angiogenesis is a dynamic balance of stimulator and inhibitors and is a 
tightly regulated process is healthy individuals (Folkman 1997). New capillary 
blood vessel growth is controlled by interplay of regulatory proteins that either 
stimulate or inhibit angiogenesis as required (Iruela-Arispe and Dvorak 1997; 
Pepper 1997). Generally the balance is tipped towards inhibition. Several cell 
types in the tissue stroma, such as endothelial cells, macrophages and 
fibroblasts contribute to the maintenance of this angiogenic balance 
(Crowther, Brown et al. 2001; Pollina, Legesse-Miller et al. 2008). However, 
in pathological conditions such as cancer, this balance is tipped towards 
angiogenic stimulation (Fig 1.2). Several pro-angiogenic and anti-angiogenic 
mediators have been discovered and studied extensively till date, as potential 





Fig 1.2 - Angiogenic balance - Angiogenesis is a fine balance between pro- 
and anti-angiogenic factors. Excessive and insufficient angiogenesis leads to a 
range of diseases.  
 
1.4 Pro-angiogenic factors 
 Several inducers of angiogenesis have been characterized over the 




Table 1.1 - List of known pro-angiogenic factors 
  
1.4.1 Growth factors 
 The most widely studied growth factor families that positively regulate 
angiogenesis are the vascular endothelial growth factor (VEGF) family and the 
fibroblast growth factor (FGF) family. Other pro-angiogenic growth factors 
include the transforming growth factor β (TGFβ), platelet-derived growth 
factor (PDGF), hepatocyte growth factor (HGF). Several protein growth 
factors are also known such as leptin, proliferin, pleiotropin and progranulin. 
 VEGF was discovered as a potent diffusible, endothelial specific 
molecule that plays a role in physiological and pathological angiogenesis. 
Several studies have documented its role in mitogenesis, angiogenesis, 
Growth Factors Cytokines Angiopoeitins 
Vascular Endothelial 
Growth factor  
Interleukins – 




Fibroblast growth factor  Chemokines – 
CXC and CC 
family  
 
Transforming growth factor 





Placental growth factor    
Hepatocyte growth factor   
Leptin   
Proliferin   
Pleiotropin   
Progranulin   
7 
 
endothelial cell survival and vascular permeability (Ferrara 2004; Ribatti 
2005). 
  FGF1, FGF2 and FGF4 of the fibroblast growth factor family have 
been characterized as pro-angiogenic influencing endothelial cell proliferation, 
migration and morphogenesis. They are also involved in modulating cell-cell 
adhesion and induce ECM degradation (Presta, Dell'Era et al. 2005; 
Murakami, Elfenbein et al. 2008). 
1.4.2 Interleukins and chemokines 
 Interleukins are a large family of inflammatory cytokines. Although, 
some members have been reported to have an anti-angiogenic function, 
predominantly they are recognised as pro-angiogenic. Many of the 
interleukins, such as IL-1α, IL-6 and IL-20 have been shown to exert their pro-
angiogenic effects via the upregulation of VEGF and its secretion (Salven, 
Hattori et al. 2002; Hsieh, Chen et al. 2006). IL-6 deficient mice lack the 
ability for neoangiogenesis (Gertz, Kronenberg et al. 2012). In addition, IL-6 
has been closely associated with tumor progression in many cancers such as 
gastric cancer (Huang, Wu et al. 2004) , cervical cancer (Wei, Kuo et al. 2003) 
and basal cell carcinoma (Jee, Chu et al. 2004), via influencing tumor 
angiogenesis. Other interleukins which have been shown to be expressed by 
endothelial cells and affect in vitro angiogenesis include IL-8, IL-19, and IL-
33 (Heidemann, Ogawa et al. 2003; Choi, Choi et al. 2009; Jain, Gabunia et al. 
2011). 
 Another unique family of cytokines that have emerged as important 
regulators of angiogenesis are the chemokine family. Among these, the CXC 
8 
 
chemokine family, with an ELR motif at its N-terminus has been shown to 
regulate angiogenesis positively. Some examples are interleukin-8 (IL-8), 
epithelial neutrophil activating protein-78 (ENA-78), growth-related genes 
(GRO-α, -β, and -γ), granulocyte chemotactic protein-2 (GCP-2) (Belperio, 
Keane et al. 2000; Dimberg 2010). Members of the CC chemokine family 
have also been reported to have angiogenic roles and several are also 
implicated in tumor progression via influencing angiogenesis, for examples, 
CCL1, CCL2, CCL11, CCL15, CCL16 and CCL23 (Bernardini, Spinetti et al. 
2000; Salcedo, Ponce et al. 2000; Salcedo, Young et al. 2001; Hwang, Kim et 
al. 2004; Strasly, Doronzo et al. 2004; Hwang, Son et al. 2005).  
1.4.3 Angiopoietins 
 Ang-1 and Ang-2 from the angiopoietin family have been extensively 
studied for their involvement in both physiological and pathological 
angiogenesis. Ang-1 has been generally believed to be a survival factor, 
mediating vessel maturation and adhesion and migration of endothelial cells. 
Ang-2 on the other hand, disrupts the connections between the endothelium 
and perivascular cells and promotes cell death and vascular regression.  Both 
molecules are believed to play crucial roles in tumor angiogenic switch with 
the balance shifting towards Ang-2 during tumor progression. Several 
important reviews have documented the knowledge of angiopoietins in 
angiogenesis over the years (Tsigkos, Koutsilieris et al. 2003; Tait and Jones 




1.5 Anti-angiogenic factors 
 More than 30 endogenously derived angiogenesis inhibitors have been 
discovered so far and more are being discovered continually (Nyberg, Xie et 
al. 2005; Kumar S 2012) (Table 1.2). These are either proteins or protein 
fragments produced in the body and have the ability to regulate angiogenesis 
negatively. They can be broadly divided into gene products (proteins), protein 
fragments either matrix-derived or non-matrix derived, soluble receptors and 
antibodies and others. Recently microRNAs have emerged as an important 




Table 1.2 - List of anti-angiogenic factors 
Gene products References 
Chemokines (PF4, IP-10, CXCL-14)  (Bikfalvi 2004; Shellenberger, 
Wang et al. 2004; Feldman, 
Weinreich et al. 2006; Yates-
Binder, Rodgers et al. 2012) 
Tissue Inhibitors of Matrix 
Metalloproteases 
(Ikenaka, Yoshiji et al. 2003; 
Ma, Chen et al. 2003; Seo, Li et 
al. 2003; Stetler-Stevenson and 
Seo 2005) 
Interleukins (IL-10, IL-12) (Voest, Kenyon et al. 1995; 
Huang, Xie et al. 1996; Stearns, 
Rhim et al. 1999; Airoldi, Di 
Carlo et al. 2007) 
TSP-1 and TSP-2 (Streit, Riccardi et al. 1999; 
Chen, Herndon et al. 2000; Lee 
and Iruela-Arispe 2008; Rusnati, 
Urbinati et al. 2010) 
Interferons (IFN-α,β) (Sidky and Borden 1987; 
Persano, Moserle et al. 2009; 
Indraccolo 2010) 
Vasohibin (Watanabe, Hasegawa et al. 
2004; Kern, Steurer et al. 2009) 
Chondromodulin (Hayami, Shukunami et al. 1999) 
Troponin-I  (Moses, Wiederschain et al. 
1999) 
Maspin (Zhang, Volpert et al. 2000; 
Chua, Setzer et al. 2009) 
Pigment Epithelial-derived factor (Dawson, Volpert et al. 1999; 
Abe, Shimizu et al. 2004; 
Browne, Stellmach et al. 2006; 
Amaral and Becerra 2008) 
Vascular Endothelial Factor Inhibitor 
 
(Zhai, Ni et al. 1999; Metheny-
Barlow and Li 2006) 
Fragments  
Arresten (Colorado, Torre et al. 2000) 
Canstatin (Kamphaus, Colorado et al. 
2000) 
Endorepellin (Brown, Sasaki et al. 1997; Talts, 
Andac et al. 1999; Mongiat, 
Sweeney et al. 2003) 
Endostatin (O'Reilly, Boehm et al. 1997; 
Kim, Jang et al. 2000; Rehn, 
Veikkola et al. 2001; Shichiri 
and Hirata 2001; Dixelius, Cross 
et al. 2002; Kreuger, Matsumoto 
et al. 2002; Wickström, Alitalo 




Tumstatin (Maeshima, Colorado et al. 
2000; Maeshima, Colorado et al. 
2000; Pasco, Ramont et al. 2004) 
Anastellin (Yi and Ruoslahti 2001) 
Fibulin fragments (Albig and Schiemann 2004) 
Collagen fragments (Karagiannis and Popel 2007; 
Mundel, Yliniemi et al. 2008) 
Angiostatin (Cornelius, Nehring et al. 1998; 
Ji, Castellino et al. 1998; Moser, 
Stack et al. 1999; Tarui, Miles et 
al. 2001) 
Cleaved prolactin (D'Angelo, Struman et al. 1995; 
D'Angelo, Martini et al. 1999; 
Pan, Nguyen et al. 2004) 
Cleaved antithrombin III (O'Reilly, Pirie-Shepherd et al. 
1999) 
PEX (Brooks, Silletti et al. 1998; 
Pfeifer, Kessler et al. 2000) 
Prothrombin Kringle-2 (Lee, Rhim et al. 1998) 
Vasostatin 
 
(Pike, Yao et al. 1998; Yao, Pike 
et al. 2000; Yao, Pike et al. 
2002)  
Monoclonal Antibodies  
Trastuzumab (Hortobagyi 2005; Santin, 
Bellone et al. 2008; Vecchione, 
Orditura et al. 2009) 
Bevacizumab (Los, Roodhart et al. 2007; Rini 
2007; Specenier 2012) 
Cetuximab (Van Cutsem, Köhne et al. 2009; 
Bonner, Harari et al. 2010) 
Rituximab (Scott 1998) 
Vitaxin (Gutheil, Campbell et al. 2000; 
Posey, Khazaeli et al. 2001) 
Anti-angiogenin antibody (Fett, Olson et al. 1994) 
Anti-Ang-2 antibody (Leow, Coffman et al. 2012) 
Anti-EphB2 antibody (Krasnoperov, Kumar et al. 
2010) 
Small molecule drugs  
Gefitinib (Cohen, Williams et al. 2003) 
Lapatinib (Moy, Kirkpatrick et al. 2007) 
Erlotinib (Cohen, Johnson et al. 2005) 
Sunitinib (Goodman, Rock et al. 2007) 
Sorafenib (Ratain, Eisen et al. 2006; Lang 
2008) 
Imatinib (Habeck 2002) 
Micro RNA  
miR-221/222  (Felli, Fontana et al. 2005; 
Poliseno, Tuccoli et al. 2006) 
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miR-15, 16 (Hua, Lv et al. 2006) 
miR-21 (Sabatel, Malvaux et al. 2011) 
miR-34a (Zhao, Li et al. 2010) 
miR-519c (Cha, Chen et al. 2010) 
miR-107 (Yamakuchi, Lotterman et al. 
2010) 
miR-17-92 cluster (Bonauer, Carmona et al. 2009; 
Doebele, Bonauer et al. 2010) 
 
1.5.1 Gene products 
 Gene products include proteins which directly act as endogenous 
inhibitors of angiogenesis. Examples include inhibitors from the CXC 
chemokine network such as platelet factor-4 (PF4), interferon-gamma induced 
protein 10 (IP-10) and CXCL14, interleukins, IL-10 and IL-12, members of 
the tissue inhibitors of metalloproteases (TIMPs) and very recently members 
of the ADAMTS family (Discussed in detail in section 1.9). PF4 and IP-10 
both are reported to generate anti-angiogenic fragments (Bikfalvi 2004; 
Shellenberger, Wang et al. 2004; Feldman, Weinreich et al. 2006; Yates-
Binder, Rodgers et al. 2012). Among the interleukins, IL-10 and IL-12 have 
been shown to be potent suppressors of melanoma tumor growth as well as 
other types of cancer via the inhibition of angiogenesis (Voest, Kenyon et al. 
1995; Huang, Xie et al. 1996; Stearns, Rhim et al. 1999; Airoldi, Di Carlo et 
al. 2007). Members of the TIMP family, TIMP-1, TIMP-2 and TIMP-3 have 
also been shown to regulate angiogenesis (Ikenaka, Yoshiji et al. 2003; Ma, 
Chen et al. 2003; Seo, Li et al. 2003; Stetler-Stevenson and Seo 2005). 
 Another well-known example of anti-angiogenic proteins are the 
Thrombospondins. TSP-1 and TSP-2 are matricellular glycoproteins that are 
anti-angiogenic both in vitro and in vivo and are potent suppressors of 
malignant tumor growth (Streit, Riccardi et al. 1999; Chen, Herndon et al. 
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2000; Lee and Iruela-Arispe 2008). In fact, TSP-1 is considered as a paradigm 
for the development of anti-angiogenic agents with multiple mechanisms of 
action (Rusnati, Urbinati et al. 2010). Angiogenesis inhibitors have also been 
reported from the interferon (IFN) family. Both IFN-α and IFN-β have been 
reported as suppressors of tumor angiogenesis (Sidky and Borden 1987). IFN-
α has been shown to have direct inhibitory effects on endothelial cells 
impairing both their proliferation as well as migration (Indraccolo 2010). It 
has been shown to counteract the angiogenic switch and impair tumor cell 
proliferation in pre-invasive lesions (Persano, Moserle et al. 2009). 
 Several other important negative regulators of angiogenesis are 
vasohibin, chondromodulin, maspin, pigment epithelial-derived factor 
(PEDF), troponin-I, and vascular endothelial growth inhibitor (VEGI) 
(Hayami, Shukunami et al. 1999; Moses, Wiederschain et al. 1999; Watanabe, 
Hasegawa et al. 2004; Kern, Steurer et al. 2009) (Dawson, Volpert et al. 1999; 
Zhai, Ni et al. 1999; Zhang, Volpert et al. 2000; Abe, Shimizu et al. 2004; 
Browne, Stellmach et al. 2006; Metheny-Barlow and Li 2006; Amaral and 
Becerra 2008; Chua, Setzer et al. 2009). 
 More and more endogenous protein angiogenesis inhibitors are 
continually being discovered. Among them a recent angiogenesis inhibitor is 
the isthmin protein. Identified as a gene highly expressed in the midbrain-
hindbrain boundary of xenopus embryos, isthmin suppresses angiogenesis 
both in vitro and in vivo and also suppresses in vivo tumor growth (Xiang, Ke 
et al. 2011). Recently, isthmin has been shown to also inhibit glioma growth 




1.5.2 Protein Fragments 
 Several endogenous angiogenic inhibitors have been discovered that 
are fragments of proteins (either ECM molecules or non-matrix), which have 
previously not been characterized to have any role in regulation of 
angiogenesis. The matrix-derived angiogenesis inhibitors include arresten, 
canstatin, tumstatin, endorepellin, endostatin, and fragments from fibronectin, 
fibulin and collagens. The non-matrix derived angiogenesis inhibitors include 
angiostatin, cleaved antiThrombin III, and cleaved prolactin. Another class of 
angiogenesis inhibitors include specific domains of molecules such as the PEX 
domain in MMP-2, the kringle 2 domain in prothrombin and vasostatin 
generated as fragments  (Nyberg, Xie et al. 2005; Sund, Nyberg et al. 2010).  
 One example of a well characterized endogenous matrix-derived 
inhibitor is endostatin a 20 kDa fragment derived from the C-terminal NC1 
domain of type XVIII collagen that efficiently inhibits angiogenesis and 
suppresses tumor growth and metastasis (O'Reilly, Boehm et al. 1997). It 
exerts its effects via several mechanisms (Kim, Jang et al. 2000; Rehn, 
Veikkola et al. 2001; Shichiri and Hirata 2001; Dixelius, Cross et al. 2002; 
Kreuger, Matsumoto et al. 2002; Wickström, Alitalo et al. 2002; Ling, Yang et 
al. 2007) (Fig 1.3). 
 Among the non-matrix derived angiogenesis inhibitors, a well 
characterized example is angiostatin. Angiostatin is a collection of fragments 
of plasminogen that result in 38-45 kDa anti-angiogenic peptides comprised of 
the kringle domains 1-4 (Cornelius, Nehring et al. 1998). It is generated by the 
action of MMPs in tumors, resulting in tumor growth inhibition (Ji, Castellino 
et al. 1998). Angiostatin signals through the αvβ3 integrin to inhibit EC 
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migration (Tarui, Miles et al. 2001). It has also been shown to directly bind to 
ATP synthase and trigger apoptotic events (Moser, Stack et al. 1999).
 Specific domains of molecules such as the PEX domain in MMP-2, the 
kringle 2 domain in prothrombin and vasostatin have also been generated as 
fragments and characterized as anti-angiogenic. PEX, a fragment of MMP-2 
that comprises of the C-terminal homopexin-like domain prevents MMP-2 
binding to αvβ3 on the surface of endothelial cells abolishing all 
collagenolytic activity and thus disrupting angiogenesis (Brooks, Silletti et al. 
1998) (Fig 1.3). Overexpression of PEX suppressed endothelial cell invasion 
and formation of capillary-like structures, blocking of bFGF-induced MMP-2 
activation and angiogenesis, and inhibition of tumor induced angiogenesis and 







Fig 1.3 - Possible mechanisms of endogenous angiogenesis inhibitors - 
Proteolytically derived and non-proteolytically derived angiogenesis 
inhibitors could mediate regression of angiogenic blood vessels by binding to 
endothelial cell surface receptors or other molecules. (Modified from Cao et 









Monoclonal antibodies  
Antibody based therapeutics for specific targeting of angiogenesis 
related molecules has over the years led to clinical development of several of 
them. Some of the well-known examples of monoclonal antibodies include 
Avastin or Bevacizumab, Trastuzumab, Cetuximab, Rituximab and Vitaxin. 
Bevacizumab was the first anti-VEGF antibody to be FDA approved for 
treatment for metastatic colorectal cancer, kidney cancer, NSCLC and 
Glioblastoma (Los, Roodhart et al. 2007; Rini 2007; Specenier 2012). 
Trastuzumab or Herceptin is a monoclonal antibody targeting the HER2/neu 
receptor approved to treat breast cancers (Hortobagyi 2005) . Studies are 
undergoing for the use for Trastuzumab to treat other cancers such as Gastric 
cancer and endometrial cancers (Santin, Bellone et al. 2008; Vecchione, 
Orditura et al. 2009). Cetuximab or Erbitux is a chimeric mouse/human 
monoclonal antibody targeting the EGF receptor approved to treat metastatic 
colorectal cancer and head and neck cancer (Van Cutsem, Köhne et al. 2009). 
It has also been approved for squamous cell carcinoma in conjunction with 
radiation therapy (Bonner, Harari et al. 2010) . Rituximab or Rituxan is a 
chimeric monoclonal antibody that targets the CD20 antigen exclusively found 
on B cells. It has potential for treatment of lymphomas, leukaemias and 
autoimmune disorders. It was approved by FDA to treat B-cell lymphomas in 
combination with chemotherapy (Scott 1998). Recently in 2010, it was also 
approved for maintenance treatment of follicular lymphoma after the initial 
treatment. Vitaxin is an anti-αvβ3 integrin antibody that interferes in blood 
vessel formation by inducing apoptosis of newly generated endothelial cells 
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(Gutheil, Campbell et al. 2000). Phase I clinical trials in patients with 
metastatic cancer were successful (Posey, Khazaeli et al. 2001). It is currently 
undergoing phase II clinical trials for colorectal cancer therapy.  
Other monoclonal antibodies targeting specific pro-angiogenic 
factors have also been developed. Some examples include anti-angiogenin 
antibody, anti-Ang-2 antibody and anti-EphB2 antibody. Anti-angiogenin or 
26-2F antibody destroyed the ribonucleolytic activity of angiogenin and 
inhibited angiogenesis in vivo in CAM model (Fett, Olson et al. 1994). More 
recently, novel EphB4 monoclonal antibodies hAb47 and hAb131 were 
developed. EphB4 that is extensively expressed on many epithelial cancers 
could be targeted by these antibodies by two different mechanisms to result in 
tumor angiogenesis and growth inhibition. Combination therapy with 
bevacizumab improved the response, thus identifying a potential drug 
candidate (Krasnoperov, Kumar et al. 2010). Another potential clinical drug is 
the human anti-Ang-2 antibody (MED13617). It prevented Ang-2 binding to 
its Tie2 receptor resulting in inhibition of angiogenesis and tumor growth in 
vivo. This antibody was also found to be successful both as a single agent as 
well as in combination with bevacizumab, thus underscoring its value in 
clinical intervention (Leow, Coffman et al. 2012).  
 Small molecule drugs 
Several small molecule drugs have emerged over the decades that 
specifically target an oncogene or its receptor. These are either FDA approved 
drugs or currently in clinical trials. However, the success rate has been limited. 
Some examples include, Gefitinib, Lapatinib, Sunitinib, Sorafenib, Erlotinib 
and Imatinib. Imatinib is a small molecule drug that specifically target the 
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Bcr-Abl fusion protein for the treatment of chronic myelogenous leukemia 
(CML), the first tyrosine kinase inhibitor to be approved in 2001 (Habeck 
2002). Gefitinib and Erlotinib are EGFR tyrosine kinase inhibitors, FDA 
approved for the treatment of Non Small Cell Lung Cancer (NSCLC) patients 
(Cohen, Williams et al. 2003; Cohen, Johnson et al. 2005). Another EFGR 
inhibitor is Lapatinib, approved for the treatment of HER2 overexpressing 
breast cancer patients in combination with Trastuzumab treatment (Moy, 
Kirkpatrick et al. 2007). Sunitinib is a multi-targeted TKI having anti-
angiogenic and anti-tumor activities achieved through the selective inhibition 
of VEGFR, PDGFR, Kit, Flt3, Ret, and CSF1R. It was FDA approved for the 
treatment of gastrointestinal stromal tumors and renal cell carcinoma 
(Goodman, Rock et al. 2007). Sorafenib is another example of a multi-kinase 
inhibitor that targets broadly angiogenic factors, VEGFR and PDGFR, 
approved for use against renal cell carcinoma and inoperable hepatocellular 
carcinoma (Ratain, Eisen et al. 2006; Lang 2008). Most of these approved 
drugs have been documented to have severe side effects such as cardiac 
toxicity, insterstitial lung disease, diarrhoea, rashes etc. More drugs are being 
tested either alone or in combination therapy with a goal to improve efficacy 
and reduce toxicity.  
MicroRNA 
The importance of microRNA as angiogenesis regulators was 
discovered when Dicer and Drosha knockdowns resulted in profound 
dysregulation of angiogenesis related genes both in vitro and in vivo 
(Kuehbacher, Urbich et al. 2007; Suárez, Fernández-Hernando et al. 2007). 
Several microRNAs have been attributed with an anti-angiogenic function 
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including miR221/222, miR-15, miR-16, miR-21, miR-34a, miR-519c, miR-
107 and the miR-17-92 cluster. All of these miRNAs exert their anti-
angiogenic effects via multiple mechanisms. Overexpression of miR221/222 
in endothelial cells resulted in inhibition of migration and in vitro tube 
formation (Poliseno, Tuccoli et al. 2006). Studies have reported that 
miR221/222 exerts its affects via blocking the c-Kit receptor (Felli, Fontana et 
al. 2005). miR-15 and miR-16 have the ability to inhibit VEGF-induced 
angiogenesis as they were shown to downregulate VEGF expression 
endothelial cells (Hua, Lv et al. 2006). miR-21, the most highly expressed miR 
in ECs, was reported as new angiomiR which negatively regulates 
angiogenesis via targeting RhoB (Sabatel, Malvaux et al. 2011). miR-34a has 
been implicated in the inhibition of EPC-mediated angiogenesis and induces 
senescence via the inhibition of Sirt1, a regulator of EC homeostasis (Zhao, Li 
et al. 2010). miR-519c and miR-107 are both negative regulators of 
angiogenesis via the inhibition of hypoxic signaling. miR-519c has been 
shown to inhibit HIF-1α induced angiogenesis and tumor invasion and 
metastasis of a CLI-5 lung adenocarcinoma model (Cha, Chen et al. 2010). 
miR-107 has been shown to regulate by a bipartite mechanism both the cell 
cycle and hypoxic signaling to control tumor growth and angiogenesis 
(Yamakuchi, Lotterman et al. 2010). Several members of the miR 17-92 
cluster have been shown to have anti-angiogenic roles such as miR-92a, miR-
17 and miR-20a. miR-92a was shown to inhibit angiogenesis in several in 
vitro and in vivo assays most likely via the integrin subunits α5 (ITGA5) 
(Bonauer, Carmona et al. 2009). Other members of the miR 17-92 cluster were 
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also shown to exhibit similar anti-angiogenic function (Doebele, Bonauer et al. 
2010).  
1.6 The angiogenic cascade 
 The angiogenic cascade occurs as an orderly series of events (Fig 1.4).  
 
Fig 1.4 - The Angiogenic cascade - The angiogenic process is a sequence of 
events that starts with pro-angiogenic signals from the tumor that bind to 
receptors on nearby ECs, leading to EC activation. This is followed by 
concomitant basement membrane degradation, EC proliferation and 
migration towards the tumor. Vessel remodelling and stabilization occurs and 
blood flow to the tumor is established. (Adapted from 
http://www.angio.org/understanding/process.php) 
 Diseased or injured tissues (tumor) produce and release angiogenic 
growth factors (proteins) that diffuse into the nearby tissues. The angiogenic 
growth factors bind to specific receptors on ECs of nearby pre-existing blood 
vessels and activate them. The EC machinery produces proteolytic enzymes to 
degrade the surrounding basement membrane. ECs proliferate and migrate 
towards the tumor. Adhesion molecules such as integrins (αvβ3, αvβ5) guide 
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the sprouting new blood vessel sprout forward. Additional enzymes are 
produced to dissolve the tissue in front of the sprouting vessel tip in order to 
accommodate it. As the vessel extends, the tissue is remodelled around the 
vessel. Lumen formation begins and individual blood vessel tubes connect to 
form blood vessel loops that can circulate blood. Finally, newly formed blood 
vessel tubes are stabilized by specialized muscle cells (smooth muscle cells, 
pericytes) that provide structural support. Blood flow then begins. Some of the 
key steps in the process are discussed in detail below. 
1.6.1 Endothelial cell activation 
 Hypoxia and nutrient deprivation in tumors beyond a millimetre in size 
activate the angiogenic switch (Folkman and Hanahan 1991). Tumor cells 
exploit their microenvironment by releasing cytokines and growth factors to 
activate normal, quiescent cells around them and initiate a cascade of events 
that quickly becomes dysregulated (Weis and Cheresh 2005). ECs respond to 
guidance cues from several cell types in the local microenvironment that help 
orchestrate an angiogenic response. Fibroblasts are prompted to deposit ECM 
proteins on which the activated ECs migrate. The ECM compartment also 
contains components such as bone morphogenetic proteins (BMPs), 
thrombospondins (TSPs), a disintegrin and metalloprotease (ADAM) family 
members, secreted protein, acidic and rich in cysteine (SPARC), syndecans 
and perlecan, which have the capacity to govern the sequestration or release of 
soluble factors within the matrix, thus controlling the  EC response (Kalluri 




1.6.2 Extracellular matrix remodelling 
 Extracellular matrix degradation is an important and initial step in the 
angiogenic cascade. The basement membrane and ECM are required to be 
broken down before the ECs can migrate and proliferate towards an 
angiogenic stimulus (Fig 1.5). This step is mediated by several classes of 
proteolytic enzymes. Proteases switch on neovascularization by activation, 
liberation, and modification of angiogenic growth factors and degradation of 
the endothelial and interstitial matrix. They also modify the properties of 
angiogenic growth factors and cytokines (Noël, Maillard et al. 2004; van 





Fig 1.5 - Extracellular matrix remodelling - Tumor cells secrete proteolytic 
enzymes and also induce the secretion of enzymes such as MMPs from 
activated ECs, platelets leading to the degradation of basement membrane 
and ECM. They also induce the deposition of a provisional ECM over which 
ECs can migrate and form new sprouts. (Adapted from Weis et al, Nature 
Medicine, 2011, 17, 1359-1370). 
 
 The proteolytic enzymes that are involved in the angiogenic process 
include the metalloproteases, the cathepsin cysteine proteases and the serine 
proteases. The metalloproteases include the MMPs, ADAMs and ADAMTSs 
(Seiki 2003; Visse and Nagase 2003; Mott and Werb 2004). Two additional 
large families of metalloproteases, the ADAM (a disintegrin and 
metalloprotease domain) family, which are membrane-spanning proteins, and 
the ADAMTS (a disintegrin and metalloprotease with thrombospondin motifs) 
family, which are secreted into the interstitial space, bind to and cleave several 
extracellular matrix proteins (Seals and Courtneidge 2003; Porter, Clark et al. 
2005). 
 The cysteine cathepsins are lysosomal enzymes that have been shown 
to be involved in ECM remodelling and tumor invasion (Turk, Turk et al. 
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2002). The chief serine proteases that are involved in angiogenesis include 
plasminogen activators (PAs) and plasmin. Urokinase-type PA (u-PA), tissue-
type PA (t-PA) and plasmin have been  recognized as proteases that are 
involved in cell migration and invasion and modulate angiogenesis in 
pathological conditions (Andreasen, Kjøller et al. 1997) (Pepper 2001). 
1.6.3 Endothelial cell proliferation, migration and adhesion 
 Proteolytic degradation of the ECM is followed by migration of 
“leader” endothelial cells through the degraded matrix. They are followed by 
proliferating endothelial cells, which are stimulated by a variety of growth 
factors, some of which are released from the degraded ECM. A variety of 
angiogenesis inducers have been described (Table 1.1), which were discussed 
in detail in section 1.4. Liekens et al., have provided a comprehensive list of 
angiogenesis inducers that result in EC proliferation, EC migration or both as 
assessed by in vitro studies (Liekens, De et al. 2001). 
 The processes of cell invasion, migration, and proliferation not only 
depend on angiogenic enzymes, growth factors, and their receptors, but are 
also mediated by cell adhesion molecules. During invasion and migration, the 
interaction of the endothelial cells with the ECM is mediated by integrins 
(Hynes 2007). Besides integrins, a number of other cell adhesion molecules 
are involved in angiogenesis such as VE-cadherin, members of the 
immunoglobulin superfamily such as intercellular adhesion molecule-1 
(ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) and members of 
the selectin family (Brooks 1996; Wallez, Vilgrain et al. 2006; Francavilla, 
Maddaluno et al. 2009). 
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1.7 Cancer metastasis 
 Metastasis is the spread of malignant cells from a primary tumor to 
distant sites. It can be depicted as a two-phase process. The first phase is the 
physical translocation of cancer cell to a distant organ and the second phase is 
the ability of the cancer cell to form a metastatic lesion at that distant site 
(Chaffer and Weinberg 2011). Like angiogenesis, metastasis also occurs as 
sequential steps called the “metastatic cascade”. This involves the following 
processes epithelial-mesenchymal transition (EMT), intravasation, transport 
through the blood vessels, homing and extravasation, establishment at a 
secondary anatomical site and outgrowth of secondary tumors (Geiger and 





Fig 1.6 - The metastatic cascade - The metastatic process can be divided into 
two phases – Physical translocation from primary tumor to distant organ and 
colonization at a distant site. This involves a series of steps. A. Cancer cells 
first undergo EMT and acquire an invasive phenotype. B. They then invade 
into the surrounding tissue and intravasate into newly formed blood vessels 
that feed the primary tumor. C. Cells transit through the blood vessel. D. they 
then extravasate and invade into a distant site. E. Cells must survive the 
immune environment and F. adapt and proliferate to form secondary 
metastases. (Adapted from Chaffer et al, Science., 2011, 331, 1559-1564). 
 
 The first step in metastasis is the detachment of epithelial tumor cells 
from the primary tumor. This involves a process called “Epithelial-
Mesenchymal transition” (Thiery 2002). EMT is characterized by loss of cell 
polarity and loss of epithelial cell adhesion proteins (Jechlinger, Grunert et al. 
2003; Christofori 2006). EMT aids in metastasis in several ways, first loss of 
cell adhesion promotes local invasion, and second it causes the secretion of 
proteolytic enzymes such as MMPs, which further aid in invasion. These 
molecules are able to remodel the ECM within the tumor microenvironment 
thereby releasing and processing mitogenic and angiogenic factors sequestered 
by the ECM. 
 The second step in the metastasis involves the process of intravasation 
of the invasive tumor cells into the blood vessels. Tumor cells first orient 
themselves towards vessels followed by directional migration (Wyckoff, Jones 
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et al. 2000; Sahai 2007). Tumor associated macrophages (TAMs) have been 
shown to play a crucial role in this process (Wyckoff, Wang et al. 2007). 
 Following intravasation into blood vessels, the subsequent steps in 
metastasis involves the travel of tumor cells through the blood vessels and 
extravasation into a distant favourable metastatic site. Very few tumor cells 
circulating in the vasculature are able to survive and reach their preferred sites 
either because they get trapped or undergo anoikis (Fidler 1970; Chambers, 
Groom et al. 2002). Tumor cell extravasation involves similar steps as 
observed in intravasation. Extravasation is controlled by integrins and the 
selectin proteins that control the interaction of tumor cells with endothelial 
cells (Felding-Habermann, O'Toole et al. 2001; Witz 2008). Interaction with 
platelets is also important for extravasation (Im, Fu et al. 2004). These 
interactions within the vasculature suppress anoikis and sheer stress 
experienced by the tumor cells within the vessels. 
 The final step in the metastatic process is colonization and outgrowth 
of secondary tumors. Metastasis is not random; tumors have distinct 
preference for secondary sites or organs. This observation resulted in the 
“Seed and Soil hypothesis”, which states that the choice of the site for a 
secondary tumor is made not only by the tumor cell (the “seed”), but is largely 
influenced also by the nature of the target organ (the “soil”) (Fidler 2003). 
Such a homing can be explained by different mechanisms. First, endothelia of 
different vessels in different tissues express a distinct set of cell adhesion 
molecules (Ruoslahti and Rajotte 2000). The second, tumor cells expressing 
the corresponding receptor can use this system to home to specific tissues 
(Müller, Homey et al. 2001; Brown and Ruoslahti 2004). The third is the 
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expression of several genes by tumor cells for tissue-specific metastasis 
(Kang, Siegel et al. 2003; Gupta, Nguyen et al. 2007). Lastly, the 
premetastatic niche described above forms in different organs, depending on 
the primary tumor type. Different niche patterns can be induced with 
conditioned medium from tumor cells, consistent with the pattern of 
metastasis from those tumors (Kaplan, Riba et al. 2005; Kaplan, Rafii et al. 
2006). 
1.8 Thromsbospondin type I repeat domain (TSR) 
 TSRs are protein domains of around 60 amino acids in length, and 
were first identified in the endogenous angiogenesis inhibitor TSP-1 (Tucker 
2004). Crystal structure of TSRs of TSP-1 revealed three anti-parallel strands 
with two regular ß sheets and one ripped conformation (Tan, Duquette et al. 
2002). Moreover, CWR-layered structure (comprised of interdigitating side 
chain stacking of cysteine, tryptophan and arginine in layers from three 
strands) and CSVTCG motif are important features of TSR. TSRs are present 
only in secreted proteins or extracellular regions of transmembrane proteins. 
The location of TSR implicates its involvements in cellular migration, 
communication, and tissue remodelling in complex tissues (Tucker 2004). 
TSR domain have been identified in multiple protein families, such as 
thrombospondins, a disintegrin and metalloprotease with thrombospondin 
motifs (ADAMTS) protein family, brain-specific angiogenesis inhibitor (BAI) 
as well as Fspondin family and some semaphorins (Adams and Tucker 2000). 
There are 41 TSR domain containing proteins in the human genome, including 
many predicted proteins with no known functions. The zinc metalloproteases 
ADAMTS1 and 8, have been demonstrated to possess angioinhibitory 
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properties (Iruela-Arispe, et al., 2003). Both TSP-1 and -2 also inhibit 
angiogenesis by inhibiting EC proliferation and inducing EC apoptosis (Tan, 
Duquette et al. 2002). The studies of TSRs in TSP-1 and other anti-angiogenic 
proteins such as brain specific angiogenesis inhibitor 1 (BAI1), TSP-2 and 
ADAMTS1 indicate that TSRs play critical roles in the anti-angiogenic 
function (Tucker 2004). Furthermore, the recent clinical trials of the anti-
angiogenic peptides derived from the TSRs of thrombospondin-1 to treat 
cancer further demonstrated the importance of TSRs in anti-angiogenesis. 
Biochemical interaction analysis revealed two types of adhesive receptors as 
cellular binding partners for TSRs: CD36 and glycoconjugates that are 
assumed to be linked to proteoglycans. CD36 expression has been documented 
to be expressed in ECs (Bongrazio, Da Silva-Azevedo et al. 2006). In addition, 
point mutation study indicated the importance of the CSVTCG motif of TSRs 
in TSP-1’s anti-angiogenic activities (Crombie, Silverstein et al. 1998). In 
conclusion, the presence of TSRs in a wide variety of anti-angiogenic proteins 
suggests that the presence of the TSR domain may render the protein to be 
anti-angiogenic. 
1.9 The ADAMTS family 
 The ADAMTS (A Disintegrin-like and Metalloprotease with 
ThromboSpondin motifs) is a family of secreted proteases that are found in 
both mammals and invertebrates. The ADAMTSs are closely related to the 
ADAM proteases that are involved in ectodomain shedding or activation of 
diverse cell surface molecules, including growth factors and adhesion, 
receptors (Seals and Courtneidge 2003). However unlike the ADAMs which 
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are transmembrane, ADAMTSs are secreted proteins, of which, some bind to 
the ECM (Tang 2001; Porter, Clark et al. 2005). 
  Phylogenetic analyses of the human ADAMTSs have revealed 
that based on sequence similarities they can be classified into seven 
subgroups. These are (a) ADAMTS1, 4, 5, 8 and 15; (b) ADAMTS2, 3 and 
14; (c) ADAMTS9 and 20; (d) ADAMTS7 and 12, plus ADAMTS6 and 10; 
(e) ADAMTS16 and 18; (f) ADAMTS17 and 19; and (g) ADAMTS13, which 
is least like any other ADAMTS (Nicholson, Malik et al. 2005; Porter, Clark 
et al. 2005). 
 ADAMTS proteases are involved in maturation of procollagen and von 
Willebrand factor, as well as in extracellular matrix proteolysis relating to 
morphogenesis, angiogenesis, ovulation, cancer, and arthritis. Based on their 
functions, they can also be loosely subdivided into proteoglycanases 
(ADAMTS1, -4, -5, -9, -15, -20), procollagen N-proteases (ADAMTS2, -3, -
14), cartilage oligomeric matrix protein degradation (ADAMTS7, -12), the 
von-Willebrand factor cleaving protease (ADAMTS13) and orphan 
ADAMTSs with unknown function although emerging studies have revealed 
new functions for these (Porter, Clark et al. 2005). 
1.9.1 Domain organization 
 The ADAMTSs are multi-domain proteins with conserved domain 
structures; however there is great variability in the C-terminal regions of the 
family members (Fig 1.7). The ADAMTSs are all synthesized initially as 
inactive pre-proenzymes: from the N- to the C-terminus, they each comprise: 
(i) a signal peptide; (ii) a pro-domain, the presence of which may preserve 
enzymatic latency with the exception of ADAMTS7 (Somerville, Longpré et 
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al. 2004) and ADAMTS13 (Majerus, Zheng et al. 2003); (iii) a 
metalloprotease catalytic domain with a reprolysin- type zinc-binding motif, 
HEXXHXXG/N/SXXHD [where ‘X’ represents any amino acid residue and 
the conserved aspartic acid residue (highlighted in bold) distinguishes the 
ADAMs and ADAMTSs from other metalloproteases] (iv) a disintegrin-like 
domain, which shares sequence similarity to the soluble snake venom 
disintegrins; (v) a central TSR repeat seen in TSP1 and TSP2 
(thrombospondins 1 and 2 respectively); (vi) a cysteine-rich domain with high 
sequence homology among the ADAMTSs, containing ten conserved cysteine 
residues; (vii) a spacer region of variable length with no distinguishing 
structural features; and (viii) a variable number of C-terminal TSR repeats: 
these range from 14 C-terminal repeats in the case of ADAMTS20 and the 
long isoform of ADAMTS9 to none in the case of ADAMTS4 (Tortorella, 
Burn et al. 1999; Llamazares, Cal et al. 2003; Somerville, Longpre et al. 
2003). Some of the ADAMTSs have further C-terminal protein modules such 







Fig 1.7 - Domain structure of ADAMTS - Schematic representation of 
domain structure and evolutionary relationships of the 19 ADAMTS family 
members. CS, chondroitin sulphate; CUB, complement C1r/C1s, Uegf 
(epidermal growth factor-related sea urchin protein) and BMP-1 (bone 
morphogenic protein-1); PLAC, protease and lacunin; TSR, thrombospondin 
I-like repeat; vWFCP, von Willebrand factor-cleaving protease. (Adapted 
from Jones et al, Arthritis Research and Therapy., 2005, 7, 160-169). 
 
1.9.2 Expression and regulation 
 A detailed mRNA expression analysis of ADAMTS has been reviewed 
previously (Porter, Clark et al. 2005). Expression of ADAMTS in various 
cancer cell lines or cancer tissues have also been reported [Reviewed in 
(Rocks, Paulissen et al. 2008; Kumar, Rao et al. 2012)] (Table 1.4). 
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 Regulation of ADAMTS occurs at several levels – regulation of 
expression, posttranscriptional and posttranslational regulation and inhibition. 
Regulation of expression by cytokines such as IL-1, IL-17, TNF-α and TGF-β 
has been reported in several ADAMTS (Cal, Arguelles et al. 2001) (Kuno, 
Kanada et al. 1997; Yamanishi, Boyle et al. 2002; Bevitt, Mohamed et al. 
2003; Wang, Lee et al. 2003; Wei, Kuo et al. 2003; Sylvester, Liacini et al. 
2004). In mouse cartilage explants both ADAMTS4 and 5 were upregulated 
(Stanton, Rogerson et al. 2005). In osteoarthritic cartilage samples from 
patients also differential regulation of ADAMTS was observed. Eight of the 
ADAMTS genes showed dysregulation: ADAMTS1, 5, 9 and 15 (all 
aggrecanases) are down-regulated, and ADAMTS2, 12, 14 and 16 are up-
regulated in osteoarthritis cartilage with respect to phenotypically normal 
cartilage obtained from fracture patients (Kevorkian, Young et al. 2004).  
Post-trancriptional regulation by alternative splicing has been observed 
for several ADAMTS proteins such as ADAMTS6, 7 and 9 (Bevitt, Mohamed 
et al. 2003; Bevitt, Li et al. 2005). ADAMTS6 and 7 were reported to 
terminate after the first C-terminal TSR (Hurskainen, Hirohata et al. 1999) and 
ADAMTS9 was reported to terminate after three C-terminal TSRs (Clark, 
Kelner et al. 2000). ADAMTS16 and 18 also undergoes alternative splicing to 
generate shorter forms (Cal, Obaya et al. 2002). 
Post-translational regulation via N-terminal processing, has been 
reported by a signal peptidase during translation and transit of the protein 
through the endoplasmic reticulum membrane. In addition, they are all 
synthesized as zymogens and prodomain cleavage by proprotein convertases is 
a common feature within this family. Pro-protein processing has been 
35 
 
examined for ADAMTS1 (Rodriguez-Manzaneque, Milchanowski et al. 
2000), ADAMTS7 (Somerville, Longpré et al. 2004), ADAMTS9 
(Somerville, Longpre et al. 2003) and ADAMTS12 (Cal, Arguelles et al. 
2001). Prodomain cleavage generally occurs via the conventional secretory 
pathway intracellularly with the exception of ADAMTS5, 9 and 15. 
 Secreted ADAMTSs can also undergo cleavage at the C-terminal end. 
C-terminal processing has been described for ADAMTS1 (Vázquez, Hastings 
et al. 1999; Rodriguez-Manzaneque, Milchanowski et al. 2000), ADAMTS4 
(Gao, Westling et al. 2002), ADAMTS8 (Vázquez, Hastings et al. 1999), 
ADAMTS9 (Somerville, Longpre et al. 2003) and ADAMTS12 (Cal, 
Arguelles et al. 2001), and best studied in ADAMTS1 and ADAMTS4. 
Cleavage events occur within the spacer region and in the case of 
ADAMTS12, within the mucin domain. The ancillary C-terminal domains of 
the ADAMTSs have a profound impact on both substrate specificity and 
localization of the enzymes. Thus cleavage at the C-terminus indicates 
regulatory mechanisms that alter the functions and activities of these enzymes. 
 The most significant endogenous inhibitors of the ADAMTSs are the 
Tissue inhibitors of Matrix Metalloproteases (TIMPs). The aggrecanases 
ADAMTS4 and ADAMTS5 are both potently inhibited by TIMP-3, with Ki 
values in the sub-nanomolar range, although they are essentially insensitive to 
TIMP-1, -2 and -4 (Kashiwagi, Tortorella et al. 2001; Rodríguez-Manzaneque, 
Westling et al. 2002). Another endogenous inhibitor of both ADAMTS4 and -
5 is α2-macroglobulin. α2-macroglobulin inhibited the activity of both 
ADAMTS4 and ADAMTS5 in a concentration-dependent manner (Tortorella, 
Arner et al. 2004). The aggrecanolytic activity of ADAMTS1, 4 and 5 is 
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effectively inhibited by catechin gallate esters (Vankemmelbeke, Jones et al. 
2003) . Synthetic inhibitors have also been shown to inhibit ADAMTSs: 
ADAMTS1 is inhibited by EDTA, 1, 10-phenanthroline (Kuno, Terashima et 
al. 1999), BB-94 (Rodríguez-Manzaneque, Westling et al. 2002) and MMP 
inhibitor 2 (Rodriguez-Manzaneque, Milchanowski et al. 2000); ADAMTS12 
is inhibited by BB-94 (Cal, Arguelles et al. 2001).  
1.9.3 Function 
 ADAMTS proteins are involved in a variety of processes including 
collagen processing as procollagen N-protease; cleavage of the matrix 
proteoglycans aggrecan, versican and brevican; angiogenesis; cancer and 
blood coagulation homoeostasis as the von Willebrand factor cleaving 
protease. They have also been reported to have roles in organogenesis, 
inflammation and fertility.  
Procollagen N-proteases: ADAMTS2, 3 and 14 are involved in processing 
procollagens to collagens by removal of the N-terminal propeptides (Colige, 
Beschin et al. 1995; Fernandes, Hirohata et al. 2001). ADAMTS2 gene 
mutations correlate with the incidence of both Ehlers–Danlos syndrome type 
VII C and dermatosparaxis in cattle (Colige, Sieron et al. 1999). adamts2 
knockout mice seem normal at birth but soon develop fragile skin, and male 
mice are infertile with decreased testicular sperm, suggesting that ADAMTS2 
has important functions both in regulating the formation and structure of skin 
and in the maturation of spermatogonia (Li, Arita et al. 2001) . In cartilage 
however, loss of ADAMTS2 is compensated by ADAMTS3 (Fernandes, 
Hirohata et al. 2001) . ADAMTS14 has been identified as a homologue of 
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ADAMTS2, functioning as the major type I procollagen N-propeptidase 
activity in tendon (Colige, Vandenberghe et al. 2002). 
Proteoglycanases: ADAMTS1, 4, 5, 9, 15, 20 are the ADAMTSs that have 
been characterized to cleave hyalectans or more recently broadly 
proteoglycans. All of them have the ability to cleave aggrecan and many of 
them have additional proteoglycanase substrates such as versican and brevican 
(Porter, Clark et al. 2005). ADAMTS4 and 5, as aggrecanases have been 
implicated in the pathophysiology of osteoarthritis (Gendron, Kashiwagi et al. 
2007; Majumdar, Askew et al. 2007). Cleavage of brevican by ADAMTS4 
and 5 aids in glioma cell invasion (Gary, Kelly et al. 1998). Besides these 
ADAMTSs also cleave the Small Leucine Rich Proteoglycans (SLRPs) such 
as biglycan, decorin, fibromodulin and keratocan (Melching, Fisher et al. 
2006; Rees, Waggett et al. 2009). 
Development: ADAMTS1 and 20 have been indicated to have role in 
development. Studies in mice indicate that ADAMTS20 is required for the 
migration of melanoblasts during embryogenesis, and that mutation of 
ADAMTS20 causes a white-spotting mutation, Belted (Rao, Foernzler et al. 
2003). ADAMTS1-null mice display several developmental abnormalities, 
primarily within the urogenital systems, affecting normal growth, organ 
morphology and function, and female fertility (Shindo, Kurihara et al. 2000; 
Yokoyama, Wada et al. 2002) .  
Blood coagulation: ADAMTS13 cleaves the large multimeric von Willebrand 
factor (vWF) precursor to generate vWF of optimal size for proper coagulation 
(Fujikawa, Suzuki et al. 2001; Zheng, Chung et al. 2001). Mutations in 
ADAMTS13 correlate with the occurrence of the hereditary form (Levy, 
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Nichols et al. 2001), and autoantibodies against ADAMTS13 with the sporadic 
form (Scheiflinger, Knöbl et al. 2003), of thrombotic thrombocytopenic 
purpura, a disease in which the cleavage of vWF is decreased resulting in large 
vWF multimers. The disease is characterized by  formation of blood clots in 
small blood vessels throughout the body, which can lead to microangiopathic 
hemolytic anemia and eventually organ damage (Moake 2002). 
Inflammation: Several ADAMTS have been implicated with a role in 
inflammation including ADAMTS1 and 4. Clues for such an involvement 
arise from regulation of ADAMTS by inflammatory cytokines such as IL-1, 
TNF-α, IL-17 and TGF-β (Kuno, Kanada et al. 1997; Koshy, Lundy et al. 
2002; Yamanishi, Boyle et al. 2002; Bevitt, Mohamed et al. 2003). Both 
molecules have been shown to be important in atherosclerosis, which is 
recognized as an inflammatory disorder (Jönsson-Rylander, Nilsson et al. 
2005; Wågsäter, Björk et al. 2008; Salter, Ashlin et al. 2010). 
Angiogenesis: Before the start of this project, very few ADAMTS family 
members have been shown to be involved in angiogenesis mainly as 
angiogenesis inhibitors such as ADAMTS-1, -8 and -12. ADAMTS-1 and -8 
was found to be anti-angiogenic both in vitro and in vivo (Vázquez, Hastings 
et al. 1999). Contrary reports exist with regards to the effects of ADAMTS1 
on tumor angiogenesis. In T47D human breast carcinoma model ADAMTS1 
suppresses tumor angiogenesis whereas in TA3 mammary carcinoma it was 
shown to promote (Iruela-Arispe, Carpizo et al. 2003; Liu, Xu et al. 2006). 
ADAMTS12 is another family member which has been shown to negatively 
influence angiogenesis by suppressing the capillary network formation of 




Fig 1.8 - ADAMTS in angiogenesis and cancer - ADAMTS family memberssuch 
ADAMTS1, 8, 12 have been been implicated in angiogenesis and/or cancer, with 
predominantly a inhibitory role. (Modified from Kumar et al, Cancers., 2012, 4, 
1252-1299). 
 
Cancer: Several ADAMTS family members have been shown to be 
differentially expressed and regulated in various tumors suggesting their 
potential involvement in cancer. Many of them have been reported to be 
downregulated in cancer, predominantly through epigenetic silencing. Somatic 
mutations have also been observed (Table 1.3). However, until 2010, very few 
studies clarify the roles of ADAMTSs in cancer in detail except ADAMTS1, 
12 and 18. 
  ADAMTS1, the prototype member of ADAMTS family has been 
shown to play contradicting roles in tumor progression. ADAMTS1 has been 
reported to promote tumor growth by eliciting a stromal reaction in vivo 
(Rocks, Paulissen et al. 2008). However, in the case of metastasis, an earlier 
report shows that full-length ADAMTS1 and the C-terminal ancillary regions 
of the protein both exhibit anti-metastatic activity when overexpressed in CHO 
cell line (Kuno, Bannai et al. 2004). Surprisingly another report demonstrated 
that the full-length ADAMTS1 is pro-metastatic while the C-terminal ancillary 
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regions are anti-metastatic in two tumor models - TA3 mammary carcinoma 
and Lewis lung carcinoma (Liu, Xu et al. 2006). In the case of ADAMTS12, it 
was observed that overexpression of the protein in Madine Darby Kidney cells 
(MDCK) resulted in an abrogation of tumorigenic ceffects of hepatocyte 
growth factor (Llamazares, Obaya et al. 2007). In addition, overexpression of 
ADAMTS12 in A549 lung carcinoma cells also resulted in tumor growth 
suppression in nude mice (Llamazares, Obaya et al. 2007). ADAMTS18 has 
also been attributed with a tumor suppressor role as overexpression of 
ADAMTS18 resulted in inhibition of both anchorage-dependent and –
independent nasopharyngeal and esophageal carcinoma cell growth (Jin, 
Wang et al. 2007). 
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Table 1.3 - Expression and regulation of ADAMTS in cancer 
Protein Cancer type Regulation 
ADAMTS1 Lung cancer Down-regulation of ADAMTS1 mRNA in NSCLC cell lines and epigenetic regulation via 
hypermethylation of its promoter (Choi, Kim et al. 2008) 
 
Pancreatic cancer ADAMTS1 mRNA expression significantly lower in pancreatic cancer compared to noncancerous 
pancreas (Masui, Hosotani et al. 2001) 
Enhanced expression of ADAMTS1 mRNA in lymph node metastasis or severe retroperitoneal invasion  
(Masui, Hosotani et al. 2001) 
 
Prostate cancer Markedly low protein levels in prostate cancer cells (Gustavsson, Wang et al. 2009) 
 
Chondrosarcoma Transcriptional up-regulation in response to TNF-α (Hatipoglu, Hirohata et al. 2009) 
 
ADAMTS2 Osteosarcoma 8-fold increase in ADAMTS2 mRNA levels (Wang, Lee et al. 2003) 
 
ADAMTS4 Breast cancer Enhanced mRNA expression in breast cancer compared to normal breast tissue (Porter, Scott et al. 
2004) 
Head and neck squamous cell 
carcinoma 




Increased expression of ADAMTS4 mRNA (Held-Feindt, Paredes et al. 2006) 
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Protein Cancer type Regulation 
ADAMTS5 Breast carcinoma Down-regulation of ADAMTS5 transcript (Porter, Scott et al. 2004) 
 
Prostate cancer Down-regulation of ADAMTS5 mRNA in prostate cancer cell lines (Cross, Chandrasekharan et al. 2005) 
 
Glioblastoma Overexpression of ADAMTS5 mRNA and protein (Nakada, Miyamori et al. 2005; Held-Feindt, Paredes 
et al. 2006) 
 
ADAMTS8 Lung cancer Down-regulation of ADAMTS8 at the mRNA level in NSCLC (Heighway, Knapp et al. 2002) 
Down-regulation due to epigenetic silencing (Dunn, Panutsopulos et al. 2004) 
 
Brain Down-regulation due to promoter hypermethylation (Dunn, Reed et al. 2006) 
 
ADAMTS9 Breast carcinoma Down-regulation of ADAMTS9 transcript (Porter, Scott et al. 2004) 
 
Esophageal squamous cell 
carcinoma 
Hypermethylation of ADAMTS9 in esophageal tumors (Lo, Leung et al. 2007) 
Nasopharyngeal carcinoma Promoter hypermethylation and association of lower levels of ADAMTS9 protein with lymph node 
metastasis in NPC (Lung, Lo et al. 2008) 
 







Protein Cancer type Regulation 
ADAMTS13 Prostate, renal, testicular, head 
and neck squamous, 
colorectal, rectal, NSCLC, 
gastric, melanoma, 
adenocarcinoma and breast 
carcinoma. 
Correlation of presence or absence of tumor metastasis with lower or higher vWF cleaving respectively 
(Oleksowicz, Bhagwati et al. 1999) . 
Colon cancer, leukemia, 
multiple myeloma, breast, 
stomach cancer,  
non-Hodgkin’s lymphoma 
Decreased activity of ADAMTS13 in plasma of malignant patients (Koo, Oh et al. 2002) 
Brain and prostate cancers Mild reduction in ADAMTS13 activity but no correlation with malignancy and metastasis (Böhm, 
Gerlach et al. 2003) 
ADAMTS15 Colorectal and pancreatic 
cancer 
Inactivation and loss of normal function of the protein due to somatic mutations (Jones, Zhang et al. 
2008; Viloria, Obaya et al. 2009) 
Colorectal cancer 
 
Loss of heterozygosity in ADAMTS15 locus (Connolly, Gabra et al. 1999) 
Breast cancer 
 
Grade-specific down-regulation of ADAMTS15 transcript in breast cancer (Porter, Scott et al. 2004) 
Prostate cancer Down-regulation of ADAMTS15 mRNA linked to poor prognosis in prostate cancer (Cross, 
Chandrasekharan et al. 2005) 




Other functions: The orphan ADAMTSs with as yet uncharacterized roles 
includes ADAMTS6, 7, 10, 12 and 16, 19. Among them, ADAMTS7 and 12 
have been characterized to have several roles such as chondrogenesis, 
endochondral ossification, and the pathogenesis of arthritis, atherosclerosis, 
and cancer (Rocks, Paulissen et al. 2008). A report described ADAMTS10 
mutations in three families with autosomal recessive WMS (Weill-Marchesani 
syndrome), predicting premature truncation of the protein within the 
metalloprotease domain (Dagoneau, Benoist-Lasselin et al. 2004). The clinical 
features of WMS, which include short stature, brachydactyly, eye and cardiac 
anomalies and progressive joint stiffness, suggest a role for ADAMTS10 both 
in growth and in skin, lens and cardiac development in humans. 
1.10 ADAMTS4 
 ADAMTS4 (A Disintegrin And Metalloprotease with 
ThromboSpondin Motif 4), is a multi-domain zinc metalloprotease belonging 
to the ADAMTS family of proteases. Also known as aggrecanase-1, it was 
first purified from IL-1 stimulated bovine nasal cartilage conditioned media 
and was subsequently cloned as an 837 amino acid protein (Tortorella, Burn et 
al. 1999). ADAMTS4 is located at 1q21-23. It is one of the main enzymes 
digesting aggrecan in cartilage and responsible for cartilage destruction in 
rheumatoid arthritis and osteoarthritis (Nagase and Kashiwagi 2003; Naito, 
Shiomi et al. 2007). Along with ADAMTS1, 5, 8, and 15, ADAMTS4 belongs 
to one phylogenetic sub-group within the ADAMTS family (Nicholson, Malik 
et al. 2005). Within this group, ADAMTS4 is most closely related to 
ADAMTS1 with 64% similarity based on protein sequence. 
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1.10.1 Domain structure 
 
Fig 1.9 - Domain structure of ADAMTS4 - Schematic representation of 
ADAMTS4 multi-domain structure. The amino acid position of each domain is 
marked by a number and the name of each domain is labeled at the top. 
 ADAMTS4 is a 75 kDa mature secreted protein with a long signal peptide 
(residues 1-52), a prodomain that maintains enzyme latency with a probable 
cysteine switch at Cys194 (residues 52-212). The catalytic domain has a zinc 
binding motif similar to that found in the matrix metalloproteases (MMPs) and 
ADAMs (residues 212-429), which is followed by a disintegrin-like domain 
(residues 429-521). The protein is unique in having a single central TSR motif 
closely related to ADAMTS1 TSR (residues 521-575). This is followed by a 
cysteine-rich region (residues 575-687) and a spacer domain (residues 687-837) 
at its C-terminus (Tortorella, Burn et al. 1999) (Fig 1.9). 
1.10.2 Expression and Regulation 
 ADAMTS4 mRNA expression was reported in brain, lung and heart 
along with very low levels in placenta and skeletal muscle (Tortorella, Burn et 
al. 1999). A recent study using RT-PCR analysis of 15.5–17.5 dpc mouse 
embryos, new-born and 7-day old animals, showed high expression of 
ADAMTS4 in all stages in the murine kidney, with highest expression in 15.5 
dpc embryos (Boerboom, Lafond et al. 2011). 
 ADAMTS4 could be regulated by a variety of mechanisms such as 
inhibition, regulation by cytokines, alternative splicing. ADAMTS4 enzymatic 
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activity was inhibited by several hydroxamate inhibitors (Tortorella, Burn et 
al. 1999). Additionally, ADAMTS4 was demonstrated by several groups to be 
inhibited by tissue inhibitors of matrix metalloproteases (TIMPs), most potent 
among them being TIMP-3 followed by TIMP-1, TIMP-2 and TIMP-4 
respectively (Hashimoto, Aoki et al. 2001; Kashiwagi, Tortorella et al. 2001; 
Wayne, Deng et al. 2007). Inhibition was also shown to be mediated by α2-
macroglobulin by proteolysis of the bait region within α2-macroglobulin, 
resulting in physical entrapment of ADAMTS4 (Tortorella, Arner et al. 2004). 
 ADAMTS4 is also regulated by several growth factors and cytokines. 
IL-1 stimulation of chondrocytes or bovine nasal or articular cartilage led to an 
increase in detectable aggrecanase activity, without increasing measured 
ADAMTS4 protein (Pratta, Scherle et al. 2003). TNF-α or retinoic acid 
stimulation also increased activity without increasing ADAMTS4 protein 
levels (Caterson, Flannery et al. 2000). However, in IL-1-treated pig articular 
cartilage explants, increased ADAMTS4 protein levels were apparent 
(Kashiwagi, Enghild et al. 2004). ADAMTS4 mRNA was also regulated by a 
combination of IL-1α and oncostatin M (Koshy, Lundy et al. 2002). IL-1β has 
been shown to induce ADAMTS4 in human tendon cells, an inflammatory 
response in tendon injuries (Tsuzaki, Guyton et al. 2003). IL-17, a major 
proinflammatory cytokine produced mainly by synovial membranes in 
rheumatoid arthritis, also up-regulates ADAMTS4 in bovine articular 
chondrocytes (Sylvester, Liacini et al. 2004). In prostatic stromal cultures, 
TGF-β treatment caused an increase in ADAMTS4 expression (Cross, 
Chandrasekharan et al. 2005). Another study also reports the potential 
involvement of NFATp and Runx2 in regulating ADAMTS4 expression 
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transcriptionally (Thirunavukkarasu, Pei et al. 2006). Besides these, 
ADAMTS4 is also regulated by the inflammatory cytokine interferon-γ (IFN-
γ), in macrophage-rich areas of atherosclerotic plaques (Wagsater, Bjork et al. 
2008). 
 Another level of transcriptional regulation was alternative splicing of 
ADAMTS4 observed in human osteoarthritic synovial cocultures, resulting in a 
protein product with a completely different C-terminal spacer domain, which 
may have relevance in altered substrate specificity (Wainwright, Bondeson et 
al. 2006). 
 Besides these the ADAMTS4 promoter is also regulated by elements in 
the 5’ flanking region of the ADAMTS4 gene. ADAMTS4 promoter activity 
was characterized by reporter gene analysis in chondrocytes and NIH3T3 
cells. Using deletion variants it was suggested that the region between -383 
and +10 relative to the tentative transcription start site is necessary for full 
promoter activity; this region contains one Sp1 and three AP2 sites. In 
addition, the segment between -726 and -384 appears to contain silencer 
element(s). A complete deletion mutant of the nuclear factor I (NFI) binding 
site at -441 to -429 resulted in recovery of the promoter activity in 
chondrocytes, but not in NIH3T3 cells. Thus, the NFI site is involved in 
negative regulation of the human ADAMTS4 promoter activity in 
chondrocytes (Mizui, Yamazaki et al. 2000). 
1.10.3 Proteolytic processing 
 ADAMTS4 like other family members is produced as a zymogen and 
must be activated by removal of prodomain by furin cleavage at the N-
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terminus of the catalytic domain at position 213 of the protein. Furin mediated 
cleavage of ADAMTS4 occurs within trans-Golgi network by means of 
multiple consensus sites located between amino acids 208–215, at the end of 
the prodomain (Tortorella, Burn et al. 1999; Wang, Tortorella et al. 2004).  
Prodomain cleavage could also be mediated by other proteases as complete 
processing of prodomain was observed in the furin-deficient cell line RPE40 
(Wang, Tortorella et al. 2004). The full-length zymogen form of ADAMTS4 is 
100 kDa and it is found to be predominantly within the cells. Only the mature, 
prodomain removed 75kDa form is secreted into the extracellular matrix and 
is highly enriched in this compartment. However it is interesting to note that, 
despite activation by prodomain removal, this form of ADAMTS4 remains 
inactive as it is trapped within the ECM probably through interaction with 
fibronectin, an abundant ECM molecule (Hashimoto, Shimoda et al. 2004). 
 In addition, ADAMTS4 also undergoes further C-terminal processing 
either by autocatalytic cleavage or cleavage by glycophosphatidyl inositol-
anchored membrane type-4 matrix metalloprotease at its C-terminus 
(Flannery, Zeng et al. 2002; Gao, Plaas et al. 2004). Cleavages between 
Lys694-Phe695 and Thr581-Phe582 resulted in the release of two truncated 
isoforms of 53 kDa and 40 kDa that lack the C-terminal cysteine-rich and 




Fig 1.10 - N-terminal truncated forms of ADAMTS4 - ADAMTS4 
undergoes C-terminal cleavage at Lys694-Phe695 and Thr581-Phe582 to result in 
two truncated forms 53 kDa and 40 kDa respectively. The amino acids at the 
cleavage position have been indicated. 
 
 Such cleavage events have been show to alter the activity of the 
protein. ADAMTS4 anchors to the ECM through its C-terminal spacer region, 
where it has been shown to bind to fibronectin (Hashimoto, Shimoda et al. 
2004). Loss of spacer domain releases the protein from the ECM and in turn 
modulates substrate specificity (Hashimoto, Shimoda et al. 2004; Kashiwagi, 
Enghild et al. 2004). 
1.10.4 Substrates 
 ADAMTS4 was first discovered as an aggrecanase from IL-1 
stimulated bovine nasal cartilage. Since then several substrates of ADAMTS4 
have been identified. Majority of them are proteoglycans in the ECM, either 
Chondroitin Sulfate proteloglycans (CSPG)/lecticans such as aggrecan, 
versican, brevican, neurocan and phosphacan or small leucine rich 
proteoglycans such as decorin, biglycan, fibromodulin and the recently 
discovered keratocan. Besides these, ADAMTS4 also cleaves other 
matricellular proteins in the ECM such as hevin (Weaver, Workman et al. 
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2010), matrilin-2 and -3 (Wang, Luo et al. 2004; Hills, Mazzarella et al. 2007) 
and reelin, an ECM glycoprotein (Hisanaga, Morishita et al. 2012). 
 The CSPGs are all related to each other by the presence of an N-
terminal G1 and C-terminal G3 globular domain, with a centrally located 
glycosaminoglycan attachment region. ADAMTS4 cleaves aggrecan, a 
cartilage proteoglycan, in two distinct regions, one is in the interglobular 
domain (IGD) at TEGE373↓374ARGS and the other is at several sites in the CS-
2 domain, the latter being the more preferential site (Tortorella, Pratta et al. 
2000; Tortorella, Liu et al. 2002). ADAMTS4 also cleaves versican, a 
proteoglycan that is highly expressed in the vascular compartment and also in 
tumor stroma, at two different sites. In human aorta, ADAMTS4 cleaves 
versican V1 at the Glu441-Ala442 bond, within the sequence DPEAAE441-
A442RRGQ (Sandy, Westling et al. 2001). In addition, in human brain, it has 
been shown to cleave versican V0 or V2, the most abundant form in the brain 
at Glu405-Gln406 to generate the Glial hyaluronate binding protein (GHAP) 
(Westling, Gottschall et al. 2004). Brevican is a brain-specific lectican that is 
expressed in high amounts in brain tumors. Brevican is processed by 
ADAMTS4 at a single site at the E395↓396S bond, within the central domain of 
the core protein (Matthews, Gary et al. 2000; Nakamura, Fujii et al. 2000). 
Other lecticans such as neurocan and phosphacan are also cleaved by 




Fig 1.11 - Substrates of ADAMTS4 - The modular domain structure of the 
lecticans, major ADAMTS4 substrates (a) aggrecan, (b) versican, (c) 
neurocan and (d) brevican are shown. Black arrows mark the ADAMTS 
cleavage sites that are conserved between mammalian species.(Modified from 
Stanton et al., Biochim Biophys Acta, 2011, 12, 1616-1629). 
 
 ADAMTS4 also cleaves the SLRP family of proteoglycans. Bovine 
fibromodulin is cleaved at a single site (Y44↓45A) by recombinant ADAMTS4 
generating a fragment approximately 5–10 kDa smaller than the full-length 
protein (Kashiwagi, Enghild et al. 2004; Gendron, Kashiwagi et al. 2007). 
Cleavage of fibromodulin was also observed in human articular cartilage. 
Biglycan and decorin are both cleaved by recombinant ADAMTS enzymes in 
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vitro (Kashiwagi, Enghild et al. 2004; Melching, Fisher et al. 2006; Gendron, 
Kashiwagi et al. 2007). There is a single cleavage site in the fifth leucine-rich 
repeat of biglycan at the N149↓150C bond, which is recognised by ADAMTS4. 
ADAMTS4 was also revealed to cleave the newly discovered SLRP family 
member keratocan in tendon (Rees, Waggett et al. 2009). 
 Besides these, ADAMTS4 also cleaves the other matrix proteins in the 
ECM. ADAMTS4 cleaves the SPARC family member hevin in the brain 
releasing a 40 kDa fragment. This specific proteolysis is integral to cell 
morphology and extracellular matrix deposition in the developing brain 
(Weaver, Workman et al. 2010). ADAMTS4 was also reported to cleave 
matrilin-2 and matrilin-3, adaptor proteins that are important as modulators of 
ECM assembly (Wang, Luo et al. 2004; Hills, Mazzarella et al. 2007). 
Recombinant ADAMTS4 effectively cleaved intact matrilin-3 at the predicted 
motif at Glu435/Ala436 generating two species of 45 and 5 kDa. In addition to 
these very recently reelin another brain glycoprotein important for 
development and normal function was also discovered as a substrate of 
ADAMTS4. Reelin is subject to specific proteolysis at two distinct (N-
terminal and C-terminal) sites, and these cleavages significantly diminish 
Reelin activity. ADAMTS4 cleaves Reelin in an isoform-specific manner, 
with p50 cleaving the N-terminal site only, while p75 cleaves both sites 
(Hisanaga, Morishita et al. 2012). 
1.10.5 ADAMTS4 as an aggrecanase 
 ADAMTS4 was first discovered as aggrecanase-1 from IL-1 
stimulated bovine nasal cartilage (Tortorella, Burn et al. 1999). Aggrecanase 
activity is the best characterized function of ADAMTS4 until now. Aggrecan 
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is named for its ability to form multimolecular aggregates. It is heavily 
substituted with CS chains that attract water, enabling cartilage and tendon to 
resist compressive and shear forces. In tendon aggrecan has the additional role 
of reducing the friction between adjacent collagen fibres. Aggrecan is highly 
sensitive to proteolysis between the G1 and G2 globular domains, in a region 
comprising a linear sequence of ~150 amino acids called the IGD. Proteolysis 
in the IGD releases the entire CS-rich region essential for the biomechanical 
properties of aggrecan, and is therefore the most detrimental for function. 
 ADAMTS enzymes with aggrecanase activity cleave at the 
TEGE373↓374ARGS bond in the IGD, this signature activity of the 
aggrecanases is widely reported in humans and in animals, in vitro and in vivo, 
in cartilage and tendon. However, cleavage at TEGE373↓374ARGS is the less-
preferred action of these enzymes, at least in cartilage. Studies with bovine 
cartilage aggrecan have shown that recombinant ADAMTS4 and 5 
preferentially cleave aggrecan in the CS-2 domain (Tortorella, Pratta et al. 
2000; Tortorella, Liu et al. 2002). The two most preferred cleavage sites in 
bovine cartilage aggrecan are at KEEE1667↓1668GLGS, followed by 
GELE1480↓1481GRGT. Thereafter, cleavage occurs at TEGE373↓374ARGS in the 
IGD and at TAQE1771↓1772AGEG and VSQE1871↓1872LGQR in the CS-2 
domain (Refer to Fig 1.11). In cytokine-stimulated mouse cartilage, cleavage 
at FREEE1467↓1468GLGS precedes cleavage at SELE1279↓1280GRGT and 
FREEE1467 fragments are subsequently converted to SELE1279 fragments by 
ADAMTS enzymes in cartilage explant cultures (East, Stanton et al. 2007). 
Whether a similar sequence of ADAMTS cleavage events occurs in tendon 
has yet to be determined. 
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 ADAMTS4 along with ADAMTS5 is a major enzyme responsible for 
pathological degradation of aggrecan at the Glu373-Ala374 bond in the IGD 
(Sandy and Verscharen 2001; Little, Hughes et al. 2002; Little, Meeker et al. 
2007). Aggrecan is the major component of cartilage and severe cartilage 
degradation is a hallmark of osteoarthritis. Studies with ADAMTS4 KO mice 
revealed that in mice, the enzyme is not the major aggrecanase (Stanton, 
Rogerson et al. 2005). However, ADAMTS4 may contribute to cartilage 
degradation in other species including humans (Naito, Shiomi et al. 2007; 
Powell, Little et al. 2007; Song, Tortorella et al. 2007). 
 ADAMTS4 and ADAMTS5 are thus attractive targets for the 
development of novel OA therapies, and several synthetic ADAMTS4 and 
ADAMTS5 inhibitors are in the early stages of development (Yao, 
Wasserman et al. 2001; Tortorella, Tomasselli et al. 2009; Chockalingam, Sun 
et al. 2011; De Savi, Pape et al. 2011). 
1.10.6 ADAMTS4 knockout mice  
 ADAMTS4 KO mice were generated by Glasson et al., to study the 
effect of lack of enzymatic activity of this protein throughout development and 
during growth, maturation, and aging (Glasson, Askew et al. 2004; Glasson, 
Askew et al. 2005). ADAMTS4 KO mice were also created by Stanton et al., 
to analyse the contribution of ADAMTS4 to cartilage pathology compared to 
ADAMTS5 (Stanton, Rogerson et al. 2005). Glasson et al., generated 
ADAMTS4–KO mice from inbred 129SvEv-Brd   mice   carrying   a   
cre/loxP-type   conditional   KO (CKO) allele of the ADAMTS4 gene. The 
conditional allele contained loxP sites flanking exon 4 so that cre 
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recombination resulted in deletion of exon 4, which encodes the majority of 
the enzyme active site. Mice carrying the ADAMTS4 CKO allele were created 
by homologous recombination in ES cells followed by blastocyst injection to 
generate chimeric mice. The ADAMTS4–KO mouse line was produced by 
crossing CKO mice with protamine-cre (prot-cre)–transgenic mice, which 
resulted in cre-mediated deletion of exon 4 in the sperm of male offspring 
carrying both the mutant ADAMTS4 and prot-cre alleles (Glasson, Askew et 
al. 2004).  
The approach used by Stanton et al., made use of mice bearing loxP 
sites flanking exon 4 of ADAMTS4. To delete the loxP- flanked region of the 
gene, homozygous flox/flox mice were bred with mice expressing the Cre 
transgene under the control of   the   cytomegalovirus   promoter.   This   
generated mice heterozygous for the Cre-excised (∆-cat) allele and bearing the 
Cre-transgene (∆-cat/wt;Cre+/-). Cre expression in the progeny commences   in   
the   blastocyst,   so   genomic   sequences flanked   by loxP   sites   are   
ablated   in   all   cells,   including   germ   cells.   Litters containing   both 
control and ∆-cat   mice were generated by breeding ∆-cat/wt;Cre+/- mice with 
homozygous flox/flox mice.  
 Analysis of gross appearance, body weight, and serum chemistry and 
hematology revealed no significant difference between WT and ADAMTS4–
KO animals at either 14–18 weeks of age or 1 year of age. In addition, all 
tissues examined were histologically normal, and histologic analysis of a wide 
variety of tissues revealed no difference between the KO and WT animals. 
This suggested that ADAMTS4 enzymatic activity was not necessary for 
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normal development, growth, or function of any organ examined (Glasson, 
Askew et al. 2004). Mice were completely viable, fertile and phenotypically 
normal (Stanton, Rogerson et al. 2005). 
 In addition, as a major aggrecanase, to further evaluate the contribution 
of this enzyme to the process of joint disease, joint instability was surgically 
induced in these KO mice, and the rate of progression and severity of OA was 
compared in wild-type (WT) versus KO mice.  Evidence suggested that 
ADAMTS4 was the primary aggrecanase in murine growth plates; however, 
deletion of its enzymatic activity did not affect normal long bone remodeling. 
Also, in the mouse, ADAMTS4 is not the primary enzyme responsible for 
aggrecan   degradation   at   the   TEGE373–374ARGS   site as cleavage at this 
site was apparent even in the KO mice (Glasson, Askew et al. 2004; Glasson, 
Askew et al. 2005). The study by Stanton et al., also confirmed that 
ADAMTS4 was not the primary aggrecanase in mouse cartilage both in vitro 
and in vivo (Stanton, Rogerson et al. 2005). 
1.10.7 ADAMTS4 in angiogenesis and cancer 
 Recent evidences have pointed to a role for ADAMTS4 in 
angiogenesis and cancer. A novel anti-angiogenic peptide derived from the 
ADAMTS4 TSR termed adamtsostatin-4 has been identified through a 
bioinformatics approach. Adamtsostatin-4 inhibited HUVEC proliferation 
with a biphasic response and also inhibited VEGF-induced HUVEC migration 
(Karagiannis and Popel 2007). Another study also reported an elevated 
expression of ADAMTS4 mRNA in vascular endothelium in response to 
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VEGF stimulation (Kahn, Mehraban et al. 2000). In vitro studies have also 
indicated an inhibitory role for ADAMTS4 in endothelial cells. 
 Many of ADAMTS4’s substrates are proteoglycans abundantly present 
in ECM. Hence, it is possible that this multi-domain metalloprotease may play 
a role in tumor angiogenesis and tumor progression. ADAMTS4 expression 
has also been also seen to be upregulated in several other cancers such as 
breast (Porter, Scott et al. 2004), head and neck squamous cell carcinoma 
(Demircan, Gunduz et al. 2009) and human glioblastoma (Held-Feindt, 
Paredes et al. 2006). In Ewings sarcoma (EWS), high expression of 
ADAMTS4 was observed in all primary EWS samples and EWS-derived cell 
lines suggesting that it is a novel tumor marker for EWS (Minobe, Ono et al. 
2010).  
1.11 Aim of this study 
 Angiogenesis inhibition has been recognised as a promising approach 
in anti-cancer therapy since the discovery of angiogenic switch as an 
indispensable event for tumor progression. Several angiogenesis inhibitors 
have been discovered in recent years although they have not been successful in 
clinical trials. Over the years, many TSR containing proteins have emerged as 
inhibitors of angiogenesis such as TSP-1, BAI-1 and several ADAMTS family 
members. Besides this, proteolytic enzymes such as the MMPs have been 
shown to play key roles in tumor progression and metastasis. 
 In the case of ADAMTS4, peptides from ADAMTS4 TSR have been 
reported to be anti-angiogenic. In addition, in vitro studies have also 
implicated the protein with an anti-angiogenic function. Expression of 
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ADAMTS4 has also been reported in several human cancers. However, its 
exact roles in tumor progression are still unclear. Thus there is a strong 
indication of ADAMTS4 involvement in cancer and angiogenesis. In addition, 
as a metalloprotease that contributes towards cleavage of several ECM 
components, it is possible that ADAMTS4 may influence tumor progression 
and/or metastasis via its enzymatic activity. We thus hypothesized in this 
thesis that ADAMTS4 may play a role in angiogenesis, tumor progression and 
metastasis. The specific aims of this project are: 
1) Determine the role of ADAMTS4 in cancer using a mouse melanoma 
model. 
2) Characterization of the role of naturally occurring ADAMTS4 fragments in 
cancer and angiogenesis. 
3) Elucidate the domains responsible for ADAMTS4’s function in cancer. 




Materials and Methods 
 
2.1 Cell culture 
2.1.1 Isolation and culture of human umbilical vein endothelial cells 
(HUVEC) 
 The source of human umbilical vein endothelial cells (HUVECs) is 
human umbilical cord vein from consented maternity ward patients. The fresh 
cord was isolated from the placenta and immersed into sterile bottle filled with 
sterile PBS buffer. The cell isolation is preferably carried out immediately; 
otherwise, the cord can be kept in 40C for 24 h before cell isolation. Briefly, 
the cord was wiped with sterile sponge and 1-2 cm section at both ends 
removed to make a straight clean cut. Adapters were inserted into vein at each 
end of the cord and secured tightly with silk thread. The vein was flushed with 
sterile PBS to drain out any blood present. Sterile collagenase (Sigma, USA) 
0.2% was infused into vein, and both ends of cord were clamped shut with 
haemostat such that the whole surface of vein was covered with collagenase. 
After 15 min incubation at RT, the clamps were released and the ECs together 
with the collagenase solution collected into 50 ml tube. The cord was flushed 
with 2 ml sterile PBS once more and the effluent was collected into the same 
tube. The cell suspension was spun down at 1,500 rpm for 5 min at RT. The 
cell pellet was resuspended in 5 ml culture medium and cells cultured in T-25 
culture flask (NUNC, Denmark) pre-coated with 0.2% gelatin (Sigma, USA) 
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in a 370C incubator (SANYO, Japan) under 5% CO2. Cell medium was 
replaced 3 h later and the cells were cultured routinely for further use. 
2.1.2 Culture of tumor cell lines and primary cells 
 For primary HUVECs, cells were cultured in tissue culture flasks 
(Greiner Bio-one GmBH, Germany), precoated with 0.2% gelatin (Sigma, 
USA), in a 370C incubator at 5% CO2. The culture medium used was CSC 
complete medium (Cell Systems, USA) supplemented with 50 μg/ml 
Gentamycin (Sigma, USA) and the medium was replaced every two days or 
less. When cells reach 80%-90% confluence for subculture, the medium was 
discarded and the adherent cell monolayer was gently washed with warm 
sterile phosphate-buffered saline (PBS, 8 g/l NaCl, 0.2 g/l KCl, 1.44 g/l 
Na2HPO4, 0.24 g/l KH2PO4, pH 7.4). Appropriate amounts of 0.25% trypsin-
EDTA (Life Technologies, USA) was added to the cell monolayer until most 
of the cells became detached. Cells were neutralized in complete medium and 
centrifuged for 3 mins at 1,500 rpm. Then the supernatant were removed and 
the cell pellet was resuspended in medium and divided into new tissue culture 
wares with a ratio of 1:2. 
 For cell lines culture, 4T1 or B16F10 tumor cells obtained from ATCC 
and B16F10-Luc cells obtained from Caliper Life Sciences were cultured in 
Dulbecco’s Modified Eagle Medium (DMEM) (Life technologies, USA) 
supplemented with 10% heat-inactivated Fetal Bovine Serum (FBS) (Life 
technologies, USA) and 1% Penicillin-Streptomycin (Life technologies, USA). 
The B16F10-Luc2 cells are B16F10 cells stably expressing a mammalian 
codon optimized firefly luciferase gene under the control of the human 
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ubiquitin C promoter to be used for in vivo non-invasive live imaging studies 
(obtained from Caliper Life Sciences, USA). All cells were grown in a 
humidified incubator with 5% CO2 at 370C and were maintained through 
subcultures at a ratio of 1:3. Subculturing of cells was performed as the 
method described above.  
2.1.3 Preservation of HUVECs and tumor cell lines 
 All cells are preserved in liquid nitrogen. To cryo-preserve cells, 90-
100% confluent cells were trypsinized and pelleted down. The cells were then 
resuspended and dispensed into 2 ml cryovials (NUNC, ThermoScientific, 
USA) and tissue culture grade Dimethyl sulfoxide (Sigma, USA) was added to 
a final concentration of 10% as a cryoprotectant. The cryovials were then 
placed in a Cryo 10C cooler (Nalgene, USA) at -800C overnight and 
subsequently transferred to the vapour phase of liquid nitrogen for long term 
storage. 
2.1.4 Cell number quantification 
 Cell number was determined using the nucleocounter (Chemometec, 
Denmark). Briefly, appropriate volume of diluted cell suspension was taken in 
a 1.5 ml tube and equal volumes of Reagent A (Lysis buffer) and Reagent B 
(Stabilizing buffer) were added and vortexed to mix thoroughly. 50 µl of this 
mixture was then aspirated into the nucleocasette (Chemometec, Denmark), 
containing propidium iodide. DNA bound dye was analysed in the 




2.2 Construction of expression plasmids 
2.2.1 Cloning of ADAMTS4 full-length gene 
 Full-length ADAMTS4 cDNA cloned in pCEP4 vector was kindly 
provided by Prof. H. Nagase, Oxford University. The gene was amplified from 
pCEP4 vector to contain the native signal peptide using the following set of 
primers: 5’- GCC ACC ATG TCC CAG ACA GGC TCG - 3’ and 5’- ATC 
TTT ATA ATC TTT CCT GCC CGG CCA GG - 3’. This PCR product was 
subsequently cloned into pEF6/V5-His TOPO vector (Invitrogen, USA) by 
TA-based cloning method. Positive colonies were screened by PCR and 
confirmed by sequencing. 
2.2.2 Site-directed mutagenesis and creation of ADAMTS4 E362A mutant 
 Site-directed mutagenesis was employed for the creation of pEF6/V5-
His TOPO–FL-E362A, the active site mutant of full-length ADAMTS4 with 
its own native signal peptide using the QuikChange® Site-directed 
mutagenesis kit (Stratagene, USA). 
 Briefly, a 50 µl sample reaction was set-up consisting of 5µL of 10X 
reaction buffer, 10-50 ng of template DNA (ADAMTS4-FL-WT), 125 ng of the 
oligonucleotide primer 1 – 5’- GCC TTC ACT GCT CAT GCA CTG GGT 
CAT GTC TTC AAC ATG – 3’, 125 ng of the oligonucleotide primer 2 – 5’- 
G CAT GTT GAA GAC ATG ACC CAG TGC ATG AGC AGC AGT GAA 
GG – 3’, 1 µl of dNTP mix and 1 µl of Pfu Turbo DNA polymerase (2.5U/µl). 
A reaction cycle comprising of the following steps was run: Initial 
denaturation at 950C for 30 sec, denaturation at 950C for 30 sec, 550C 
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annealing for 1 min and extension process at a temperature of 680C for 1 
min/kb of plasmid length for 12 cycles. 1 µl of DpnI restriction enzyme was 
subsequently added to digest the parental supercoiled DNA for 1 hour at 370C. 
This mixture was then transformed into XL-1 blue super competent cells for 
screening the mutant colonies. Positive colonies were confirmed by 
sequencing. 
2.2.3 Cloning of ADAMTS4 truncations 
 ADAMTS4 53 kDa N-terminal fragment (N-p53) and its active site 
mutant (N-p53-M) with its own native signal peptide sequence were created 
by PCR amplifying from pEF6/V5-His TOPO-FL-WT and pEF6/V5-His 
TOPO-FL-E362A respectively using the following set of primers: 5’- GCC 
ACC ATG TCC CAG ACA GGC TCG – 3’ and 5’- TTT CCT GAA GGA 
GCC TGA CTG CTT G – 3’. The amplified products were then subcloned 
again into pEF6/V5-His TOPO vector by TA-based cloning method. All 
positive colonies were confirmed by sequencing. 
 cDNA containing various C-terminal truncations D-S, T-S, C-S and 
TSR were previously amplified from the full-length ADAMTS4 gene and 
cloned into pSecTag2B vector by previous lab members. These constructs 
utilized the Igκ signal peptide sequence in the vector for secretion into the 
conditioned medium. 
2.2.4 Vectors used 
pGEM-T Easy vectors: The pGEM®-T Easy Vector System is convenient 
system for the cloning of PCR products (Fig. 2.1). The vector is prepared by 
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cutting Promega’s pGEM®-T Easy Vector with EcoRV and adding a 3´ 
terminal thymidine to both ends. These single 3´-T overhangs at the insertion 
site greatly improve the efficiency of ligation of a PCR product into the 
plasmids by preventing recircularization of the vector and providing a 
compatible overhang for PCR products generated by certain thermostable 
polymerases. 
pSecTag2A, B, and C vector: The pSecTag2A, B, and C expression vector is 
designed for high-level stable and transient expression in mammalian hosts 
(Fig. 2.2). Proteins expressed from pSecTag2A, B, and C are fused at the N-
terminus to the murine Ig κ-chain leader sequence for protein secretion and at 
the C-terminus to a peptide containing c-myc epitope and six tandem histidine 
residues for detection and purification. The Zeocin™ resistance gene allows 
selection in mammalian cells in the presence of the antibiotic Zeocin. 
pEF6/V5-His TOPO vector: The pEF6/V5-His TOPO expression system 
provides a highly efficient strategy for the direct insertion of Taq polymerase-
amplified PCR products into a plasmid vector for high level expression in 
mammalian cells (Fig. 2.3). Proteins expressed from pEF6/V5-His TOPO are 
fused at the C-terminus to V5-epitope and polyhistine (6XHis) tag for 
detection and purification. The Blasticdin (bsd) resistance gene allows for 














Fig 2.3 - pEF6/V5-His TOPO Vector map (Reproduced from 
www.invitrogen.com). 
 
2.3 Expression of recombinant ADAMTS4  
2.3.1 Recombinant protein expression in mammalian cells 
 Recombinant ADAMTS4 and its various truncated forms were 
expressed in HEK 293T human embryonic kidney cell line. Briefly, plasmids 
encoding ADAMTS4 or its various truncated forms were transfected using 
either branched polyethyleneimine (bPEI) (Sigma, USA) into HEK 293T cells. 
Briefly, 50-60% subconfluent cells in 6-well plates (Greiner Bioone, 
Germany) were prepared a day before. For transfection with bPEI, 1/10th 
volume of PBS of the final volume was mixed with plasmid DNA and bPEI at 
a ratio of 1.5:2.  The mixtures were then incubated at room temperature for 30 
minutes. The transfection reagent: DNA complexes were then added dropwise 
to the cells to evenly distribute the mixture over the cells. Fresh complete 
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medium was added to the transfected cells and incubated for 24 hours. Cells or 
conditioned medium were subsequently harvested as required. 
2.3.2 Purification of recombinant ADAMTS4 proteins using C-terminal 
6X His tag 
 Recombinant ADAMTS4 protein expressed in HEK 293T cells were 
partially purified using epitope-tagged protein isolation by utilizing the 6X His 
tag at the C-terminus of the recombinant protein. Briefly, conditioned medium 
from cultured HEK 293T cells transfected ADAMTS4-FL-WT were collected 
and concentrated using Centricon centrifugal filters (Millipore, USA). The 
recombinant protein in the medium was then purified using the µMACS™ 
His-tagged isolation kit (Miltenyi Biotec, Germany). 1 ml of concentrated 
conditioned medium was mixed well with 50 µl of magnetic Anti-His 
microbeads and incubated overnight on rotary shaker at 40C. The next day, the 
µ column was placed in the magnetic field of the µMACS separator and pre 
charged by adding 200 µl of lysis buffer. The labelled conditioned medium 
was allowed to run through the column. The column was subsequently washed 
4 times with 200 µl of wash buffer 1 and once with 100 µl of wash buffer 2. 
Then 20 µl of pre heated elution buffer was added to the column and 
incubated for 5 mins at RT. This was followed by final elution with 50 µl of 
preheated elution buffer. This sample was analysed by SDS-PAGE. 
2.3.3 Determination of total protein concentration 
 Protein concentration was measured using Bradford method. A BSA 
standard curve was generated between the linear range 0.2 to 1.0 mg/ml. 1-5 
µl of protein sample was added to the diluted Bradford dye reagent (1:5) and 
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incubated at RT for 5 min. Blank samples were conditioned media or lysis 
buffer. Protein concentration was measured at absorbance 595 nm using a 
spectrophotometer. 
2.4 Mass spectrometry analysis 
 Briefly, recombinant ADAMTS4 full-length was expressed in HEK 
293T cells and partially purified using magnetic Anti-His beads (Miltenyi 
Biotec, Germany). The purified protein was analysed by SDS-PAGE and 
stained by coomassie blue stain (Sigma, USA). All prominent bands were then 
excised separately and subjected to in-gel digestion. In-gel digestion of 
ADAMTS4 bands and desalting of the samples was performed by Protein and 
proteomics Centre staff at NUS, prior to mass analyses. Mass analyses were 
performed using an ABI Voyager STR (MALDI-Tof-MS) analyzer (Applied 
Biosystems, USA). 
2.5 Protein N-terminal sequencing  
 For N-terminal sequencing analysis, partially purified preparations of 
recombinant ADAMTS4 from HEK293T cells were subjected to SDS-PAGE, 
transferred to polyvinylidenedifluoride membranes and stained with 
Coomassie Blue. Excised bands were subjected to automated sequencing using 
an ABI Procise 494 protein sequencer (Applied Biosystems, USA). 
2.6 Aggrecanase activity assay 
 The proteolytic activity of full-length wild-type and mutant (E362A) 
was assessed using aggrecan as substrate. Conditioned medium from 
transiently transfected HEK293T cells with the respective constructs were 
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concentrated and purified using Ni-NTA beads. Recombinant protein was 
eluted from the beads using 250 mM imidazole in HEPES buffer and equal 
amounts of total protein of both the full-length wild-type and mutant proteins 
were incubated with 500 nM aggrecan from bovine articular cartilage (Sigma-
Aldrich; Buchs, SG, Switzerland) and aggrecanase assay was performed. 
Briefly, recombinant purified protein was incubated with 500 nM aggrecan 
from bovine articular cartilage (Sigma-Aldrich) in a buffer containing 50 mM 
Tris-HCl pH 7.4, 100 mM NaCl and 10 mM CaCl2 at 370C for 16 hours. Next, 
fragments were enzymatically de-glycosylated using aggrecan chondroitinase 
ABC (0.1 U per 10 µg of aggrecan; Sigma-Aldrich) at 37°C for 1 hour, 
followed by 2 hours incubation at 37°C with 0.002 U per 10 µg aggrecan of 
endo-β-galactosidase (Sigma-Aldrich). Reaction products were analyzed by 
Western blot using neo-epitope specific AGEG antibody (kind gift from Prof. 
H. Nagase, Oxford University). As a positive control, aggrecan digestion was 
carried out by enzymatically active pure recombinant ADAMTS4 fragment, 
CHO-derived, Phe213-Cys685, with a C-terminal 10-His tag (R&D systems; 
Minneapolis, MN, USA) under the same experimental conditions, while 
aggrecan incubation without any enzyme acts as negative control. 
2.7 In vitro cell assays 
2.7.1 EC in vitro capillary network formation 
 Capillary network formation was preformed by using In Vitro 
Angiogenesis Assay Kit (Chemicon, USA). ECMatrixTM solution and the 
ECMatrixTM diluent buffer were thawed on ice. The ECMatrixTM consists of 
laminin, collagen type IV, heparan sulphate proteoglycans, entactin and 
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nidogen. It also contains various growth factors (TGF-b, FGF) and proteolytic 
enzymes (plasminogen, tPA, MMPs) that occur normally in EHS tumors. It is 
optimized for maximal tube-formation. 
 100 μl of 10X  ECMatrixTM diluent buffer was added to 900 μl of 
ECMatrixTM solution in a sterile microfuge tube to make 1 ml of matrigel 
solution. The gel was mixed well slowly and 10 μl was transferred to each 
well of a µ slide angiogenesis device quickly at 40C. The slide was incubated 
at 370C for one hour to allow the matrix solution to solidify. ECs (20000) were 
starved with CSC incomplete medium (Cell Systems, USA) containing 2% 
fetal bovine serum (FBS), then harvested and suspended in 2% FBS media 
containing different concentrations of recombinant human ADAMTS4, CHO-
derived, Phe213-Cys685, with a C-terminal 10-His tag (R&D Systems, USA) 
for 30 min. Cell suspension was added onto the surface of the polymerized 
ECMatrixTM and incubated at 370C for 6-8 hours in a tissue-culture incubator. 
Capillary network structures were documented using an inverted microscope 
(Zeiss Axiovert 200). 
2.7.2 EC proliferation 
 Cell proliferation was evaluated by BrdU incorporation method. ECs 
(20000 per well) were cultured overnight in a coated 96-well plate in CSC 
complete medium at 370C. Cells were starved the following day for 3 hrs in 
CSC basal medium and recombinant human ADAMTS4, CHO-derived, 
Phe213-Cys685, with a C-terminal 10-His tag (R&D Systems, USA) ranging 
from 50 nM to 500 nM was then added to the medium together with 15 ng/ml 
VEGF. After 24 h of incubation, EC proliferation was determined using BrdU 
cell proliferation kit (Chemicon, USA) according to manufacturer’s 
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instructions. BrdU reagent was added into the culture media and incubated for 
2 hrs. ECs were then fixed with fixation solution for 30 min at RT. After three 
times of PBS wash, anti-BrdU monoclonal antibody was added and incubated 
with the samples for 1 hr at RT.  Goat anti-mouse IgG-peroxidase conjugated 
secondary antibody was incubated for 30 min and then TMB Peroxidase 
substrate was added. The reaction was stopped by adding the acid stop 
solution and the plate was read using a spectrophotometer microplate reader 
set at wavelength of 450 nm. 
2.7.3 EC apoptosis 
 Apoptosis was determined by using the Cell Death detection 
ELISAPLUS kit (Roche, Switzerland). Briefly, ECs were cultured at a density 
of 1000 cells per well and serum-starved (2% FBS) for 3 hrs. Cells were then 
treated with recombinant human ADAMTS4 CHO-derived, Phe213-Cys685, 
with a C-terminal 10-His tag (R&D Systems, USA) ranging from 50 nM to 
500 nM in basal medium with 15 ng/ml of VEGF for 24 hrs. Subsequently, 
cells were lysed by adding 200 µl of lysis buffer to the wells. The plate was 
then centrifuged at 200 g for 10 mins to pellet the intact nuclei. 20 µl of the 
supernatant containing apoptotic nucleosomes was then transferred to a 
streptavidin coated microplate. 80 µl of immunoreagent consisting of a 
mixture of Anti-Histone Biotin and Anti-DNA peroxidase in incubation buffer 
was then added and incubated for 2 hours with constant shaking. The plate 
was then rinsed and the 100 µl of ABTS substrate solution was added and 
shaken for 10-20 mins until color development. The reaction was terminated 
by adding 100 µl of ABTS stop solution. The plate was then read in a 
spectrophotometer at 405 nm. 
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2.8 Western blotting 
2.8.1 Sodium Dodecyl Sulphate PolyAcrylamide Gel Electrophoresis 
(SDS-PAGE) 
 The SDS-PAGE gel was run using a Mini-PROTEAN 3 
Electrophoresis System (Bio-rad, USA). The gels were prepared dependent on 
different gel concentrations in order to detect proteins of various molecular 
weights. Briefly, separating gels were prepared by mixing appropriate amount 
of 30% acrylamide/bisacrylamid solution (29:1, acrylamide/bis; Bio-rad, 
USA) with 3.8 ml of 1.5M Tris.Cl (pH 8.8), 150 μl of 10% SDS, 150 μl of 
10% fresh ammonium persulfate (APS) (Bio-rad, USA) and H2O to a total 
volume of 15 ml. The volume can be scaled accordingly. 5 μl of TEMED 
(Bio-rad, USA) was added just prior to pouring gel. Double distilled water was 
layered on top of the separating gel. After polymerization, overlay was 
decanted and a 4% stacking gel was poured. 5 ml of 4% stacking gel was 
prepared by mixing 3.1 ml of 30% acrylamide/bisacrylamide solution with 0.5 
ml 1 M TrisCl (pH 6.8), 40 μl of 10% SDS, 40 μl of 10% fresh APS, 5 μl 
TEMED and H2O. Comb was inserted correctly and allowed to polymerize 
completely before running. The protein samples were mixed with 5X loading 
buffer (0.5 mM Tris.Cl pH6.8, 10% glycerol, 2% SDS, 0.05% bromophenol 
blue), and 100 mM β-mercaptoethanol (Sigma, USA) was added just before 
boiling in 1000C heat blocker for 5 min. Samples were then loaded and the gel 
was run under constant 60 volts till the dye reached the bottom of the 
resolving gel and thereafter at 100 V till satisfactory protein separation was 
observed. Dual color Precision Plus protein standards (Bio-rad, USA) were 
run as a protein molecular weight reference. 
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2.8.2 Gel transfer 
 The separated proteins were electrophorectically transferred onto 
supported nitrocellulose membrane (Biorad, USA). The polyacrylamide gel 
was rinsed in water, placed in-between layers of Whatmann paper and 
membrane of the same size of the gel, inserted into the plastic holder with 
sponge filters soaked in transfer buffer (0.3% Tris, 1.45% glycine and 20% 
methanol). The air bubbles were removed by rolling with a glass pipet. 
Membrane was placed facing the anode. The transfer was performed in 
transfer buffer at a constant voltage of 100V for 1 h at 40C. The blotted 
membrane was marked and washed with 1X Tris-buffered saline (TBS) 
(20mM Tris-Cl pH 7.4, 150 mM NaCl) buffer and stored at 40C if not used 
immediately. 
2.8.3 Immunoblotting 
 The immunoprobing was carried out following the standard protocol. 
Briefly, the membrane was blocked with 3% BSA in 0.1% TBST (0.1% 
Tween-20 in 1X TBST) for 2 h at RT. After blocking, Membrane was then 
incubated with 1/2000 anti-His (C-Term) antibody (Invitrogen, USA), 1/5000 
anti-V5 (Invitrogen, USA), 1/500 anti-AGEG aggrecan neoepitope antibody 
(kind gift, Prof H. Nagase, Oxford University), 1/500 CD31 antibody (Santa 
Cruz, USA), ), 1/500 Phospho histone H3 antibody (Chemicon, USA), 1/1000 
diluted rabbit anti-ADAMTS4 C-terminal antibody (Biogenes GmbH, 
Germany), 1/1000 anti-ADAMTS4 N-terminal antibody (kind gift, Prof H. 
Nagase, Oxford University), 1:1000 anti-ADAMTS4 N-terminal antibody 
(Novus Biologicals, USA), 1:500 anti-DPPIV antibody (R&D Systems, USA), 
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1:500 anti-PlGF-2 antibody (R&D Systems, USA), 1:1000 anti-IL-1α 
antibody (R&D Systems, USA), 1:1000 anti-IL-10 antibody (R&D Systems, 
USA) and 1:500 anti-IGFBP-1 antibody (R&D Systems, USA) in 3% BSA in 
0.1% TBST, overnight at 40C. The next day, after washing three times with 
TBST for 10 min each, the membrane was incubated with corresponding 
1/2000 diluted anti-mouse, anti-rabbit, anti-sheep or anti-rat IgG HRP-
conjugated secondary antibody (Sigma, USA) in 0.1% TBST for 1.5 h at RT. 
The membrane was then washed for three times as above before incubating 
with the SuperSignal West Pico Substrate solution (Pierce, USA) by mixing 
equal volumes of the two reagents for 3 min and exposed to Kodak X-ray 
films (Kodak, USA) at various desired time lengths in the dark room. 
2.8.4 Stripping and reprobing 
 The membrane was stripped after chemilumiescent detection for 
reprobing with other antibodies. Briefly, the membrane was washed in TBST 
for 5 min and incubated in Stripping Buffer (25 mM glycine, 1% SDS) at RT 
for 20 min. The membrane was washed in TBST again and was ready for 
immunoprobing with the methods described above. 
2.9 Stable cell line generation 
2.9.1 Determination of antibiotic sensitivity of tumor cell lines 
 B16 cells were seeded in 6-well tissue culture plates (Greiner Bioone, 
Germany) with DMEM supplemented with 10% FBS in duplicate. Zeocin 
(100mg/ml, Invitrogen, USA) or Blasticidin (10mg/ml, Invitrogen, USA) were 
added to the wells at increasing concentrations ranging from 100 μg/ml to 
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1000 μg/ml for zeocin and 2-10 µg/ml for blasticidin. Medium was changed 
every 2 days and the cells were monitored under microscope. After 2 weeks, 
zeocin or blasticidin sensitivity concentration was determined at the 
concentration at which there was no cell survival, but viable cells were seen in 
the concentration below. 
2.9.2 Transfection of expression plasmids of ADAMTS4 and its 
truncations 
 Transfection was carried out using the TransIT®- LT1 transfection 
reagent (Mirus Bio, USA) according to the manufacturer’s instructions. 
Briefly, plasmids encoding ADAMTS4 or its various truncated forms were 
transfected using TransIT®- LT1 transfection reagent (Mirus Bio, USA) into 
B16F10 melanoma cells or 4T1 breast carcinoma cells or A549 lung 
adenocarcinoma cells. Briefly, 50-60% subconfluent cells in 6-well plates 
(Greiner Bioone, Germany) were prepared a day before. For transfection with 
TransIT®-LT1 transfection reagent, 2.5 µg of plasmid DNA and 7.5 µl of 
transfection reagent were added to 250 µl of serum-free media and mixed 
thouroughly. The mixtures were then incubated at room temperature for 30 
mins. The transfection reagent: DNA complexes were then added dropwise to 
the cells to evenly distribute the mixture over the cells. Fresh complete 
medium was added to the transfected cells and incubated for 24 hours. 
2.9.3 Selection of stable expression clones 
 Transfected cells were trypsinized and subcultured in sparse numbers 
into 4, 10 cm tissue culture dishes (NUNC, Thermoscientific, USA). The cells 
were refed with fresh medium containing appropriate concentration of zeocin 
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or blasticidin the following day and changed every third day. Resistant 
colonies were formed in approximately 3-4 weeks. These resistant colonies 
were inspected under microscope and those well separated from adjacent ones 
were selected and cloned using sterile culture inserts. For vector stable cell 
lines, pools of resistant clones were selected and cultured. The inserts were 
made by cutting the top end of blue pipette tips about 1 cm in length and 
autoclaved. The insert was placed and fixed upside down on the selected 
colony using autoclaved Vaseline (Unilever, USA). Trypsin/EDTA (100 μl) 
was added inside the insert and cells suspension was transferred to 24-well 
plate once they were detached. Complete medium plus appropriate 
concentration of zeocin or blasticidin was added to each well and cells were 
continuingly grown at tissue culture incubator. The medium was replaced 
every third day till the clones reached confluence, and were then expanded to 
6-well plate and T25 culture flasks in selection medium. Several stocks were 
made for each single colony stored at -1500C freezer. Positive clones were 
screened by Western blot and homogeneity confirmed by 
immunocytochemistry. 
2.9.4 Assessment of in vitro proliferation rates of stable cell lines 
 In vitro cell proliferation rates of the stable cell lines were assessed by 
measuring increase in cell number over time. Briefly, 1 X103 cells of each of 
the stable lines and the pooled vector control lines were seeded in duplicate in 
6-well plates (NUNC, Thermoscientific, USA) on day 0. The proliferation of 
cells was measured by counting the cell numbers on day 1, 3, 5 and 7 using the 




2.10 Luciferase assay 
 Experimental metastasis assay was performed using B16F10-Luc2 cell 
line stably and constitutively express the mammalian codon-optimized firefly 
luciferase gene. These cells were used to create stable cell lines 
overexpressing ADAMTS4 full-length wild-type and mutant. Luciferase assay 
was performed to confirm that the expression of luciferase in the B16F10-
Luc2 stable cell lines mentioned above were the same using the luciferase 
assay system (Promega, USA). Briefly, 1X104 cells were seeded the day 
before in a 96-well plate and allowed to grow overnight in complete medium. 
The next day, media was removed and the cells washed in 1X PBS once. 
Subsequently, 1X lysis reagent was added to each of the wells to lyse the cells 
and incubated for 20 mins with constant shaking. Then, 100 µl of Luciferase 
assay reagent was added and mixed well. 100 µl of the mixture was then 
added to a flat bottom white plate and the amount of light produced was 
measured using the Infinite M1000 microplate reader (Tecan, USA). 
2.11 Protein isolation from cells and tissues 
2.11.1 Collection and concentration of conditioned medium 
 B16 stable cells were cultured in DMEM medium without serum but 
containing appropriate concentration of zeocin or blasticidin for 2 days. The 
conditioned medium were then collected in a 15 ml flacon tube and 
centrifuged at 4000 rpm for 10 mins to pellet down the cell debris. The 
proteins were then precipitated using acetone. Briefly, the supernatant was 
added to 4 times the volume of pre-chilled acetone and incubated in -800C for 
5 mins. The mix was then pelleted down at 4000 rpm for 20 mins. The protein 
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pellet was then resuspended in 2X loading dye (100 mM Tris-Cl (pH 6.8), 4% 
(w/v) SDS (sodium dodecyl sulfate; electrophoresis grade), 0.2% (w/v) 
bromophenol blue, 20% (v/v) glycerol, 200 mM β-mercaptoethanol) and 
boiled for 5 mins at 1000C before storing. 
2.11.2 Protein isolation from cell lysates 
 Cultured cells were harvested by scraping with a disposable scraper. 
Briefly, the monolayer cells were rinsed with PBS, and appropriate volumes of 
RIPA lysis buffer (25mM Tris-HCl (pH 7.6), 150mM NaCl, 1% NP-40, 1% 
sodium deoxycholate, 0.1% SDS) with EDTA-free protease inhibitor cocktail 
(Roche, Germany) was added, followed by harvesting the cells by scraping. 
Cells were transferred to tube and incubated on ice for 30 min. The 
supernatant was transferred to a clean tube after centrifugation at 13,000 g at 
40C and stored at -800C until used. Protein concentration was determined 
before storage. 
2.11.3 Protein isolation from tumor tissues 
 Snap frozen tumor tissues were weighed and every 1 g of tissue was 
homogenized using mortar and pestle using liquid nitrogen. Protein was 
extracted using urea lysis buffer (100mM NaH2PO4, 10 mM Tris-Cl, 8M Urea 
pH 8.0). The solution was sonicated 10 times, with 10 sec pulses. The 







 Briefly, 5000 cells of each of the stable cell lines were seeded a day 
before. On the following day, cells were fixed in 100 µl of 4% 
paraformaldehyde in PBS for 20 mins. The cells were then washed with PBS 3 
times and blocked with 3% BSA in PBS, 3 hrs at RT. Cells were then 
permeabilized using 0.3% triton-X-100 in PBS for 15 mins. After washing 
with PBS, 3 times, primary antibody Anti-V5 or Anti-His (1:500) was added 
and incubated overnight at 40C. The next day cells were washed with PBS, 3 
times and secondary antibody anti-mouse IgG Alexafluor 568 (1:500) was 
added onto the cells and incubated at RT for 2 hrs with constant shaking. The 
cells were then again washed with PBS, 3 times. Nuclei were counterstained 
with DAPI (5mg/ml) for 10-15 mins. Cells were washed again in PBS prior to 
imaging using fluorescence microscope (Zeiss Axiovert M 200, Germany). 
2.13 Mouse experiment 
2.13.1 Mice 
 Female Balb/c, and C57BL/6J mice (7-8 weeks old) (Centre for 
Animal Resources, Singapore) were used. Animal work was carried out in the 
Animal Holding Unit of the National University of Singapore. Mice care was 
in agreement with institution animal welfare guidelines. Maximal 5 mice were 
kept in one cage and put in the isolator provided with sterile deionized water 





2.13.2 Preparation of cells for subcutaneous and tail-vein injections 
 The stable cell lines were cultured in flasks and trypsinized using 
standard protocol. After centrifugation cells were resuspended in sterile PBS 
and the uniformly distributed cell suspension was placed in ice. Cell 
concentration was determined and adjusted to contain 2.5x105 cells per 100 µl 
of PBS for tail-vein injection into each mouse and 1x 106 cells per 100 µl of 
PBS for subcutaneous injections. 
2.13.3 Syngeneic subcutaneous tumor implant model 
 Stable cell lines expressing ADAMTS4 or its various truncations (1 
million) in 1X PBS were injected subcutaneously into C57Bl/6J or Balb/c 
mice to study the effects of ADAMTS4 on tumor growth. The mice were 
weighed and 8 mice were randomized into each group. Thoroughly mixed cell 
suspensions of 100 μl volume were injected using a 24-gauge needle (Becton 
Dickinson, USA) in the dorsal midline area of each mouse. The growth of the 
tumor was monitored over 2 weeks until the tumors reached a maximum of 1.5 
cm3 in volume and tumor volume was recorded by carefully measuring the 
two perpendicular diameters of the tumors every day or every alternate  day. 
The tumor volume was calculated following the formula: 0.52 x length x 
width2 mm3 where the length is the longest dimension of the tumor and width 
is the perpendicular dimension. At the end of the study, the mice were 
terminated and the tumors were dissected, weighed and washed in ice-cold 
PBS. One half of the tumors were fixed in 4% paraformaldehyde. The other 




2.13.4 Experimental metastasis model 
 Briefly, 2.5x105 cells of stable B16F10-luc2 lines overexpressing 
ADAMTS4 full-length, active site mutant or the vector were injected into the 
tail vein of C57Bl/6J mice to analyse the effects of ADAMTS4 on 
experimental metastasis. 6-8 mice were randomized in each group. 100 µl of 
uniform cell suspension were injected into the tail vein of restrained mice 
using a 27 gauge needle (Becton Dickinson, USA). Tail veins were dilated by 
hyperthermia using an infra-red lamp, for easy insertion of the needle. 
Immediately after injection, mice tails were compressed with cotton swab to 
prevent blood loss. Animals were monitored daily and body weight recorded 
weekly. The experiment was terminated when the mice showed signs of 
sluggishness. Mice were sacrificed by CO2 asphyxiation and lungs excised.  
Tumor nodules on the surface of lungs were counted. Half the lungs were 
fixed in 4% paraformaldehyde and the rest were snap-frozen in liquid 
nitrogen. 
2.13.5 IVIS live mice imaging 
 Mice injected with B16F10-Luc2 stable cell lines overexpressing 
ADAMTS4 full-length, active site mutant or vector for the experimental tail 
vein metastasis assay were monitored by the IVIS® spectrum (PerkinElmer, 
USA) live imaging system using an open filter ranging from 500 nm to 680 
nm. Mice are injected by an intraperitoneal route with a luciferin solution (200 
× stock solution 30 mg/ml in PBS, dose of 150 mg/kg) that is allowed to 
distribute in conscious animals for about 5-15 minutes. The mice were then 
placed into a clear plexiglass anesthesia box (supplied with 2.5-3.5% 
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isofluorane) that allows unimpeded visual monitoring of the animals using 
IVIS® Spectrum Imaging System 3D Series to track and monitor the homing 
of tumor cells to the lung in vivo. Images were captured on the final day before 
sacrifice. 
2.14 Mouse angiogenesis antibody array profiling 
 An analysis of changes in angiogenesis signaling pathway proteins 
was undertaken by utilizing tumor lysates from B16/TOPO vector, B16/FL-
WT or B16/FL-E362A. Tumor lysates were hybridized with a mouse 
angiogenesis antibody array dotted with 53 mouse angiogenesis-related 
antibodies according to the manufacturer’s instructions (R&D systems; 
Minneapolis, MN, USA). Briefly, antibody array membrane was first blocked 
with Assay buffer 6 for 1 hr rocking. 300 µg of total protein from tumor 
lysates was then added to the membrane after mixing with Assay buffer 4 and 
6. This was then mixed with 15 µl of reconstituted biotinylated primary 
antibody cocktail pre incubated for 1 hr at RT and incubated overnight at 40C 
rocking. After washing membrane 3 times, streptavidin-HRP in array buffer 6 
was added to the membrane and incubated at RT for 30 mins, rocking. After 
washing excess secondary antibody, the membrane was developed by 
chemiluminescent detection system (Pierce, USA). X-ray films were scanned 
and developed positive signal spots were analysed by Image J image 







 The harvested tumors or lungs were fixed in freshly prepared 4% 
paraformaldehyde solution, by immediately transferring them into a 15 ml 
falcon tube and gently rocked for 4 hrs at RT. Frequent changes of the fixative 
was performed over a period of 48 hrs to remove the remove the blood and fix 
the tissue. 
2.15.2 Dehydration and paraffin embedding 
 The fixed tumors were then serially dehydrated by transferring them 
to 50% ethanol overnight, followed by 70% ethanol for 2-6 hrs, depending on 
the size of the tumor. The tumors were then rocked in 90% ethanol for 1 hr, 
twice and then in 100% ethanol, 3 times for half an hr each. This was followed 
by a treatment with 100% Histochoice clearing agent (Sigma, USA), 3 times, 
for half an hr each and overnight. Then the cleared tumors were immersed in 2 
changes of paraplast embedding media (Sigma, USA) at 600C for 1 hr each. 
The paraffin-infiltrated tumors were placed into an embedding boat and 
oriented into desired position before adding fresh paraffin to fill the dish. 
Bubbles were carefully avoided. 
2.15.3 Sectioning 
 The paraffin blocks were trimmed so as to have a 2-3 mm margin of 
paraffin around the edges of the tissue and mounted by paraffin onto a wooden 
block. The tissue was sectioned into 5 µm thick serial sections using a 
microtome (Reichert-Jung, Germany). The sections were transferred to a 400C 
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water bath and floated briefly. The intact and stretched sections were selected 
individually and laid on the pre-coated glass slides. The sections were 
labelled, dried in a 370C slide warmer overnight and stored until used. 
2.15.4 Dewaxing and rehydration 
 The sections were dewaxed by first melting the wax at 600C for 7 min 
followed by plunging them into 3 Histoclear washes for 10 min each. Sections 
were then rehydrated by passing through a gradient: two, 100% ethanol 
washes for 10 mins each, two 90% ethanol washes for 5 mins each, one 80% 
ethanol wash and one 70% ethanol wash, followed by rinsing them in fresh 
PBS. 
2.15.5 Antigen retrieval 
 Antigen retrieval was performed using the 2100 retriever, antigen 
retrieval machine (Proteogenix, France). Briefly, dewaxed and rehydrated 
sections were immersed in R-buffer-A pH 6.0 and subjected to >1200C and 
high pressure for 15 mins. The slides were then allowed to cool prior to PBS 
rinse and blocking. 
2.15.6 Immunofluorescence staining 
 All immunostainings were carried out by using fluorescence-
conjugated secondary antibody detection system. Briefly, after pretreatment 
and PBS wash, slides were blocked with 3% BSA in PBS. After 1 h 
incubation at RT, the slides were washed 3 times with PBS for 5 min each. 
1/500 Phospho Histone H3 antibody (Santa Cruz, USA), 1/500 PCNA 
(SantaCruz, USA) or 1/500 CD31 (SantaCruz, USA) was added onto the 
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section and incubated at 40C for overnight. The next day, the section was 
incubated with corresponding Alexafluor conjugated secondary antibodies at 
RT for 2 hr after washing 3 times. The nuclei were counterstained with DAPI 
at RT for 30 min. The section was then washed again and observed. 
Fluorescence signals were detected using (Zeiss Axiovert 200, Germany) and 
pictures of representative fields were captured at 200 X magnification for 
CD31 and 400 X magnification for phospho-histone H3. Negative control 
samples were exposed to secondary antibody alone. 
2.15.7 Mounting 
 All slides were mounted with 50% glycerol in water solution or DPX 
mounting media and covered gently using a coverslip, dried and either stored 
or used for imaging. 
2.15.8 TUNEL 
 Tumor apoptosis was assessed using the in-situ cell death detection kit 
POD (Roche, Switzerland) based on the widely used terminal 
deoxynucleotidyltransferase (TdT)-mediated dUTP nick-end labeling 
according to the manufacturer's protocol. Briefly, paraffin embedded tumor 
sections were melted at 600C. Following dewaxing and rehydration using 
xylene and a graded series of ethanol, slides were boiled in citrate buffer at pH 
6.0. The slides were then rinsed and a TUNEL reaction mix consisting of 5 µl 
of enzyme solution and 45 µl of label solution was added and incubated at 
370C in a humidified chamber for 1 hr. Subsequently slides were rinsed and 
the nuclei were counterstained with DAPI. Slides incubated with only the label 
solution served as the negative control. Sections were observed and images of 
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representative fields were captured at 400 X magnification using an inverted 
microscope (Zeiss Axiovert 200, Germany). For apoptosis quantification, the 
average number of apoptotic cells per microscopic field, from three 
microscopic fields per tumor section, three tumor sections per tumor and two 
tumors per construct were analyzed. 
2.15.9 Microvessel density (MVD) determination 
 The sections stained with CD31 were examined carefully under 
microscope. Only fields with high concentration of microvessels (vascular hot 
spots) were counted. For vessel quantification, the average number of vessels 
per microscopic field, from three microscopic fields per tumor section, three 
tumor sections per tumor and two tumors per construct were analyzed. The 
average tumor vascular density which includes all lumen and non-lumen 
CD31+ structures was computed. Non-lumen CD31+ structures include single 
cells staining positive for the marker and two or more continuous cells 
clustering together.  
2.16 Statistical analysis 
 The data were presented in the form of mean ± S.E. Two-tailed, 
unpaired student’s t test was used for comparing experimental data from 
different groups. A p-value of less than 0.05 was considered significant in all 





2.17 List of constructs used in this study 
FL-WT – Full-length wild-type ADAMTS4; FL-E362A –Full-length catalytic 
domain mutant of ADAMTS4; N-p53 – ADAMTS4 N-terminal fragment; D-S 
– ADAMTS4 without the metalloproteinase domain; T-S – construct 
containing ADAMTS4 TSR to Spacer regions; C-S – construct containing 
ADAMTS4 cysteine-rich to Spacer region; TSR – thrombospondin motif of 
ADAMTS4. The amino acid position of each domain is marked by a number 
and the name of each domain is labeled at the top. Epitope tags linked at the 
C-terminal of the constructs are labeled. Known proteolytic cleavage sites, 
epitopes of the ADAMTS4 specific antibodies and the potential N-linked 




2.18 List of stable cell lines generated/used in this study  
Number Stable cell line 
1) B16F10/TOPO 
2) B16F10/FL-WT 
3)  B16F10/FL-E362A 




















2.19 List of primers used in this project 
PCR Primers for cDNA cloning 
TS4-F GCCACCATGTCCCAGACAGGCTCG  






ATS4-53       TTTCCTGAAGGAGCCTGACTGCTTG 
Sequencing Primers 
T7-F               TAATACGACTCACTATAGGG 







Deciphering the role of ADAMTS4 in mouse 
Melanoma 
3.1 Expression analysis of ADAMTS4 
3.1.1 Expression of ADAMTS4 in human tissues and tumors 
 Tumors produce a variety of pro- and anti-angiogenic factors and a 
fine balance is necessary to maintain homeostasis (Bouïs, Kusumanto et al. 
2006; Pollina, Legesse-Miller et al. 2008). Often there are different levels of 
these factors in tissues compared to tumors. To investigate the relationship 
between ADAMTS4 expression and tumor, the expression of ADAMTS4 in 
several human normal and corresponding tumor tissues was examined by 
Western blot. 
 Since ADAMTS4 was shown to undergo proteolytic processing to 
generate fragments, two different anti-ADAMTS4 antibodies were used that 
can recognize ADAMTS4 specifically. Both the ADAMTS4 N-terminal 
antibody and the C-terminal antibody are polyclonal antibodies. The 
ADAMTS4 N-terminal antibody (a kind gift from Prof H. Nagase, Oxford 
University, UK) recognised an epitope at the metalloprotease domain, residues 
395-403 (MAHDVPEEP). The ADAMTS4 C-terminal antibody recognized an 
epitope in the C-terminal spacer domain of the protein, residues 803-816 
(PRPTPSTPRPTPQD) (our own custom made antibody by Biogenes, GmBH, 
Germany) (Fig 3.1A). The specificities of both antibodies were confirmed 
using recombinant ADAMTS4 constructs FL-WT, N-p53 and C-S. The FL-
WT construct which contains both epitopes was recognised by both antibodies 
(Fig 3.1B and C). The N-p53 construct has only the N-terminal epitope, thus it 
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was recognised only by the N-terminal antibody but not by the C-terminal 
antibody (Fig 3.1B). The C-S construct which contains only the C-terminal 
epitope was recognised by the C-terminal antibody and not the N-terminal 
antibody (Fig 3.1C). 
 
Fig 3.1 - Characterization of ADAMTS4-specific antibodies - A. Schematic 
showing the locations of the epitopes recognized by the ADAMTS4-specific 
antibodies in the recombinant constructs FL-WT, N-p53 and C-S. B. 
Immunoblot showing the detection of the FL-WT, N-p53 and C-S constructs by 
the ADAMTS4 N- and C-terminal specific antibodies. Conditioned media 
collected from cells expressing the indicated constructs are used in Western 
blot. 
 As shown in Fig 3.2, the full-length human ADAMTS4 has been 
described to be 68 kDa. In addition, two truncated fragments of 53 kDa and 40 
kDa due to autocatalytic cleavages at the C-terminal ancillary region have 
been reported (Flannery, Zeng et al. 2002). The predominant ADAMTS4 
isoform that was observed in human tissues was around 50 kDa when probed 
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with the N-terminal catalytic domain antibody, likely to be the reported 53 
kDa form. This isoform is present in both normal and cancer tissues, with a 
higher level observed in cancers of breast, colon, lung and skin comparing to 
the corresponding normal tissues and is referred to in this study as N-p53 (Fig 
3.2). So far, no cleavage in the N-terminal regions of the ADAMTS4 protein 
has been reported. However, we observed a predominant band at around 50 
kDa with the C-terminal antibody. Based on size, this could suggest a 
proteolytic cleavage within the N-terminal catalytic domain, either from 
autocatalytic cleavage or cleavage by other proteases. This C-terminal 
fragment is designated as C-p52 in this work. C-p52 is present in both normal 
and cancer tissues, but a notably higher level was observed in several cancers 
including lung, skin, liver and breast (Fig 3.2). Since varying levels of beta 
actin were observed in human tissues and tumors, equal amount of total 
protein loading was demonstrated by coomassie blue staining. Taken together, 
these results indicated that ADAMTS4 is highly expressed in many human 
cancer tissues. However, heterogenous protein expression levels were 
observed between tumors and their corresponding normal tissues, suggesting 





Fig 3.2 - Expression of ADAMTS4 in human normal and cancer tissues - 
Immunoblot showing ADAMTS4 expression in eight different matched normal 
and cancer organ tissues namely breast, colon, kidney, liver, lung, skin, 
stomach and ovary, using the N- and C-terminal specific ADAMTS4 antibody. 
N refers to normal and T refers to tumor tissue samples. Thin arrow, thick 
arrow and arrowhead indicate N-p53, C-p52 and full-length mature form of 
ADAMTS4 respectively. Each lane is loaded with 5 µg of total protein. 
Coomassie stained gel is shown below for evidence of equal loading. 
 
3.1.2 Expression of ADAMTS4 in human and mouse cancer cell lines 
 Gain-of-function approach by overexpression is widely used for gene 
functional analysis. Overexpression of gene in tumor cells is an established 
method to investigate gene function in tumor angiogenesis and tumor 
progression. To examine the role of ADAMTS4 in tumor progression, 
overexpression of ADAMTS4 in tumor cells was selected as a suitable 
method. ADAMTS4 expression in human and mouse cancer cell lines were 
also analysed in order to find the suitable host for overexpression and 
knockdown studies. 
 Endogenous ADAMTS4 expression levels were analyzed in several 
human tumor cell lines including A549 (human lung adenocarcinoma 
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epithelial cell line), G401 (rhabdoid kidney tumor cell line), HT1080 (human 
fibrosarcoma cell line), JAR (placental choriocarcinoma cell line), PC3 
(human prostate carcinoma cell line), U87GM (human glioblastoma) and 
HeLa (human cervical carcinoma cell line) as well as the mouse tumor cell 
lines, B16F10 (mouse melanoma cell line) and 4T1 (mouse mammary 
carcinoma cell line) (Fig 3.3). Whole cell lysate were extracted and subjected 
to Western blotting using the N-terminal anti-ADAMTS4 antibody from 
Thermoscientific. This antibody recognised the 53 kDa major N-terminal 
ADAMTS4 isoform. 
 The results showed that ADAMTS4 expression, like in cancer tissues, 
was also high in several human cancer cell lines such as G401, JAR, PC3 and 
HeLa, identifying these cell lines as good hosts for ADAMTS4 knockdown 
studies (Fig 3.3). ADAMTS4 expression however was relatively low in A549, 
HT1080 and U87GM cell lines, indicating that these cell lines are good 
candidates for ADAMTS4 overexpression studies (Fig 3.3). ADAMTS4 
expression in the mouse cell lines B16F10 and 4T1 were lower than the 
human cancer cell lines tested as the amount of lysate loaded was several 





Fig 3.3 - Expression of ADAMTS4 in human and mouse cancer cell lines - 
Immunoblot showing ADAMTS4 expression in human cancer cell lines (A549, 
G401, HT1080, JAR, PC3, U87GM and HeLa) and mouse cancer cell lines 
B16F10 and 4T1. Arrowheads indicate higher expression of ADAMTS4. Total 
protein 30 µg for the mouse cancer cell lines and 5 µg for the human cancer 
cell lines were loaded. Housekeeping gene beta actin levels are shown below 
for evidence of equal loading. The ADAMTS4 antibody is rabbit polyclonal 
recognising an epitope MAHDVPEEP in the metalloproteinase domain. 
 
3.1.3 Expression of ADAMTS4 in human melanoma cell lines 
 ADAMTS4 expression level in the mouse melanoma cell line had 
relatively low levels of protein expression when compared to high ADAMTS4 
expressing human cancer cell lines. Thus, in order to determine the level of 
ADAMTS4 expression in comparison to several human melanoma cell lines a 
Western blot analysis of protein expression was undertaken. ADAMTS4 
expression was analyzed in nine human melanoma cell lines namely 888Mel, 
SK28, M88, M102, M131, M134, MMAN, MMRU and SK-Mel-3 and 
expression was compared to the mouse melanoma cell line B16F10. 
 Results showed that six out of the nine human melanoma cell lines 
tested expressed high levels of ADAMTS4 (Fig 3.4). However, when same 
amount of B16F10 total protein lysate was loaded, ADAMTS4 expression was 
negligible (Fig 3.4). A band could be observed at higher exposures in the 
B16F10 lane. This suggested that B16F10 expression levels of ADAMTS4 are 
96 
 
low enough to warrant use of this cell line as a suitable host for ADAMTS4 
overexpression studies. 
 
Fig 3.4 - Expression of ADAMTS4 in human melanoma cell lines -
Immunoblot showing ADAMTS4 expression in human melanoma cell lines 
(888Mel, SK28, M88, M102, M131, M134, MMAN, MMRU and SK-Mel-3) 
compared to the mouse cancer cell line B16F10. Arrowheads indicate higher 
expression of ADAMTS4. Housekeeping gene beta actin levels are shown 
below for evidence of equal loading. The ADAMTS4 rabbit polyclonal 
antibody recognises an epitope MAHDVPEEP in the metalloproteinase 
domain. 
 
3.2 Overexpression of full-length ADAMTS4 promotes melanoma growth 
in mice 
3.2.1 Establishment of stable clones overexpressing FL-WT in B16 mouse 
melanoma 
 To investigate the roles of ADAMTS4 in tumor progression, mouse 
B16F10 melanoma cells were chosen to create a syngeneic tumor in C57Bl/6J 
mice. As show in Fig 3.4, expression level of ADAMTS4 was relatively low 
compared to other melanoma cell lines. 
 In order to obtain the stable mouse ADAMTS4-overexpressing 
B16F10 cell lines, an expression construct named FL-WT was created by 
subcloning of the human ADAMTS4 cDNA into the multiple cloning sites of 
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the mammalian expression pEF6/V5-His TOPO vector (Invitrogen, USA) (Fig 
3.5A). pEF6/V5-His TOPO expression vector was designed for high-level 
stable and transient expression in mammalian hosts. It contains the EF6 
promoter for efficient and high-level expression of the protein of interest; 
blasticidin resistance gene for selection of the transfectants; V5 epitope and 
polyhistidine-tag at C-terminal for protein detection and purification. The 
construct uses the native signal peptide of the protein for secretion into the 
media. 
 Plasmid FL-WT was transfected into B16F10 cells using branched 
PEI. Cells that had taken up this plasmid were selected in the presence of 
blasticidin (8 μg/ml). Multiple blasticidin resistant single colonies were 
isolated individually. Isolated colonies were expanded by subculture and 
analysed for the expression of FL-WT. The highest expressing clones 
designated as B16/FL-WTa, B16/FL-WTb, and B16/FL-WTc were further 
analysed for relative expression levels. In contrast, vector-transfected B16 
colonies were pooled and designated as B16/TOPO and used as control cells. 
 To determine FL-WT expression, conditioned media from the selected 
stable cell lines were collected and concentrated by acetone precipitation. FL-
WT expression was confirmed with Western blotting using anti-V5 tag 
antibody. As shown in Fig. 3.5B, FL-WT ADAMTS4 expressed by stable cell 
lines could be detected as the immature prodomain form at 100 kDa and the 
mature processed form at 75 kDa. Two (B16/FL-WTb and B16/FL-WTc) out 
of three stable cell lines were ADAMTS4-positive. No corresponding signal 
was detected in B16/TOPO cells, indicating the specificity and higher 
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expression level of ADAMTS4 in B16/FL-WTb and B16/FL-WTc. The 
expression level of FL-WTc was slightly higher than FL-WTb. 
 To further examine the homogeneity of established stable cell lines, 
immunostaining of B16/FL-WTb and B16/FL-WTc cells with anti-V5 
antibody were performed. As shown in Fig. 3.5C specific staining was only 
observable in the cytoplasm of B16/FL-WTb and B16/FL-WTc cells, 
indicating that B16/FL-WTb and B16/FL-WTc but not B16/TOPO expresses 
exogenous ADAMTS4. It is also noted that more than 95% of the cells were 
stained positive, demonstrating the high purity of B16 stable cell lines that 
overexpress ADAMTS4. 
 Taken together, stable transfection of ADAMTS4 overexpression 
construct into B16 cells resulted in enhanced ADAMTS4 expression in 
B16/FL-WTb and B16/FL-WTc two stable cell lines with high purity. 
B16/FL-WTc with the highest expression was chosen for studies and 





Fig 3.5 - Selection of FL-WT-overexpressing B16 stable cell lines - A. 
Schematic representation of ADAMTS4 FL-WT construct. The C-terminally 
located epitope tags are indicated as a legend below. B. Expression of FL-WT 
was detected by Western blotting using anti-V5 antibody. C. Immunostaining 
of B16 positive stable cell lines with anti-V5 antibody. Secondary antibody 
used was anti-mouse IgG conjugated with Alexa fluor 568. FL-WT staining 
was shown as red fluorescence. Nucleus was stained blue by DAPI. 
 
3.2.2 Overexpression of full-length ADAMTS4 did not affect in vitro cell 
proliferation rates 
 To determine whether cell proliferation is influenced by the transfection 
process or overexpression of FL-WT, the in vitro growth kinetics of these 
stable cell lines were monitored. B16/TOPO and B16/FL-WT cells were 
seeded in 6-well plate respectively after overnight starvation to synchronize 
the growth of the cells. The cell numbers were counted every alternate day 
over 7 consecutive days.  The cells were maintained in complete growth 
medium under normal culture conditions. As shown in Fig. 3.6, there was no 
significant difference in cellular proliferation of B16 cells between control 
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stable cell line and FL-WT overexpressing stable cell line. This result 
indicated that the in vitro growth characteristic of this stable cell line was not 
changed by the increased expression of FL-WT or by the transfection process. 
 
Fig 3.6 - Growth kinetics of FL-WT stable cell line - In vitro growth rates 
were not changed in FL-WT-overexpressing B16 stable cell line (B16/FL-WT) 
comparing to empty vector-transfected control cell line (B16/TOPO). 
 
3.2.3 Overexpression of full-length ADAMTS4 promotes melanoma 
growth in mice  
 To study the roles of ADAMTS4 in tumor formation and development, 
1 million of B16/FL-WT cells were inoculated subcutaneously into the right 
dorsal flank of C57BL/6J mouse. The same number of B16/TOPO cells was 
injected into the left dorsal flank in the same mouse as control. Subcutaneous 
tumor became visible around 9-10 days after tumor cell inoculation and the 
experiment was terminated at 17 days post tumor cell inoculation before the 
mice started to die (mouse was observed to start dying from 17~18 days after 
injection of B16 tumor cells). 
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 Tumor volume was measured every day after tumors became visible on 
day 10. As shown in Fig. 3.7B, a similar pattern of tumor growth among all 
tumors was observed during the early growth phase but tumor volume 
increased dramatically in B16/FL-WT at all timepoints after the early growth 
phase. At the end of the experiments (17 days after tumor cell inoculation), 
tumors were harvested and carefully excised and weighed, it was found that 
tumor weight from FL-WT-overexpressing B16 cells were enhanced 1.5-fold 
compared to control (Fig. 3.7C). 
 
Fig 3.7 - Overexpression of FL-WT promoted tumor growth in vivo - A. 
Each pair of tumor (either from B16/TOPO or B16/FL-WT cells) was 
extracted from the same mouse. B. Tumor growth curve comparing B16/FL-
WT with B16/TOPO. Tumor volume was measured daily from 10 days post s.c 
inoculation in C57Bl/6J on day 0 (n=7). Plots represent the mean tumor size 
(± SEM). C. Tumor weights of mice injected with B16/FL-WT or B16/TOPO 
post sacrifice on day 17 (n=7). Plots represent the relative mean tumor weight 




 Mouse tumors from B16/FL-WT and B16/TOPO cells of each 
individual mouse at day 17 were shown in Fig. 3.7A. Although, the in vitro 
growth rate of FL-WT overexpressing and control cells were identical, in vivo 
tumor growth was significantly enhanced in tumors formed from B16/FL-WT 
cells. 
 In order to confirm that the observed enhancement in tumor growth 
was as a result of overexpressed FL-WT protein, total protein was extracted 
from FL-WT overexpressing tumors and subjected to Western blot analysis 
using the anti-V5 antibody to detect the exogenous protein. Results confirmed 
that FL-WT overexpressing tumors indeed expressed the exogenous protein 
while no expression was detected in the control vector overexpressing tumors 
(Fig 3.8). 
 
Fig 3.8 - Tumor lysates express exogenous FL-WT - Immunoblot 
confirming the presence of overexpressed exogenous proteins in tumor lysate 
overexpressing FL-WT but not in corresponding tumor lysate overexpressing 
TOPO vector. Beta actin acts as loading control. 
 
 In conclusion, although overexpression of FL-WT did not influence in 
vitro tumor cell proliferation it significantly promoted tumor growth. These 
results suggest that the effects of FL-WT on tumor growth are indirect.  
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3.2.4 FL-WT promotes melanoma growth by stimulating tumor 
angiogenesis 
 Angiogenesis is an essential step for tumors to progress beyond a 
millimetre in size (Folkman 1972). The quantification of microvessel density 
(MVD) is currently the gold standard for neovascularisation measurements in 
solid tumors. MVD has been identified as a powerful prognostic tool in many 
human tumor types (Fox and Harris 1997). Since platelet endothelial cell 
adhesion molecules (PECAM-1/CD31) is the most specific and sensitive 
tumor endothelial marker compared to other available antibodies such as 
CD34 and von Willebrand’s Factor (vWF) (Parums, Cordell et al. 1990), 
MVD is usually assessed by immunostaining with antibody to CD31. 
Microvessels in the most active areas of neovascularisation (hot spots) of 
tumor are counted and taken as the MVD of the tumor. 
 To investigate whether the enhanced tumor growth in B16/FL-WT 
tumors was attributable to enhanced tumor angiogenesis, blood vessel density 
of various tumors were evaluated. Immunofluorescence staining of tumor 
tissue sections with anti-CD31 antibody revealed a 2-fold increase in tumor 
vascularization in FL-WT overexpressing tumors compared with control 
tumors (Fig. 3.9A, tumor vessels in red). The average tumor vascular density 
of each tumor group, which included all lumen and non-lumen CD31+ 
structures (cell clusters and spots) was increased by more than 1-fold in FL-
WT overexpressing tumors (Fig. 3.9B). This strongly suggests that continued 
presence of high level of FL-WT in the tumor milieu promotes tumor 




Fig 3.9 - B16/FL-WT tumors show enhanced vascularization compared to 
controls - A. Tumor vessels were visualized by CD31staining. Representative 
pictures are shown. Red staining indicates CD31 positive EC while blue 
staining by DAPI indicates cell nucleus. Scale bar presents 100 μM. B. 
Quantification of the microvascular density. Only angiogenesis in hot spot 
areas of a tumor section were selected for vessels analyses. For 
quantification, the average number of vessels per microscopic field, from three 
microscopic fields per tumor section, three tumor sections per tumor 
(representing the upper, middle and lower portion of the tumor) (B16/TOPO, 
B16/FL-WT) were analysed. Data were presented as mean ± SE **: P<0.01. 
 
 Uncontrolled cellular proliferation is one of the most predominant 
characteristic of tumor growth. To find out whether the enhanced growth in 
FL-WT-overexpressing tumors is a result of enhanced tumor cell proliferation, 
tumor cell proliferation was examined by immunostaining with an antibody to 
a novel proliferation marker PhosphoHistone H3 (pHH3). Conventional 
proliferation markers such as Proliferating Cell Nuclear Antigen (PCNA) and 
Ki67 are expressed throughout the cell cycle. Cells positive for these markers 
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may not survive the enter cell cycle and enter apoptosis, thus blurring the 
proliferation index measurements. Studies have demonstrated that histone H3 
is a core histone protein which, together with other histones, forms the major 
protein constituents of the chromatin in eukaryotic cells. In mammalian cells, 
phosphorylation of the Serine 10 residue of histone H3 is negligible during 
interphase but reaches a maximum for chromatin condensation during mitosis 
(Gurley, D'Anna et al. 1978; Shibata and Ajiro 1993). Thus an antibody 
against pHH3 was used as a more reliable proliferation marker. 
 As shown in Fig. 3.10A, approximately 20% tumor cells were pHH3-
positive in both tumors. The average number of proliferating cells per 
microscopic field quantified by analysing multiple tumor samples in each 
tumor group showed that there was no significant difference of cell 




Fig 3.10 - Tumor proliferation was not affected FL-WT-overexpressing 
tumors - A. pHH3 immunostaining in tumor sections. Red indicated pHH3-
positive while blue indicated nucleus. Representative pictures are shown. 
Scale bar represents 20 μM. B. Quantification of proliferating tumor cells. 
The average number of proliferating cells per microscopic field, from three 
microscopic fields per tumor section, three tumor sections per tumor 
(representing the upper, middle and lower portion of the tumor) (B16/TOPO 
or B16/FL-WT) were analysed. Data were presented as mean ± SE. 
 
 Either up-regulated proliferation or resistance to programmed cell 
death or both are characteristics of tumor development. Since cell proliferation 
was not changed in FL-WT-overexpressing B16 tumors (Fig. 3.10), it was 
analysed whether reduced tumor cell apoptosis was a reason for enhanced 
tumor growth. Terminal deoxynucleotidyl transferase dUTP nick end labeling 
(TUNEL), a commonly used method for detecting DNA fragmentation by 
labelling the terminal end of nucleic acids (Christina, Angelika et al. 2006) 
was therefore used to determine B16 tumor apoptosis. 
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 As shown in Fig. 3.11A, TUNEL staining results showed no difference 
in apoptotic tumor cells (green dots) in FL-WT-overexpressing B16 tumors 
compared to B16/TOPO control tumors. The average apoptosis index (AI) 
quantified by assessing the number of positive apoptotic cells in 3 microscopic 
fields, 3 sections in each tumor group are shown in Fig. 3.11B.  
 
Fig 3.11 - Tumor apoptosis was not affected in FL-WT-overexpressing 
tumors - A. TUNEL staining in tumor sections. Green indicated TUNEL-
positive while blue indicated nucleus. Representative pictures are shown. 
Scale bar represents 20 μM. B. Quantification of apoptotic tumor cells. The 
average number of proliferating cells per microscopic field, from three 
microscopic fields per tumor section, three tumor sections per tumor 
(representing the upper, middle and lower portion of the tumor) (B16/TOPO 
or B16/FL-WT) were analysed. Data were presented as mean ± SE. 
 
 In conclusion, these results demonstrated that the enhanced tumor 
growth by FL-WT overexpression in B16 cells is an indirect effect of 
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enhanced angiogenesis with no effects on tumor cell apoptosis or tumor cell 
proliferation. 
3.3 The pro-tumorigenic function of ADAMTS4 is dependent on its 
catalytic activity 
3.3.1 FL-E362A abolishes the catalytic activity of the protein 
 The full-length ADAMTS4 protein as shown in section 3.2 was found 
to promote B16 melanoma tumor growth via promoting tumor angiogenesis. 
In order to determine whether this tumor promoting activity is dependent on 
the catalytic activity of the protein, an enzyme-inactive active-site mutant 
(E362A) of ADAMTS4 protein was generated by site-directed mutagenesis of 
the FL-WT construct and subcloning it into the multiple cloning sites of the 
mammalian expression pEF6/V5-His TOPO vector (Invitrogen, USA). This 
mutant has been previously demonstrated to lose its enzymatic activity against 
its substrate aggrecan (Kashiwagi, Enghild et al. 2004). 
 A mutant FL-E362A plasmid was created by site directed mutagenesis 
on the FL-WT construct. In order to confirm that this construct had lost its 
enzymatic activity an aggrecanase assay was performed. HEK 293T cells were 
transfected with FL-WT and FL-E362A plasmids using branched 
polyethyleneimine. Conditioned media from transfected cells were collected 
and protein concentrated and partially purified using Ni-NTA beads. Purified 
protein was incubated with 500 nM aggrecan from bovine articular cartilage 
and aggrecanase assay was performed as described in (Llamazares, Obaya et 
al. 2007). Reaction products were analyzed by Western blot using neo-epitope 
specific AGEG antibody (kind gift from Prof. H. Nagase, Oxford University). 
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As a positive control, aggrecan digestion was carried out by commercially 
available pure recombinant ADAMTS4 under the same experimental 
conditions, while aggrecan incubation without any enzyme acts as negative 
control. 
 Results demonstrated that the FL-WT retained enzymatic activity and 
thus the ability to cleave its substrate aggrecan, while the enzyme-inactive 
mutant lost its aggrecanase ability (Fig 3.12). 
 
Fig 3.12 - FL-E362A lost its enzymatic activity - A. ADAMTS4 cleaved 
aggrecan while E362A mutant lost this enzymatic activity. Following 
incubation of aggrecan with purified wildtype ADAMTS4 (FL-WT) (lane 2), 
purified catalytic domain mutant of ADAMTS4 (FL-E362A) (lane 3), and 
recombinant ADAMTS4 control (lane 4), samples were deglycosylated and the 
aggrecan degradation products were detected by using neo-epitope specific 
AGEG antibody. B. Protein loading control. Equal amount of partially 
purified total protein of FL-WT or FL-E362A were loaded and expression of 





3.3.2 Establishment of stable clones overexpressing FL-E362A in B16 
melanoma 
 To investigate whether the tumor promoting activity of ADAMTS4 is 
dependent on the catalytic activity of the enzyme, stable mouse ADAMTS4 
mutant-overexpressing B16F10 cell lines were created. The expression 
construct FL-E362A was used (Fig 3.13A). This construct also uses the native 
signal peptide of the protein for secretion into the media. 
 Plasmid FL-E362A was transfected into B16F10 cells and stable 
clones were selected as described in section 3.2.1.  The highest expressing 
clones designated as B16/FL-E362Aa, B16/FL-E362Ab, and B16/FL-E362Ac 
were further analysed for relative expression levels. In contrast, vector-
transfected B16 colonies were pooled and designated as B16/TOPO and used 
as control cells. 
 FL-E362A expression was confirmed with Western blotting using anti-
V5 tag antibody. As shown in Fig. 3.13B, FL-E362A expressed by stable cell 
lines could be detected as the immature prodomain form at 100 kDa and the 
mature processed form at 75 kDa in the conditioned media. All three lines 
showed significant high expression (B16/FL-E362Aa, B16/FL-E362Ab and 
B16/FL-E362Ac). No corresponding signal was detected in B16/TOPO cells. 




Fig 3.13 - Selection of FL-E362A-overexpressing B16 stable cell lines - A. 
Schematic representation of ADAMTS4 FL-E362A construct. The C-terminally 
located epitope tags are indicated as a legend below. B. Expression of FL-
E362A was detected by Western blotting using anti-V5 antibody. C. 
Immunostaining of B16 positive stable cell lines with anti-V5 antibody. 
Secondary antibody used was anti-mouse IgG conjugated with Alexa fluor 
568. FL-E362A staining was shown as red fluorescence. Nucleus was stained 
blue by DAPI. 
 
 To further examine the homogeneity of established stable cell lines, 
immunostaining of two of the lines B16/FL-E362Ab and B16/FL-E362Ac 
cells with anti-V5 antibody were performed. As shown in Fig. 3.13C, specific 
staining was only observable in B16/FL-E362Ab and B16/FL-E362Ac cells, 
indicating that these lines but not B16/TOPO expresses exogenous 
ADAMTS4. It is also noted that more than 95% of the cells were stained 
positively, demonstrating the high purity of B16 stable cell lines that 
overexpress FL-E362A. 
 Taken together, stable transfection of FL-E362A overexpression 
construct into B16 cells resulted in enhanced expression in three lines, 
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B16/FL-E362Aa, B16/FL-362Ab and B16/FL-E362Ac. B16/FL-E362Ab with 
the highest expression was chosen for studies and henceforth will be referred 
to as B16/FL-E362A. 
3.3.3 Overexpression of FL-E362A did not affect cell proliferation in vitro 
 To determine whether cell proliferation is influenced by the 
transfection process or overexpression of FL-E362A, the in vitro growth 
kinetics of these stable cell lines (B16/TOPO and B16/FL-E362A) cells were 
monitored as described in section 3.2.2. As shown in Fig. 3.14, there was no 
significant difference in cellular proliferation of B16 cells between control 
stable cell line and FL-E362A overexpressing stable cell line. This result 
indicated that the in vitro growth characteristic of this stable cell line was not 
changed by the increased expression of FL-E362A or by the transfection 
process. 
 
Fig 3.14 - Growth kinetics of FL-E362A stable cell line - In vitro growth 
rates were not changed in FL-E362A-overexpressing B16 stable cell line 







3.3.4 Overexpression of ADAMTS4 active-site mutant inhibits melanoma 
growth in mice 
 To investigate whether the tumor promoting effect of ADAMTS4 is 
dependent on the catalytic activity of the protein, mouse tumorigenesis assay 
was carried out as described in section 3.2.3. 
 Tumor volume was measured every day after tumors became visible on 
day 11. As shown in Fig. 3.15B, tumor volume decreased dramatically in 
B16/FL-E362A at all timepoints after the early growth phase. At the end of the 
experiments (17 days after tumor cell inoculation), tumors were harvested and 
carefully excised and weighed, it was found that tumor weight from FL-






Fig 3.15 - Overexpression of FL-E362A inhibited tumor growth in vivo -  
A. Each pair of tumor (either from B16/TOPO or B16/FL-E362A cells) was 
extracted from the same mouse. B. Tumor growth curve comparing B16/FL-
E362A with B16/TOPO. Tumor volume was measured daily from 11 days post 
s.c inoculation in C57Bl/6J on day 0 (n=6). Plots represent the mean tumor 
size (± SEM). C. Tumor weights of mice injected with B16/FL-E362A or 
B16/TOPO post sacrifice on day 17 (n=6). Plots represent the relative mean 
tumor weight (± SEM). **P<0.05. 
 
 Mouse tumors from B16/FL-E362A and B16/TOPO of each individual 
mouse at day 17 are shown in Fig. 3.15A. Although, the in vitro growth rate of 
FL-E362A overexpressing cells and control cells were identical, in vivo tumor 
growth were significantly reduced in tumors formed from B16/FL-E362A 
cells. 
 In order to confirm that the observed reduction in tumor growth was a 
result of overexpressed FL-E362A protein, total protein was extracted from 
FL-E362A overexpressing tumors and subjected to Western blot analysis 
using the anti-V5 antibody to detect the exogenous protein. Results confirmed 
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that FL-E362A overexpressing tumors indeed expressed the exogenous protein 
while no expression was detected in the control vector overexpressing tumors 
(Fig 3.16). 
 
Fig 3.16 - Tumor lysates express exogenous FL-E362A - Immunoblot 
confirming the presence of overexpressed exogenous protein in FL-E362A 
tumor lysate, but not in corresponding TOPO vector tumor lysate. Beta actin 
acts as loading control. 
 
3.3.5 FL-E362A suppressed melanoma growth by inhibiting tumor 
angiogenesis, enhancing tumor cell apoptosis without affecting tumor cell 
proliferation 
 As in the case of FL-WT, the contribution of tumor angiogenesis, 
proliferation and apoptosis was assessed to investigate the mechanisms of FL-
E362A’s tumor inhibitory effect. 
 To investigate whether the diminished tumor growth in B16/FL-E362A 
was attributable to reduced tumor angiogenesis, blood vessel density of 
various tumors were evaluated. Immunofluorescence staining of tumor tissue 
sections with anti-CD31 antibody revealed a 50% decrease in tumor 
vascularization in FL-E362A overexpressing tumors compared with control 
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tumors (Fig. 3.17A, left panels, tumor vessels in red). The average vessel 
number per field calculated as described in section 3.2.4. was decreased by 
50% in FL-E362A overexpressing tumors (Fig. 3.17B). This strongly suggests 
that continued presence of high level of FL-E362A in the tumor milieu inhibits 
tumor angiogenesis and hence tumor growth in mice. 
 To find out whether the reduced growth in FL-E362A-overexpressing 
tumors is a result of reduced tumor cell proliferation, tumor cell proliferation 
was examined by immunostaining with an antibody to a novel proliferation 
marker PhosphoHistone H3 (pHH3). 
 As shown in Fig. 3.17A (middle panels), approximately 20% tumor 
cells were pHH3-positive in both tumors. The average number of proliferating 
cells per microscopic field quantified as described in section 3.2.4 showed that 
there was no significant difference of cell proliferation between control and 





Fig 3.17 - FL-E362A influence on tumor angiogenesis, tumor cell 
proliferation and apoptosis - A. FL-E362A influences tumor angiogenesis and 
tumor apoptosis but not tumor cell proliferation. Immunofluorescence staining 
with anti-CD31 antibody (left panels), anti-Phospho-Histone H3 antibody 
(middle panels) and In-situ TUNEL staining (right panels) of tumor sections 
from B16/TOPO or B16/FL-E362A tumors are shown. Scale bars represent 
100μm for CD31 staining and 20 μm for Phospho-Histone H3 and TUNEL. B-
D. Quantification of tumor blood vessel, tumor cell proliferation and tumor 
apoptosis. Comparison of the relative number of blood vessels, proliferating 
cells and apoptotic cells per field. Plots represent the relative mean vessel 
number, proliferating cell number and apoptotic cell number analyzed for 3 
fields per section, 3 sections per tumor (± SEM). **P<0.005. 
 
 Since cell proliferation was not changed in FL-E362A-overexpressing 
B16 tumors (Fig. 3.17A, middle panels and 3.17C), it was analysed whether 
enhanced tumor cell apoptosis was a reason for reduced tumor growth. 
TUNEL staining was performed to assess the amount of tumor cell apoptosis. 
 As shown in Fig. 3.17A (right panels), TUNEL staining results showed 
enhanced number of apoptotic tumor cells (green dots) in FL-E362A-
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overexpressing B16 tumors compared to B16/TOPO control tumors. The 
average numbers of apoptotic cells per field calculated as described in section 
3.2.4 are shown in Fig. 3.17D. 
 In conclusion, these results demonstrated that the reduced tumor 
growth by FL-E362A overexpression in B16 cells is an indirect effect of 
reduced tumor angiogenesis along with enhanced tumor cell apoptosis, 
however with no effect on tumor cell proliferation. 
3.4 Mechanism of ADAMTS4’s effects on tumor angiogenesis 
3.4.1 Overexpression of FL-WT or FL-E362A differentially regulates 
angiogenesis signaling pathway proteins 
 To decipher the mechanisms of ADAMTS4 and its derivative mediated 
pro- and anti-angiogenic activities, we analyzed the effects of FL-WT and FL-
E362A proteins on angiogenesis-related proteins in B16 tumor using a mouse 
angiogenesis antibody array. Tumor tissue lysates (300µg) from either FL-WT 
or FL-E362A overexpressing tumors were probed with the mouse 
angiogenesis antibody array and compared individually with TOPO tumor 
tissue lysates. A mean spot pixel density from array duplicates was quantified 
using Image J software. Out of the 53 proteins probed, 14 proteins showed 
contrasting changes in expression between B16/FL-WT and B16/FL-E362A 





Table 3.1 - List of angiogenesis signaling proteins differentially affected by ADAMTS4 overexpression 
Genebank Accession 
Number  
Symbol  Description  Alternate 
Nomenclature  
Fold 
change   
WT/Vector  
Fold change  
E362A/Vector  
NP_032367.3  IGFBP-1  Insulin-like growth factor binding 
protein  
-  4.32 0.27 
NP_032853.1  PlGF-2  Placental Growth Factor-2  -  3.12 1.11 
NP_034684.2  IL-1 α  Interleukin-1α  IL1-F1  2.79 0.73 
NP_033751.3  ADAMTS1  A Disintegrin And Metalloprotease with 
ThromboSpondin motifs 1  
METH1  2.47 1.27 
NP_033834.1  AR  Amphiregulin  AREG  2.40 0.99 
NP_064316.1  CXCL4  Platelet Factor 4  PF4  2.03 0.71 
NP_032853.1  Ang  Angiogenin  Ribonuclease 5  1.98 0.98 
NP_034301  Coagulation 
factor III  
Tissue factor  TF, CD142  1.97 1.27 
NP_976065.1  KC  Chemokine of the 


















Symbol  Description  Alternate 
Nomenclature  
Fold 
change   
WT/Vector  
Fold change  
E362A/Vector  
NP_034204  DPPIV  Di-Peptidyl Peptidase IV  CD26  1.06 1.95 
NP_034678.1  IL-10  Interleukin-10  CSIF  0.46 1.48 




  Five of the proteins showing contrasting expression changes were 
further validated by Western blot (Fig 3.18). While the anti-tumorigenic 
dipeptidyl peptidase IV (DPPIV/CD26) and interleukin 10 (IL-10) are up-
regulated in FL-E362A tumor, their expressions are not changed or down-
regulated in FL-WT tumor comparing to vector tumor.  
 
Fig 3.18 - Validation of differentially expressed proteins identified by 
angiogenesis antibody array by Western blot - Immunoblot showing the 
expression level of each of the five proteins - IGFBP-1, IL-1 alpha, IL-10, 
PlGF-2, DPPIV in the tumor lysates overexpressing vector, FL-WT or E362A 





 On the other hand, the pro-angiogenic protein insulin-like growth 
factor binding protein 1 (IGFBP-1), interleukin-1α (IL-1α) and placenta 
growth factor (PlGF-2) are up-regulated only in FL-WT tumors, contrasting 
with the down-regulation of IGFBP-1 and IL-1α and minimum increase in 
PlGF2 expression in FL-E362A tumors (Fig 3.18). These results suggest that 
the differential effect on B16 tumor growth and angiogenesis by WT and 






Characterization of the naturally occurring N-
terminal truncated ADAMTS4 fragments in 
angiogenesis and cancer 
4.1 Characterization of ADAMTS4 N-terminal truncated fragments in in 
vitro angiogenesis 
 Angiogenesis is a multistep and dynamic process. Initiation of 
angiogenesis coincides with the degradation of the basement membrane and 
exposure of ECs to extracellular matrix. ECs then sprout into new capillary 
network through migration, attachment and spreading, proliferation and 
morphogenesis (Davis and Senger 2005). Disruption in any of the steps could 
inhibit angiogenesis. Therefore, EC migration, attachment and spreading to 
ECM, proliferation, apoptosis and capillary network formation are various 
aspects investigated for angiogenesis in vitro. 
 ADAMTS4 undergoes cleavage at its N-terminus either 
autocatalytically or by other proteases such as the glycosylphosphatidyl 
inositol-anchored membrane type 4-matrix metalloprotease (MT4-MMP).  
Cleavage occurs at Lys694-Phe695 and Thr581-Phe582 respectively to generate 
two truncated forms – 53 kDa and 40 kDa designated as N-p53 and N-p40 in 
this study (Flannery, Zeng et al. 2002; Gao, Plaas et al. 2004). In this study, 
effect of the commercially available mammalian cell produced recombinant 
N-terminal fragment N-p53, CHO-derived, Phe213-Cys685, with a C-terminal 
10-His tag (R&D systems) was tested on EC proliferation, apoptosis and 
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differentiation. The commercially available insect cell produced recombinant 
N-p40 N-terminal fragment (Millipore) was tested for EC differentiation. 
4.1.1 ADAMTS4 N-p53 and N-p40 inhibited in vitro capillary network 
formation in a dose-dependent manner 
 ECs rapidly aligned and formed hollow tubular structures within 6-8 
hours when cultured on Matrigel (Madri and Pratt 1986). Premixed EC 
suspensions with different concentrations of either N-p53 or N-p40 were 
plated onto a pre-formed Matrigel and the extent of capillary network 
formation were monitored. The capillary network formation was documented 
at 6 h after ECs were plated onto Matrigel. As shown in Fig 4.1B, both N-p53 
and N-p40 significantly inhibited EC tube formation in a dose-dependent 
manner. This result suggests that the naturally occurring ADAMTS4 





Fig 4.1- ADAMTS4 fragments inhibited EC capillary network formation 
in a dose-dependent manner - A. Schematic representation of the domain 
structure of ADAMTS4 and its naturally occurring N-terminal fragments N-
p53 and N-p40. B. Both N-p53 and N-p40 inhibited EC tube formation. Scale 
bar represents 100 μM. 
 
4.1.2 ADAMTS4 N-p53 induced endothelial cell apoptosis in the presence 
of VEGF 
 EC apoptosis is one of the mechanisms that is a necessary step during 
blood vessel formation required for EC remodelling and to form stable vessels 
(Holash, Wiegand et al. 1999). Induction of EC apoptosis is also one of the 
mechanisms utilized by anti-angiogenic molecules to inhibit angiogenesis 
(Sulochana, Fan et al. 2005). To examine if N-p53 has the ability to induce 
apoptosis in ECs in the presence of a pro-angiogenic factor and survival factor 
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such as VEGF, EC apoptosis assay were performed by incubating cells for 24 
h with angiogenic factors or angiogenic factors in the presence of recombinant 
protein N-p53. After N-p53 treatment, the degree of cell apoptosis was 
analyzed by detection of DNA fragmentation. 
 As shown in Fig 4.2, VEGF prevents ECs from undergoing apoptosis. 
However, when N-p53 was added to the medium supplemented with VEGF, 
the EC apoptotic value was significantly increased. These results indicate that 
N-p53 induced EC apoptosis even in the presence of angiogenic growth factor. 
Taken together, N-p53 can potently induce EC apoptosis in a dose dependent 
manner in the presence of VEGF. 
 
Fig 4.2 - N-p53 induced EC apoptosis in the presence of VEGF - N-p53 
potently induced EC apoptosis in the presence of 15 ng/ml VEGF. 2%FBS 









4.1.3 ADAMTS4 N-p53 inhibited VEGF-induced endothelial cell 
proliferation 
 Vigorous EC proliferation is indispensable during the process of 
angiogenesis, which can be stimulated by VEGF, bFGF or serum (Semenza 
2007). To test if N-p53 influences EC proliferation, bromodeoxyuridine 
(BrdU) labeling method was used. BrdU is an analogue of thymidine. It can 
substitute for thymidine during DNA replication and incorporates into newly 
synthesized DNA strands of actively proliferating cells (Cappella, Gasparri et 
al. 2008). The incorporated BrdU can then be detected by anti-BrdU antibody, 
thus indicating cells that are specifically in proliferative status. 
 In our EC proliferation experiment, equal number of cells was 
incubated for 24 h with VEGF or VEGF plus recombinant N-p53 protein at 
different concentrations, prior to BrdU detection. Control cells were incubated 
with basal medium (2% FBS) without VEGF. As shown in Fig 4.3, VEGF 
significantly stimulated EC proliferation compared to control. In addition, N-




Fig 4.3 - N-p53 inhibited VEGF-stimulated EC proliferation in a dose-
dependent manner - N-p53 potently inhibited VEGF-stimulated (15 ng/ml) 
EC proliferation in a dose dependent manner. 2% FBS control was set to 1.   
Results are relative EC proliferation of three independent experiments.** 
p<0.01. 
 
4.2 Overexpression of ADAMTS4 N-p53 promotes melanoma growth in 
mice 
4.2.1 Establishment of stable B16F10 mouse melanoma cell line 
overexpressing N-p53 
 To investigate the role of the naturally occurring N-terminal fragment 
of ADAMTS4 in tumor progression stable mouse N-p53 overexpressing 
B16F10 cell lines were created. For this, an expression construct named N-p53 
was created by PCR amplifying the N-p53 fragment from the FL-WT 
construct and subcloning it into the multiple cloning sites of the mammalian 
expression vector pEF6/V5-His TOPO vector (Invitrogen, USA) (Fig 4.4A). 
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This construct also uses the native signal peptide of the protein for secretion 
into the media. 
 Plasmid N-p53 was transfected into B16F10 cells and stable clones 
were selected as described in section 3.2.1. The highest expressing clones 
designated as B16/N-p53a, B16/N-p53b, and B16/N-p53c were further 
analysed for relative expression levels. In contrast, vector-transfected B16 
colonies were pooled and designated as B16/TOPO and used as control cells. 
 N-p53 expression was confirmed with Western blotting using anti-V5 
tag antibody. As shown in Fig 4.4B, N-p53 expressed by stable cell lines could 
be detected at around 53 kDa in the conditioned medium. All three lines 
showed significant high expression (B16/N-p53a, B16/N-p53b and B16/N-
p53c). No corresponding signal was detected in B16/TOPO cells. The 
expression level of B16/N-p53c was slightly higher than the others. 
 To further examine the homogeneity of established stable cell lines, 
immunostaining of B16/N-p53a and B16/N-p53c cells with anti-V5 antibody 
were performed as described in section 3.2.1. As shown in Fig 4.4C, specific 
staining was only observable in B16/N-p53a and B16/N-p53c cells and not in 
B16/TOPO. It is also noted that more than 95% of the cells were stained 
positive, demonstrating the high purity of B16 stable cell lines that 
overexpress ADAMTS4 N-terminal fragment. 
 Taken together, stable transfection of N-p53 overexpression construct 
into B16 cells resulted in enhanced N-p53 expression in three lines B16/N-
p53a, B16/N-p53b and B16/N-p53c with high purity. B16/N-p53c with the 
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highest expression was chosen for studies and henceforth will be referred to as 
B16/N-p53. 
 
Fig 4.4 - Selection of N-p53-overexpressing B16 stable cell lines - A. 
Schematic representation of ADAMTS4 N-p53 construct. The C-terminally 
located epitope tags are indicated as a legend below. B. Expression of N-p53 
was detected by Western blotting using anti-V5 antibody. C. Immunostaining 
of B16 positive stable cell lines with anti-V5 antibody. Secondary antibody 
used was anti-mouse IgG conjugated with Alexa fluor 568. N-p53 staining was 
shown as red fluorescence. Nucleus was stained blue by DAPI. 
4.2.2 Overexpression of N-p53 did not affect cell proliferation in vitro 
 To determine whether cell proliferation is influenced by the 
transfection process or overexpression of N-p53, the in vitro growth kinetics 
of the stable cell lines (B16/TOPO and B16/N-p53) were monitored as 
described in section 3.2.2. As shown in Fig. 4.5, there was no significant 
difference in cellular proliferation of B16 cells between control stable cell line 
and N-p53 overexpressing stable cell line. This result indicated that the in 
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vitro growth characteristic of this stable cell line was not changed by the 
increased expression of N-p53 or by the transfection process. 
 
Fig 4.5 - Growth kinetics of N-p53 stable cell line - In vitro growth rates 
were not changed in N-p53 -overexpressing B16 stable cell line (B16/N-p53) 
comparing to empty vector-transfected control cell line (B16/TOPO). 
 
4.2.3 Overexpression of N-terminal autocatalytic fragment (N-p53) 
promotes melanoma growth in mice 
 To investigate the role of ADAMTS4 N-terminal fragment in tumor 
progression, mouse tumorigenesis assay was performed as described in section 
3.2.3. 
 Tumor volume was measured every day after tumors became visible on 
day 9. As shown in Fig 4.6B, tumor volume increased dramatically in B16/N-
p53 tumors at all timepoints after the early growth phase. At the end of the 
experiments (16 days after tumor cell inoculation), tumors were harvested and 
carefully excised and weighed, it was found that tumor weight from N-p53-
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overexpressing B16 cells were enhanced 3-fold compared to control (Fig 
4.6C). 
 Mouse tumors from B16/N-p53 and B16/TOPO of each individual 
mouse at day 16 are shown in Fig 4.6A. Although, the in vitro growth rate of 
N-p53 overexpressing cells and control cells were identical, in vivo tumor 
growth were significantly enhanced in tumors formed from B16/N-p53 cells. 
 
Fig 4.6 - Overexpression of N-p53 promoted tumor growth in vivo - A. 
Each pair of tumor (either from B16/TOPO or B16/N-p53 cells) was extracted 
from the same mouse. B. Tumor growth curve comparing B16/N-p53 with 
B16/TOPO. Tumor volume was measured daily from 9 days post s.c 
inoculation in C57Bl/6J on day 0 (n=7). Plots represent the mean tumor size 
(± SEM). C. Tumor weights of mice injected with B16/N-p53 or B16/TOPO 
post sacrifice on day 16 (n=7). Plots represent the relative mean tumor weight 
(± SEM). **P<0.05. 
 
 In order to confirm that the observed increase in tumor growth was as a 
result of overexpressed N-p53 protein, total protein was extracted from N-p53 
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overexpressing tumors and subjected to Western blot analysis using the anti-
V5 antibody to detect the exogenous protein. Results confirmed that N-p53 
overexpressing tumors indeed expressed the exogenous protein while no 
expression was detected in the control vector overexpressing tumors (Fig 4.7). 
 
Fig 4.7 - Tumor lysates express exogenous N-p53 - Immunoblot confirming 
the presence of overexpressed exogenous protein in N-p53 tumor lysate, but 
not in corresponding TOPO vector tumor lysate. Beta actin acts as loading 
control. 
 
4.2.4 N-p53 promotes tumor growth by stimulating tumor angiogenesis 
 The contribution of tumor angiogenesis, proliferation and apoptosis 
was assessed to investigate the mechanisms of N-p53’s tumor promoting 
effect. 
 To investigate whether the enhanced tumor growth in B16/N-p53 was 
attributable to enhanced tumor angiogenesis, blood vessel density of various 
tumors were evaluated. Immunofluorescence staining of tumor tissue sections 
with anti-CD31 antibody revealed an increase in tumor vascularization in N-
p53 overexpressing tumors compared with control tumors (Fig 4.8A, left 
panels, tumor vessels in red). The average number of vessels per field 
calculated as described in section 3.2.4 was increased by 20% in N-p53 
overexpressing tumors (Fig. 4.8B). This strongly suggests that continued 
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presence of high level of N-p53 in the tumor milieu enhances tumor 
angiogenesis and hence tumor growth in mice. 
 To find out whether the enhanced growth in N-p53-overexpressing 
tumors is a result of enhanced tumor cell proliferation, tumor cell proliferation 
was examined by immunostaining with an antibody to a novel proliferation 
marker PhosphoHistone H3 (pHH3). 
 As shown in Fig. 4.8A (middle panels), approximately around 10% 
tumor cells were pHH3-positive in both tumors. The average number of 
proliferating cells per microscopic field quantified as described in section 
3.2.4 showed that there was no significant difference of cell proliferation 
between control and N-p53-overexpressing tumors (Fig. 4.8C). 
 Since cell proliferation was not changed in N-p53-overexpressing B16 
tumors (Fig. 4.8A, middle panels and 4.8C), it was analysed whether reduced 
tumor cell apoptosis was a reason for enhanced tumor growth. TUNEL 
staining was performed to assess the amount of tumor cell apoptosis. 
 As shown in Fig. 4.8A (right panels), TUNEL staining results showed 
no difference in the number of apoptotic tumor cells (green dots) in N-p53-
overexpressing B16 tumors compared to B16/TOPO control tumors. The 
average number of apoptotic cells calculated as described in section 3.2.4 is 






Fig 4.8 - N-p53 influence on tumor angiogenesis, tumor cell proliferation 
and apoptosis - A. N-p53 influences tumor angiogenesis but not tumor cell 
proliferation or apoptosis. Immunofluorescence staining with anti-CD31 
antibody (left panels), anti-Phospho-Histone H3 antibody (middle panels) and 
In-situ TUNEL staining (right panels) of tumor sections from B16/TOPO or 
B16/N-p53 tumors are shown. Scale bars represent 100μm for CD31 staining 
and 20 μm for Phospho-Histone H3 and TUNEL. B-D. Quantification of 
tumor blood vessel, tumor cell proliferation and tumor apoptosis. Comparison 
of the relative number of blood vessels, proliferating cells and apoptotic cells 
per field. Plots represent the relative mean vessel number, proliferating cell 
number and apoptotic cell number analyzed for 3 fields per section, 3 sections 
per tumor (± SEM). **P<0.005. 
 
 In conclusion, these results demonstrated that the enhanced tumor 
growth by N-p53 overexpression in B16 cells is an indirect effect of enhanced 
tumor angiogenesis however with no effect on tumor cell proliferation or 





4.3 Overexpression of ADAMTS4 N-p53-E362A inhibits in vivo melanoma 
tumor growth 
 4.3.1 Establishment of stable B16F10 mouse melanoma cell line 
overexpressing N-p53-E362A 
 To investigate whether the tumor promoting activity of the N-terminal 
fragment of ADAMTS4 is also dependent on the catalytic activity of the 
enzyme, stable mouse N-p53 mutant-overexpressing B16F10 cell lines were 
created. The expression construct N-p53-E362A was PCR amplified from the 
FL-E362A construct and subcloned  into the multiple cloning sites of the 
mammalian expression vector pEF6/V5-His TOPO vector (Invitrogen, USA) 
(Fig 4.9A). This construct also uses the native signal peptide of the protein for 
secretion into the media. 
 Plasmid N-p53-E362A was transfected into B16F10 cells and stable 
clones were selected as described in section 3.2.1.  The highest expressing 
clones designated as B16/N-p53-E362Aa, B16/N-p53-E362Ab, and B16/N-
p53-E362Ac were further analysed for relative expression levels. In contrast, 
vector-transfected B16 colonies were pooled and designated as B16/TOPO 
and used as control cells. 
 N-p53-E362A expression was confirmed with Western blotting using 
anti-V5 tag antibody. As shown in Fig. 4.9B, N-p53-E362A expressed by 
stable cell lines could be detected at 53 kDa in the conditioned medium. All 
three lines showed significant high expression (B16/N-p53-E362Aa, B16/N-
p53-E362Ab and B16/N-p53-E362Ac). No corresponding signal was detected 
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in B16/TOPO cells. The expression level of N-p53-E362Ac was slightly 
higher than the others. 
 
Fig 4.9 - Selection of N-p53-E362A-overexpressing B16 stable cell lines - 
A. Schematic representation of ADAMTS4 N-p53-E362A construct. The C-
terminally located epitope tags are indicated as a legend below. B. Expression 
of N-p53-E362A was detected by Western blotting using anti-V5 antibody. C. 
Immunostaining of N-p53-E362A positive stable cell lines with anti-V5 
antibody. Secondary antibody used was anti-mouse IgG conjugated with Alexa 
fluor 568. N-p53-E362A staining was shown as red fluorescence. Nucleus was 
stained blue by DAPI. 
 
 To further examine the homogeneity of established stable cell lines, 
immunostaining of two of the lines B16/N-p53-E362Ab and B16/N-p53-
E362Ac cells with anti-V5 antibody were performed. As shown in Fig. 4.9C, 
specific staining was only observable in B16/N-p53-E362Ab and B16/N-p53- 
but not B16/TOPO It is also noted that more than 95% of the cells were 




 Taken together, stable transfection of N-p53-E362A overexpression 
construct into B16 cells resulted in enhanced expression in three lines, B16/N-
p53-E362Aa, B16/N-p53-362Ab and B16/N-p53-E362Ac. B16/N-p53-
E362Ac with the highest expression was chosen for studies and henceforth 
will be referred to as B16/N-p53-E362A. 
4.3.2 Overexpression of N-p53-E362A did not affect in vitro cell 
proliferation  
 To determine whether cell proliferation is influenced by the 
transfection process or overexpression of N-p53-E362A, the in vitro growth 
kinetics of the stable cell lines (B16/TOPO and B16/N-p53-E362A) were 
monitored as described in section 3.2.2. As shown in Fig. 4.10, there was no 
significant difference in cellular proliferation of B16 cells between control 
stable cell line and N-p53-E362A overexpressing stable cell line. This result 
indicated that the in vitro growth characteristic of this stable cell line was not 






Fig 4.10 - Growth kinetics of N-p53-E362A stable cell line - In vitro growth 
rates were not changed in N-p53-E362A -overexpressing B16 stable cell line 
(B16/N-p53-E362A) comparing to empty vector-transfected control cell line 
(B16/TOPO). 
 
4.3.3 ADAMTS4 N-p53-E362A overexpressing stable B16F10 cell clones 
inhibit melanoma growth in vivo 
 To investigate whether the tumor promoting effect of ADAMTS4 N-
terminal fragment is dependent on the catalytic activity of the protein, mouse 
tumorigenesis assay was carried out as described in section 3.2.3. 
 Tumor volume was measured every day after tumors became visible on 
day 9. As shown in Fig. 4.11B, tumor volume decreased dramatically in 
B16/N-p53-E362A at all timepoints after the early growth phase. At the end of 
the experiments (14 days after tumor cell inoculation), tumors were harvested 
and carefully excised and weighed, it was found that tumor weight from N-





Fig 4.11 - Overexpression of N-p53-E362A inhibited tumor growth in vivo 
- A. Each pair of tumor (either from B16/TOPO or B16/N-p53-E362A cells) 
was extracted from the same mouse. B. Tumor growth curve comparing 
B16/N-p53-E362A with B16/TOPO. Tumor volume was measured daily from 9 
days post s.c inoculation in C57Bl/6J on day 0 (n=7). Plots represent the 
mean tumor size (± SEM). C. Tumor weights of mice injected with B16/N-p53-
E362A or B16/TOPO post sacrifice on day 16 (n=7). Plots represent the 
relative mean tumor weight (± SEM). *P<0.05. 
 
 Mouse tumors from B16/N-p53-E362A and B16/TOPO of each 
individual mouse at day 16 are shown in Fig 4.11A. Although, the in vitro 
growth rate of N-p53-E362A overexpressing cells and control cells were 
identical, in vivo tumor growth were significantly reduced in tumors formed 
from B16/N-p53-E362A cells. 
 In order to confirm that the observed reduction in tumor growth was as 
a result of overexpressed N-p53-E362A protein, total protein was extracted 
from N-p53-E362A overexpressing tumors and subjected to Western blot 
analysis using the anti-V5 antibody to detect the exogenous protein. Results 
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confirmed that N-p53-E362A overexpressing tumors indeed expressed the 
exogenous protein while no expression was detected in the control vector 
overexpressing tumors (Fig 4.12). 
 
Fig 4.12 - Tumor lysates express exogenous N-p53-E362A - Immunoblot 
confirming the presence of overexpressed exogenous protein in N-p53-E362A 
tumor lysate, but not in corresponding TOPO vector tumor lysate. Note the 
non-specific band in both lanes. Beta actin acts as loading control. 
 
4.3.4 N-p53-E362A suppressed melanoma growth by inhibiting tumor 
angiogenesis, enhancing tumor cell apoptosis without affecting tumor cell 
proliferation  
The contribution of tumor angiogenesis, proliferation and apoptosis 
was assessed to investigate the mechanisms of N-p53-E362A’s tumor 
inhibitory effect. 
 To investigate whether the diminished tumor growth in B16/N-p53-
E362A was attributable to reduced tumor angiogenesis, blood vessel density 
of various tumors were evaluated. Immunofluorescence staining of tumor 
tissue sections with anti-CD31 antibody revealed a 2-fold decrease in tumor 
vascularization in N-p53-E362A overexpressing tumors compared with 
control tumors (Fig. 4.13A, left panels, tumor vessels in red). The average 
number of vessels per field calculated as described in section 3.2.4 was 
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significantly decreased by 2-fold in N-p53-E362A overexpressing tumors 
(Fig. 4.13B). This strongly suggests that continued presence of high level of 
N-p53-E362A in the tumor milieu inhibits tumor angiogenesis and hence 
tumor growth in mice. 
 To find out whether the reduced growth in N-p53-E362A-
overexpressing tumors is a result of reduced tumor cell proliferation, tumor 
cell proliferation was examined by immunostaining with an antibody to a 
novel proliferation marker PhosphoHistone H3 (pHH3). 
 As shown in Fig. 4.13A (middle panels), approximately 20% tumor 
cells were pHH3-positive in both tumors. The average number of proliferating 
cells per microscopic field quantified as described in section 3.2.4 showed that 
there was no significant difference of cell proliferation between control and N-





Fig 4.13 - N-p53-E362A influence on tumor angiogenesis, tumor cell 
proliferation and apoptosis - A. N-p53-E362A influences tumor angiogenesis 
and apoptosis but not tumor cell proliferation. Immunofluorescence staining 
with anti-CD31 antibody (left panels), anti-Phospho-Histone H3 antibody 
(middle panels) and In-situ TUNEL staining (right panels) of tumor sections 
from B16/TOPO or B16/N-p53-E362A tumors are shown. Scale bars 
represent 100μm for CD31 staining and 20 μm for Phospho-Histone H3 and 
TUNEL. B-D. Quantification of tumor blood vessel, tumor cell proliferation 
and tumor apoptosis. Comparison of the relative number of blood vessels, 
proliferating cells and apoptotic cells per field. Plots represent the relative 
mean vessel number, proliferating cell number and apoptotic cell number 
analyzed for 3 fields per section, 3 sections per tumor (± SEM). **P<0.005. 
 
 Since cell proliferation was not changed in N-p53-E362A-
overexpressing B16 tumors (Fig. 4.13A, middle panels and 4.13C), it was 
analysed whether enhanced tumor cell apoptosis was a reason for reduced 




 As shown in Fig. 4.13A (right panels), TUNEL staining results showed 
enhanced number of apoptotic tumor cells (green dots) in N-p53-E362A-
overexpressing B16 tumors compared to B16/TOPO control tumors. The 
average number of apoptotic cells quantified as described in section 3.2.4 is 
shown in Fig. 4.13D. 
 In conclusion, these results demonstrated that the reduced tumor 
growth by N-p53-E362A overexpression in B16 cells is an indirect effect of 
reduced tumor angiogenesis along with enhanced tumor cell apoptosis, 





Role of ADAMTS4 C-terminal ancillary domains 
in tumorigenesis  
5.1 Overexpression of C-terminal ancillary domains inhibits melanoma 
growth in mice  
 Our studies demonstrated that ADAMTS4 promoted B16 melanoma 
tumor growth in vivo and the catalytic activity of the protein is important for 
this pro-tumorigenic role. However surprisingly, the enzyme active mutant 
form of the protein was found to inhibit tumor growth. Thus, in order to 
determine the exact domains responsible for this anti-tumorigenic function of 
ADAMTS4 mutant, domain deletion studies were undertaken. Recombinant 
constructs representing the various C-terminal regions of the protein were 
generated and their effects on tumor progression were analyzed. 
5.1.1 Establishment of stable B16F10 mouse melanoma cell line 
overexpressing C-terminal ancillary domains (D-S and T-S) 
 In order to determine the exact domains responsible for the anti-
tumorigenic function of ADAMTS4 enzyme inactive mutant, sequential 
domain deletion constructs representing the C-terminal regions from 
Disintegrin-like domain to Spacer domain (D-S) and TSR domain to spacer 
domain (T-S). Both constructs did not contain the catalytic domain and 
therefore were enzymatically inactive. 
146 
 
 In order to obtain the stable mouse D-S and T-S overexpressing 
B16F10 cell lines, expression constructs D-S and T-S were created by PCR 
amplifying these regions from FL-WT and subcloning into the multiple 
cloning sites of the mammalian expression vector pSecTag2B vector 
(Invitrogen, USA) (Fig 5.1A). pSecTag2B expression vector was designed for 
high-level stable and transient expression in mammalian hosts. It contains 
CMV promoter for efficient and high-level expression of the protein of 
interest; Zeocin resistance gene for selection of the transfectants; murin Ig κ-
chain leader sequence at N-terminal for protein secretion; c-myc epitope and 
polyhistidine-tag at C-terminal for protein detection and purification. 
 Plasmids D-S and T-S were transfected into B16F10 cells by lipid-
based transfection. Cells that had taken up this plasmid were selected by 
Zeocin at 400 μg/ml. Multiple Zeocin resistant single colonies were isolated 
individually. Isolated colonies were expanded by subculture and analysed for 
the expression of D-S and T-S. The highest expressing clones designated as 
B16/D-Sa, B16/D-Sb, and B16/T-Sa, B16/T-Sb were further analysed for 
relative expression levels. In contrast, vector-transfected B16 colonies were 
pooled and designated as B16/pSectag and used as control cells. 
 D-S and T-S expression in the conditioned medium was confirmed 
with Western blotting using anti-His tag antibody. As shown in Fig. 5.1B, D-S 
and T-S expressed by stable cell lines could be detected at around 50 kDa and 
42 kDa respectively. All lines showed significant expression (B16/D-Sa, 
B16/D-Sb and B16/T-Sa, B16/T-Sb). No corresponding signal was detected in 
B16/pSecTag cells. The expression level of B16/D-Sb and B16/T-Sb were 
slightly higher than the other corresponding line. The purity of these lines was 
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also confirmed by immunostaining for the exogenous protein (data not 
shown). 
 
Fig 5.1 - Selection of D-S and T-S overexpressing B16 stable cell lines - A. 
Schematic representation of ADAMTS4 D-S and T-S constructs. The C-
terminally located epitope tags are indicated as a legend below. B. Expression 
of D-S and T-S was detected by Western blotting using anti-His antibody. C. 
In vitro growth rates were not changed in D-S and T-S -overexpressing B16 
stable cell line (B16/D-S and B16/T-S) comparing to empty vector-transfected 
control cell line (B16/pSecTag). 
 
 Taken together, stable transfection of D-S and T-S overexpression 
constructs into B16 cells resulted in enhanced expression in two lines for each 
construct, B16/D-Sa, B16/D-Sb and B16/T-Sa, B16/T-Sb. The lines with the 
highest expression were chosen for studies and henceforth will be referred to 
as B16/D-S and B16/T-S. 
 In addition, to determine whether cell proliferation is influenced by the 
transfection process or overexpression of D-S and T-S, the in vitro growth 
kinetics of the stable cell lines (B16/pSecTag, B16/D-S and B16/T-S) were 
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monitored as described in section 3.2.2. As shown in Fig. 5.1C, there was no 
significant difference in cellular proliferation of B16 cells between control 
stable cell line and D-S and T-S overexpressing stable cell lines. This result 
indicated that the in vitro growth characteristics of these stable cell lines were 
not changed by the increased expression of D-S and T-S or by the transfection 
process. 
5.1.2 Overexpression of ADAMTS4 C-terminal ancillary domains inhibits 
melanoma growth in mice 
 To investigate the effects of the C-terminal ancillary domains lacking 
the catalytic activity on tumor progression, mouse tumorigenesis assay was 
carried out as described in section 3.2.3. using the recombinant constructs D-S 
and T-S. 
 Tumor volume was measured every alternate day after tumors became 
visible on day 8. As shown in Fig. 5.2A and B, tumor volume decreased 
dramatically in both B16/D-S and B16/T-S compared to their respective 
controls in the same mouse. At the end of the experiments (14 days after 
tumor cell inoculation), tumors were harvested and carefully excised and 
weighed, it was found that tumor weight from both D-S and T-S 
overexpressing B16 cells were reduced 1.5-fold  and 2-fold compared to 
respective controls (Fig. 5.2C and D). 
 Although, the in vitro growth rate of D-S and T-S overexpressing cells 
and control cells were identical, in vivo tumor growth were significantly 
decreased in tumors formed from B16/D-S and B16/T-S cells. This suggested 
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that the inhibitory effects of the ADAMTS4 active-site mutant could be 
attributed to one of the domains common to both D-S and T-S. 
 
Fig 5.2 - Overexpression of D-S and T-S inhibited tumor growth in vivo - 
A and B. Tumor growth curve comparing B16/D-S and B16/T-S with 
B16/pSecTag. Tumor volume was measured every alternate day from 8 days 
post s.c inoculation in C57Bl/6J on day 0 (B16/D-S, n=4; B16/T-S, n=7). 
Plots represent the mean tumor size (± SEM). C and D. Tumor weights of mice 
injected with B16/D-S, B16/T-S or B16/pSecTag post sacrifice on day 14 
(B16/D-S, n=4; B16/T-S, n=7). Plots represent the relative mean tumor 
weight (± SEM). **P<0.05. 
 
5.1.3 D-S and T-S suppressed melanoma growth by inhibiting tumor 
angiogenesis, enhancing tumor cell apoptosis without affecting tumor cell 
proliferation  
The contribution of tumor angiogenesis, proliferation and apoptosis 




 To investigate whether the diminished tumor growth in B16/D-S and 
B16/T-S was attributable to reduced tumor angiogenesis, blood vessel density 
of various tumors were evaluated. Immunofluorescence staining of tumor 
tissue sections with anti-CD31 antibody revealed a 1-fold decrease in tumor 
vascularization in B16/D-S and B16/T-S overexpressing tumors compared 
with control tumors as seen by the average number of vessels per field 
calculated as described in section 3.2.4 (Fig. 5.3A and D). This strongly 
suggests that continued presence of high level of D-S and T-S in the tumor 
milieu inhibits tumor angiogenesis and hence tumor growth in mice. 
 To find out whether the reduced growth in D-S and T-S overexpressing 
tumors is a result of reduced tumor cell proliferation, tumor cell proliferation 
was examined by immunostaining with an antibody against the conventional 
proliferation marker proliferating cell nuclear antigen (PCNA). As shown in 
Fig. 5.3B and E, the average number of proliferating cells per microscopic 
field quantified as described in section 3.2.4 showed that there was no 





Fig 5.3 - D-S and T-S influence on tumor angiogenesis, tumor cell 
proliferation and apoptosis - A-C. D-S influences tumor angiogenesis and 
apoptosis but not tumor cell proliferation. B-D. T-S influences tumor 
angiogenesis and apoptosis but not tumor cell proliferation. Quantification of 
tumor blood vessel, tumor cell proliferation and tumor apoptosis. Comparison 
of the relative number of blood vessels, proliferating cells and apoptotic cells 
per field. Plots represent the relative mean vessel number, proliferating cell 
number and apoptotic cell number analyzed for 3 fields per section, 3 sections 
per tumor (± SEM). **P<0.005. 
 
 Since cell proliferation was not changed in D-S and T-S 
overexpressing B16 tumors (Fig. 5.3B and E), it was analysed whether 
enhanced tumor cell apoptosis was a reason for reduced tumor growth. 
TUNEL staining was performed to assess the amount of tumor cell apoptosis. 
As shown in Fig. 5.3C and F, the average number of apoptotic cells quantified 
as described in section 3.2.4 showed that there was approximately 2-fold 
increase in tumor cell apoptosis in both D-S and T-S tumors. 
 In conclusion, these results demonstrated that the reduced tumor 
growth by D-S and T-S overexpression in B16 cells is an indirect effect of 
reduced tumor angiogenesis along with enhanced tumor cell apoptosis, 
without affecting tumor cell proliferation. 
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5.2. Overexpression of C-terminal domains lacking the TSR does not 
affect in vivo melanoma tumor growth  
 Our results using the D-S and T-S recombinant constructs 
demonstrated that the anti-tumorigenic function of ADAMTS4 active-site 
mutant could be attributed to a domain common to both these constructs. In 
order to determine whether it is the TSR domain that is present in both these 
constructs is responsible for this role, a deletion construct lacking the TSR 
domain was created from the cysteine-rich region to the spacer domain named 
C-S. 
5.2.1 Establishment of stable B16F10 mouse melanoma cell line 
overexpressing C-terminal ancillary domains (C-S) 
 In order to obtain the stable mouse C-S overexpressing B16F10 cell 
lines, expression construct C-S was created by PCR amplifying this region 
from FL-WT and subcloning into the multiple cloning sites of the mammalian 
expression vector pSecTag2B vector (Invitrogen, USA) (Fig 5.4A). 
 Plasmid C-S was transfected into B16F10 cells and stable clones 
selected as described in section 3.1.1. Isolated colonies were expanded by 
subculture and analysed for the expression of C-S. Only one high expressing 
clone was obtained designated B16/C-S. In contrast, vector-transfected B16 
colonies were pooled and designated as B16/pSecTag and used as control 
cells. 
 C-S expression in the conditioned medium was confirmed with 
Western blotting using anti-His tag antibody. As shown in Fig. 5.4B, C-S 
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expressed by stable cell line could be detected at around 31 kDa. The line 
showed significant expression (B16/C-S). No corresponding signal was 
detected in B16/pSecTag cells. The purity of these lines was also confirmed 
by immunostaining for the exogenous protein (data not shown). 
 
Fig 5.4 - Selection of C-S overexpressing B16 stable cell lines - A. Schematic 
representation of ADAMTS4 C-S. The C-terminally located epitope tags are 
indicated as a legend below. B. Expression of C-S was detected by Western 
blotting using anti-His antibody. C. In vitro growth rates were not changed in 
C-S overexpressing B16 stable cell line (B16/C-S) comparing to empty vector-
transfected control cell line (B16/pSecTag). 
 
 In addition, to determine whether cell proliferation is influenced by the 
transfection process or overexpression of C-S, the in vitro growth kinetics of 
the stable cell lines (B16/pSecTag and B16/C-S) were monitored as described 
in section 3.2.2. As shown in Fig. 5.4C, there was no significant difference in 
cellular proliferation of B16 cells between control stable cell line and C-S 
overexpressing stable cell line. This result indicated that the in vitro growth 
characteristics of these stable cell lines were not changed by the increased 
expression of C-S or by the transfection process. 
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5.2.2 Overexpression of ADAMTS4 C-terminal ancillary regions lacking 
TSR domain does not affect tumor growth in vivo 
 To investigate whether the TSR domain is responsible for the anti-
tumorigenic effects of the ADAMTS4 active site mutant the effects of the C-
terminal ancillary domains lacking the TSR domain on tumor progression, 
mouse tumorigenesis assay was carried out as described in section 3.2.3. using 
the recombinant constructs C-S. 
 Tumor volume was measured every alternate day after tumors became 
visible on day 8. As shown in Fig. 5.5A, no effect on tumor volume was 
observed compared to control in the same mouse. At the end of the 
experiments (14 days after tumor cell inoculation), tumors were harvested and 
carefully excised and weighed, it was found that tumor weight from C-S 
overexpressing B16 cells did not change  compared to its control (Fig. 5.5B). 
 This suggested that the inhibitory effects of the ADAMTS4 active-site 





Fig 5.5 - Overexpression of C-S had no effect tumor growth in vivo - A.  
Tumor growth curve comparing B16/C-S with B16/pSecTag. Tumor volume 
was measured every alternate day from 8 days post s.c inoculation in 
C57Bl/6J on day 0 (n=6). Plots represent the mean tumor size (± SEM). B. 
Tumor weights of mice injected with B16/C-S or B16/pSecTag post sacrifice 
on day 14 (B16/C-S, n=6). Plots represent the relative mean tumor weight (± 
SEM). **P<0.05. 
 
5.2.3 Overexpression of ADAMTS4 C-S did not affect tumor 
angiogenesis, tumor cell proliferation or tumor cell apoptosis 
 Tumor angiogenesis, proliferation and apoptosis were assessed to 
investigate whether there were any changes in these processes despite the   
observed lack of effect on tumor growth by C-S overexpression. 
 To investigate whether there was any effect on tumor angiogenesis, 
blood vessel density of various tumors were evaluated. Immunofluorescence 
staining of tumor tissue sections with anti-CD31 antibody revealed no 
difference in tumor vascularization in B16/C-S overexpressing tumors 
compared with control tumors as seen by the average number of vessels per 
field calculated as described in section 3.2.4 (Fig. 5.6A). This suggests that 
there was no effect on tumor angiogenesis consistent with the lack of effect on 
tumor growth in mice. 
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 To find out whether tumor cell proliferation was affected the 
proliferation index was examined by immunostaining with an antibody against 
the conventional proliferation marker proliferating cell nuclear antigen 
(PCNA). As shown in Fig. 5.6B, the average number of proliferating cells per 
microscopic field quantified as described in section 3.2.4 showed that there 
was no significant difference of cell proliferation between control and C-S 
overexpressing tumors as well. 
 
Fig 5.6 - C-S influence on tumor angiogenesis, tumor cell proliferation and 
apoptosis - A-C. C-S has no effect on tumor angiogenesis, proliferation or 
apoptosis Quantification of tumor blood vessel, tumor cell proliferation and 
tumor apoptosis. Comparison of the relative number of blood vessels, 
proliferating cells and apoptotic cells per field. Plots represent the relative 
mean vessel number, proliferating cell number and apoptotic cell number 
analyzed for 3 fields per section, 3 sections per tumor (± SEM). **P<0.005. 
 
 Since both cell proliferation and angiogenesis were not changed in C-S 
overexpressing B16 tumors (Fig. 5.6A and B), it was analysed whether tumor 
cell apoptosis was affected. As shown in Fig. 5.6C, the average number of 
apoptotic cells quantified as described in section 3.2.4 showed that there was 
no change in tumor cell apoptosis in C-S tumors. 
 In conclusion, these results demonstrated that the lack of effects on 
tumor angiogenesis, proliferation and apoptosis corroborated the lack of effect 
on tumor growth upon overexpression of C-S.  This suggests that the effects 
on tumor angiogenesis and apoptosis observed in the case of the ADAMTS4 
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active site mutant as well as the other C-terminal regions (D-S and T-S) were 
most likely due to the TSR domain. 
5.3 Overexpression of TSR domain alone inhibits in vivo melanoma tumor 
growth  
 Our results demonstrated that the TSR domain is required for the anti-
tumorigenic effect of the ADAMTS4 active site mutant as well as the C-
terminal ancillary regions (D-S and T-S). In order to determine whether this 
domain can function alone and is sufficient to exert similar effects a 
recombinant TSR construct was created. 
5.3.1 Establishment of stable B16F10 mouse melanoma cell line 
overexpressing TSR 
 In order to obtain the stable mouse TSR overexpressing B16F10 cell 
lines, expression construct TSR was created by PCR amplifying this region 
from FL-WT and subcloning into the multiple cloning sites of the mammalian 
expression vector pSecTag2B vector (Invitrogen, USA) (Fig 5.7A).  
 Plasmid TSR was transfected into B16F10 cells and stable clones 
selected as described in section 3.1.1. Isolated colonies were expanded by 
subculture and analysed for the expression of TSR. . The highest expressing 
clones designated as B16/TSRa and B16/TSRb, were further analysed for 
relative expression levels. In contrast, vector-transfected B16 colonies were 
pooled and designated as B16/pSecTag and used as control cells. 
 TSR expression in the conditioned medium was confirmed with 
Western blotting using anti-His tag antibody. As shown in Fig. 5.7B, TSR 
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expressed by both stable cell lines could be detected at around 15 kDa. Both 
B16/TSRa and B16/TSRb showed significant expression. No corresponding 
signal was detected in B16/pSecTag cells. The purity of these lines was also 
confirmed by immunostaining for the exogenous protein (data not shown). 
However B16/TSRa with the higher expression was chosen for further studies 
and henceforth designated as B16/TSR. 
 
Fig 5.7 - Selection of TSR overexpressing B16 stable cell lines - A. 
Schematic representation of ADAMTS4 TSR. The C-terminally located epitope 
tags are indicated as a legend below. B. Expression of TSR was detected by 
Western blotting using anti-His antibody. C. In vitro growth rates were not 
changed in TSR overexpressing B16 stable cell line (B16/TSR) comparing to 
empty vector-transfected control cell line (B16/pSecTag). 
 
 In addition, to determine whether cell proliferation is influenced by the 
transfection process or overexpression of TSR, the in vitro growth kinetics of 
the stable cell lines (B16/pSecTag and B16/TSR) were monitored as described 
in section 3.2.2. As shown in Fig. 5.7C, there was no significant difference in 
cellular proliferation of B16 cells between control stable cell line and TSR 
overexpressing stable cell line. This result indicated that the in vitro growth 
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characteristics of these stable cell lines were not changed by the increased 
expression of TSR or by the transfection process. 
5.3.2 Overexpression of ADAMTS4 TSR inhibits tumor growth in vivo via 
inhibiting tumor angiogenesis and enhancing tumor apoptosis 
 To investigate whether TSR domain alone can function independently 
and is sufficient to exert its anti-tumorigenic, mouse tumorigenesis assay was 
carried out as described in section 3.2.3. using the recombinant constructs 
TSR. 
 Tumor volume was measured every third day after tumors became 
visible on day 6. As shown in Fig. 5.8A, tumor volume decreased dramatically 
in B16/TSR tumors compared to control in the same mouse. Although, the in 
vitro growth rate of TSR overexpressing cells and control cells were identical, 
in vivo tumor growth were significantly decreased in tumors formed from 
B16/TSR cells. This suggested that the ADAMTS4 TSR is sufficient and can 




Fig 5.8 - Overexpression of TSR inhibited tumor growth in vivo - A. 
Tumor growth curve comparing B16/TSR with B16/pSecTag. Tumor volume 
was measured every third day from 6 days post s.c inoculation in C57Bl/6J on 
day 0 (B16/TSR, n=6). Plots represent the mean tumor size (± SEM). B and C. 
TSR influences tumor angiogenesis and apoptosis. Quantification of tumor blood 
vessel and tumor apoptosis. Comparison of the relative number of blood vessels 
and apoptotic cells per field. Plots represent the relative mean vessel number and 
apoptotic cell number analyzed for 3 fields per section, 3 sections per tumor (± 
SEM). *P<0.05, **P<0.005. 
 
 The contribution of tumor angiogenesis, proliferation and apoptosis 
was assessed to investigate the mechanisms of TSR’s tumor inhibitory effect. 
To investigate whether the diminished tumor growth in B16/TSR was 
attributable to reduced tumor angiogenesis, blood vessel density of various 
tumors were evaluated. Immunofluorescence staining of tumor tissue sections 
with anti-CD31 antibody revealed a 3-fold decrease in tumor vascularization 
in B16/TSR overexpressing tumors compared with control tumors as seen by 
the average number of vessels per field calculated as described in section 3.2.4 
(Fig. 5.8B). This strongly suggests that continued presence of high level of 
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TSR in the tumor milieu inhibits tumor angiogenesis and hence tumor growth 
in mice. 
 To find out whether the reduced growth in TSR overexpressing tumors 
is a result of reduced tumor cell proliferation, tumor cell proliferation was 
examined by immunostaining with an antibody against the conventional 
proliferation marker proliferating cell nuclear antigen (PCNA). The average 
number of proliferating cells per microscopic field quantified as described in 
section 3.2.4 showed that there was no significant difference of cell 
proliferation between control and TSR overexpressing tumors (data not 
shown). 
 Since cell proliferation was not changed in TSR overexpressing B16 
tumors, it was analysed whether enhanced tumor cell apoptosis was a reason 
for reduced tumor growth. TUNEL staining was performed to assess the 
amount of tumor cell apoptosis. As shown in Fig. 5.8C, the average number of 
apoptotic cells quantified as described in section 3.2.4 showed that there was 
approximately 1-fold increase in tumor cell apoptosis in TSR overexpressing 
tumors. 
 In conclusion, these results demonstrated that the reduced tumor 
growth by TSR overexpression in B16 cells is an indirect effect of reduced 
tumor angiogenesis along with enhanced tumor cell apoptosis, with no effect 





Identification of novel C-terminal fragments of 
ADAMTS4 in cultured mammalian cells 
6.1 Expression and purification of recombinant His-tagged ADAMTS4 
 The above results demonstrated that the C-terminal ancillary regions of 
ADAMTS4 inhibited tumor growth in mouse melanoma. Although cleavages 
at the C-terminus of the protein have been previously reported, no cleavage at 
the N-terminal region such as within the catalytic domain has been reported so 
far. When we probed for ADAMTS4 protein in human tissue or cancer lysates 
with a C-terminal specific antibody, we observed multiple positive fragments 
in addition to the full-length protein, with C-p52 the most abundant (Fig. 3.2). 
This result suggests the likely presence of truncated ADAMTS4 C-terminal 
fragments containing the TSR domain in vivo. Since our results outlined in 
Chapter 5 revealed an anti-tumorigenic/anti angiogenic function of such 
fragments, we sought to validate whether such C-terminal ancillary-region 
only fragments are present in cells. 
 In order to determine whether C-terminal fragments of ADAMTS4 
were generated in cultured cells by cleavage at the N-terminus of the protein, 
the recombinant construct FL-WT was transfected into HEK 293T cells by 
lipid transfection method. Secreted protein in the conditioned medium was 
collected and subjected to partial purification by Ni-NTA based method 
utilising the C-terminally located 6X-His epitope tag in the recombinant FL-
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WT construct. The purified preparation was run on SDS-PAGE and the bands 
stained using coomassie blue stain. 
 As shown in Fig 6.1, the full-length mature ADAMTS4 protein 
migrated at around 75 kDa. Faint amounts of the zymogen form were also 
visible at around 100 kDa, probably due to protein from cellular debris in the 
purified preparation. Since the expressed protein was purified using the C-
terminally located 6X-His tag, it is most likely that the bands separated on 
SDS gel represent C-terminal fragments of ADAMTS4. The identity of these 
bands were analysed by tandem mass spectrometry (MS/MS). 
 
Fig 6.1 - Characterization of ADAMTS4 C-terminal fragments - 
Coomassie stained gel of partially purified recombinant ADAMTS4 from 
conditioned media of transiently transfected HEK293T cells showing inactive 
zymogen, mature active processed form and four probable C-terminal 





6.2 Mass spectrometric analysis of C-terminal fragments 
 Tandem mass spectrometry has been widely used for the analysis of 
individual protein sequences as well as the sequences of multiple proteins in a 
mixture. For mass spectrometry, the sequence of steps includes first isolation 
of a mixture of proteins from a source such as cell culture. The proteins are 
then separated on an SDS gel. They are then digested by proteolytic enzymes 
(trypsin, chymotrypsin, elastase) to yield shorter pieces (peptides). The 
resulting peptides are loaded onto an HPLC column coupled to a mass 
spectrometer. The peptides are ionized before entering the mass spectrometer 
(Steen and Mann 2004). A tandem MS/MS has two phases the first phase 
allows for determination of mass-to-charge ratio of the whole peptide (the 
precursor ion) and the second phase determines the masses of large number of 
smaller peptide fragments, each differing by a single amino acid, thus 
deducing the sequence of the protein (Hernandez, Müller et al. 2006). 
 The peptide mass fingerprint analysis from the MS/MS data was 
performed using the web-based tool MASCOT. MASCOT is a powerful 
probability based scoring software that computes the probability that the 
observed match between the experimental data and mass values calculated 
from a candidate peptide or protein sequence is a random event. The correct 
match, which is not a random event, then has a very low probability (Perkins, 
Pappin et al. 1999). 
 As shown in Table 6.1, the mature ADAMTS4 protein received the 
highest MASCOT score of 776. Bands 1, 2, 3 were also identified as 
ADAMTS4 as observed from the high MASCOT score as well as the 
predicted peptides listed with ion scores. Band 6 received a lower MASCOT 
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score with fewer peptide matches to ADAMTS4 than the other bands.  Bands 
4 and 5 were identified as alpha-tubulin and elongation factor-1-alpha.  
 













776 R.LVILGSGEEGPQVGPSAAQTLR.S (153) 
R.SFCAWQR.G (33) 




R.ALGYYYVLEPR.V (60)    
R.YGYNNVVTIPAGATHILVR.Q (90)   
R.YSGATAASETLSGHGPLAQPLTLQVL
VAGNPQDTR.L (147)   
 
ADAMTS4 








Band-2 593 R.GLNTPEDSDPDHFDTAILFTR.Q (44) 
R.SCNTEDCPTGSALTFR.E (129) 
K.SFPGPMDWVPR.Y (55) 







Band-3 614 R.SCNTEDCPTGSALTFR.E (121)   
K.SFPGPMDWVPR.Y (49)     
K.SFPGPMDWVPR.Y (14) 
R.ALGYYYVLEPR.V (55)     
R.VVDGTPCSPDSSSVCVQGR.C (123)     





Band-4 564 - α-tubulin 
Band-5  249 - Elongation 
factor-1-α1 





 The approximate molecular weights of the observed bands 1-4 were 
determined using the quantity one software (BioRad; Hercules, CA, USA) to 
be around 57 kDa, 52 kDa, 49 kDa and 25 kDa respectively. In conclusion, 
this result suggested that ADAMTS4 undergoes cleavage at the N-terminus to 
generate several C-terminal ancillary region-only fragments in cultured 
mammalian cells. 
6.3 N-terminal sequencing analysis of the major C-terminal fragment 
 Our results for ADAMTS4 expression in normal and tumor tissue 
lysates show a strong band at 50 kDa using antibody against the C-terminal 
region of ADAMTS4 (Fig 3.2). This band most likely corresponds to the 52 
kDa band 2 in Fig 6.1. Thus we chose to further characterize this protein band 
using protein N-terminal sequencing.  
 Protein N-terminal sequencing is based on the Edman degradation 
method, which determines the sequence of amino acids in a protein by 
sequencial chemical degradation from the N-terminus of the protein using 
Phenyl isothiocyanate (PITC). For Edman degradation, partially purified 
recombinant ADAMTS4 from cultured 293T cells were subjected to SDS-
PAGE and transferred onto a PVDF membrane. Protein band 2 was excised 
and subjected to protein sequencing.  
 The amino acid spectrum of the first five amino acids of protein band 2 
is shown in Fig 6.2. Residues 2, 3, 4 and 5 were identified to be aspartic acid 
(Asp/D), lysine (Lys/K), proline (Pro/P) and glutamic acid (Glu/E), which are 
residues 426-429 in the human ADAMTS4 protein sequence. This represents a 






Fig 6.2 - Amino acid spectrum of protein band 2 by N-terminal 
sequencing - Panel 1 shows the blank run, Panel 2 shows the PTH amino acid 
standard spectrum. Panels 3-7 show the first five amino acid residues of 
protein band 2. Residues 2, 3, 4 and 5 are respectively Asp, Lys, Pro and Glu. 
Residue 1 is ambiguous. 
 
 However, there was ambiguity in identification of the first residue. It 
has been frequently reported that the Edman degradation method is not 100% 
efficient. Several limitations of the method exist. Successful protein 
sequencing depends on the purity, amount of molecular weight of the sample. 
During sequential cleavage, cleavage efficiency is affected by the amino acid 
derivative being cleaved as well as the next amino acid in the chain. 
Incomplete cleavage often leads to amino acid background resulting in 
unreliable sequences. In addition, if a single protein band is contaminated with 
a mixture of many proteins of the same size, identification of the first residue 
becomes problematic. Thus, background amino acid contamination might 
interfere with the identification of the first one or two amino acids of the 
protein (http://biolchem.bs.jhmi.edu/tssf/Documents/SamplePrep.pdf). 
 Based on amino acid sequence, the theoretical molecular weight for 
band 2 is 45 kDa while the observed molecular weight is 52 kDa. This 
difference could be due to the presence of the C-terminal tags as well as the 
occurrence of potential post translational modifications such as glycosylation. 
 Hence, we identified novel ADAMTS4 truncated fragments containing 
only the C-terminal ancillary domains based on the N-terminal residues 2-5 
from cultured human cells and Band 2 is potentially anti-angiogenic/anti-





Determining the role of ADAMTS4 in mouse 
breast cancer 
7.1 Overexpression of full-length ADAMTS4 promotes in vivo 4T1 tumor 
growth 
 The above results have demonstrated a dual role for ADAMTS4 in 
mouse melanoma. The full-length protein is pro-tumorigenic dependent on the 
catalytic activity of the protein, while the ancillary regions of the protein are 
anti-tumorigenic. In order to determine whether these roles are a cancer 
specific role restricted to melanoma or is applicable to other cancers as well, 
the effect of ADAMTS4 overexpression in a mouse breast cancer model was 
evaluated. 
7.1.1 Establishment of stable 4T1 breast adenocarcinoma cell line 
overexpressing FL-WT 
 To investigate the roles of ADAMTS4 in breast cancer tumor 
progression, mouse 4T1 breast cancer cells were chosen to create a syngeneic 
tumor in Balb/c. 
 In order to obtain the stable mouse ADAMTS4-overexpressing 4T1 
cell lines, plasmid FL-WT was transfected into 4T1 cells and stable clones 
were selected as described in section 3.2.1. Isolated colonies were expanded 
by subculture and analysed for the expression of FL-WT. FL-WT expression 
in the conditioned medium was confirmed with Western blotting using anti-V5 
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tag antibody. As shown in Fig. 7.1A, FL-WT expressed by stable cell lines 
could be detected as the immature prodomain form at 100 kDa and the mature 
processed form at 75 kDa. The highest expressing clones designated as 
4T1/FL-WTa and 4T1/FL-WTb. In contrast, vector-transfected 4T1 colonies 
were pooled and designated as 4T1/TOPO and used as control cells. No 
corresponding signal was detected in 4T1/TOPO cells. The expression level of 
FL-WTb was slightly higher than FL-WTa. 
 
Fig 7.1 - Selection of FL-WT-overexpressing 4T1 stable cell lines - A. 
Expression of FL-WT was detected by Western blotting using anti-V5 
antibody. B. In vitro growth rates were not changed in FL-WT overexpressing 
4T1 stable cell line (4T1/FL-WT) comparing to empty vector-transfected 
control cell line (4T1/TOPO). C. Immunostaining of 4T1 positive stable cell 
lines with anti-V5 antibody. Secondary antibody used was anti-mouse IgG 
conjugated with Alexa fluor 568. FL-WT staining was shown as red 
fluorescence. Nucleus was stained blue by DAPI. 
 
 Further, to determine whether cell proliferation is influenced by the 
transfection process or overexpression of FL-WT, the in vitro growth kinetics 
of the stable cell lines (4T1/TOPO and 4T1/FL-WT) were monitored as 
described in section 3.2.2. As shown in Fig. 7.1B, there was no significant 
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difference in cellular proliferation of 4T1 cells between control stable cell line 
and FL-WT overexpressing stable cell line. This result indicated that the in 
vitro growth characteristics of these stable cell lines were not changed by the 
increased expression of FL-WT or by the transfection process. 
 The homogeneity of established stable cell lines were also investigated 
by immunostaining of 4T1/FL-WTa and 4T1/FL-WTb cells with anti-V5 
antibody were performed. As shown in Fig. 7.1C specific staining was only 
observable in the cytoplasm of 4T1/FL-WTa and 4T1/FL-WTb cells, but not 
4T1/TOPO. It is also noted that more than 95% of the cells were stained 
positive, demonstrating the high purity of 4T1 stable cell lines that 
overexpress ADAMTS4. 
 Taken together, stable transfection of ADAMTS4 overexpression 
construct into 4T1 cells resulted in enhanced ADAMTS4 expression in 
4T1/FL-WTa and 4T1/FL-WTb two stable cell lines with high purity. 4T1/FL-
WTb with the higher expression was chosen for further studies and henceforth 
will be referred to as 4T1/FL-WT. 
7.1.2 ADAMTS4 full-length overexpressing stable 4T1 cell clones 
promoted tumor growth in vivo 
 To investigate the role of ADAMTS4 FL-WT in breast cancer tumor 
progression, mouse tumorigenesis assay was performed as described in section 
3.2.3. 
 Tumor volume was measured every alternate day after tumors became 
visible on day 9. As shown in Fig 7.2B, tumor volume increased dramatically 
in 4T1/FL-WT tumors at all timepoints after the early growth phase. At the 
end of the experiments (23 days after tumor cell inoculation), tumors were 
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harvested and carefully excised and weighed, it was found that tumor weight 
from FL-WT-overexpressing 4T1 cells were enhanced 6-fold compared to 
control (Fig 4.6C). 
 Mouse tumors from 4T1/FL-WT and 4T1/TOPO of each individual 
mouse at day 23 are shown in Fig 7.2A. Although, the in vitro growth rate of 
FL-WT overexpressing cells and control cells were identical, in vivo tumor 
growth were significantly enhanced in tumors formed from 4T1/FL-WT cells. 
 
Fig 7.2 - Overexpression of FL-WT promoted 4T1 tumor growth in vivo - 
A. Each pair of tumor (either from 4T1/TOPO or 4T1/FL-WT cells) was 
extracted from the same mouse. B. Tumor growth curve comparing B16/N-p53 
with 4T1/TOPO. Tumor volume was measured every alternate day from 9 
days post s.c inoculation in C57Bl/6J on day 0 (n=6). Plots represent the 
mean tumor size (± SEM). C. Tumor weights of mice injected with 4T1/FL-WT 
or 4T1/TOPO post sacrifice on day 23 (n=6). Plots represent the relative 




 In conclusion, ADAMTS4 FL-WT promoted mouse breast cancer 
growth similar to that of mouse melanoma, demonstrating that the tumor 
promoting effect of ADAMTS4 is not cancer specific. 
7.2 Overexpression of ADAMTS4 active-site mutant (E362A) inhibits 4T1 
breast cancer growth in mice 
7.2.1 Establishment of stable 4T1 breast adenocarcinoma cell line 
overexpressing FL-E362A 
 To investigate whether the catalytic activity of the protein is important 
for the pro-tumorigenic effects of ADAMTS4 in breast cancer tumor 
progression stable mouse ADAMTS4-mutant overexpressing 4T1 cell lines 
were used. Plasmid FL-E362A was transfected into 4T1 cells and stable clones 
were selected as described in section 3.2.1. Isolated colonies were expanded 
by subculture and analysed for the expression of FL-E362A. FL-E362A 
expression in the conditioned medium was confirmed with Western blotting 
using anti-V5 tag antibody. As shown in Fig. 7.3A, FL-E362A expressed by 
stable cell lines could be detected as the immature prodomain form at 100 kDa 
and the mature processed form at 75 kDa. The highest expressing clones were 
designated as 4T1/FL-E362Aa and 4T1/FL-E362Ab. In contrast, vector-
transfected 4T1 colonies were pooled and designated as 4T1/TOPO and used 
as control cells. No corresponding signal was detected in 4T1/TOPO cells. 




Fig 7.3 - Selection of FL-E362A-overexpressing 4T1 stable cell lines - A. 
Expression of FL-E362A was detected by Western blotting using anti-V5 
antibody. B. In vitro growth rates were not changed in FL-E362A 
overexpressing 4T1 stable cell line (4T1/FL-E362A) comparing to empty 
vector-transfected control cell line (4T1/TOPO). C. Immunostaining of 4T1 
positive stable cell lines with anti-V5 antibody. Secondary antibody used was 
anti-mouse IgG conjugated with Alexa fluor 568. FL-E362A staining was 
shown as red fluorescence. Nucleus was stained blue by DAPI. 
 
 Further, to determine whether cell proliferation is influenced by the 
transfection process or overexpression of FL-E362A, the in vitro growth 
kinetics of the stable cell lines (4T1/TOPO and 4T1/FL-E362A) were 
monitored as described in section 3.2.2. As shown in Fig. 7.3B, there was no 
significant difference in cellular proliferation of 4T1 cells between control 
stable cell line and FL-E362A overexpressing stable cell line. This result 
indicated that the in vitro growth characteristics of these stable cell lines were 
not changed by the increased expression of FL-E362A or by the transfection 
process. 
 The homogeneity of established stable cell lines were also investigated 
by immunostaining of 4T1/FL-E362Aa and 4T1/FL-E362Ab cells with anti-
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V5 antibody were performed. As shown in Fig. 7.3C specific staining was 
only observable in the cytoplasm of 4T1/FL-E362Aa and 4T1/FL-E362Ab 
cells, but not 4T1/TOPO. It is also noted that more than 95% of the cells were 
stained positive, demonstrating the high purity of 4T1 stable cell lines that 
overexpress ADAMTS4. 
 Taken together, stable transfection of FL-E362A overexpression 
construct into 4T1 cells resulted in enhanced ADAMTS4 mutant expression in 
4T1/FL-E362Aa and 4T1/FL-E362Ab two stable cell lines with high purity. 
4T1/FL-E362Aa with the higher expression was chosen for further studies and 
henceforth will be referred to as 4T1/FL-E362A. 
7.2.2 ADAMTS4 FL-E362A overexpressing stable 4T1 cell clones 
inhibited tumor growth in vivo 
 To investigate whether the 4T1 tumor promoting effect of ADAMTS4 
FL-WT is dependent on the catalytic activity of the protein, mouse 
tumorigenesis assay was carried out as described in section 3.2.3.  
 Tumor volume was measured every alternate day after tumors became 
visible on day 9. As shown in Fig. 7.4B, tumor volume decreased dramatically 
in 4T1/FL-E362A at all timepoints after the early growth phase. At the end of 
the experiments (23 days after tumor cell inoculation), tumors were harvested 
and carefully excised and weighed, it was found that tumor weight from FL-





Fig 7.4 - Overexpression of FL-E362A inhibited 4T1 tumor growth in vivo 
- A. Each pair of tumor (either from 4T1/TOPO or 4T1/FL-E362A cells) was 
extracted from the same mouse. B. Tumor growth curve comparing 4T1/FL-
E362A with 4T1/TOPO. Tumor volume was measured on alternate days from 
9 days post s.c inoculation in C57Bl/6J on day 0 (n=6). Plots represent the 
mean tumor size (± SEM). C. Tumor weights of mice injected with 4T1/FL-
E362A or 4T1/TOPO post sacrifice on day 23 (n=6). Plots represent the 
relative mean tumor weight (± SEM). *P<0.05. 
 
 Mouse tumors from 4T1/FL-E362A and 4T1/TOPO of each individual 
mouse at day 23 are shown in Fig 7.4A. Although, the in vitro growth rate of 
FL-E362A overexpressing cells and control cells were identical, in vivo tumor 
growth were significantly reduced in tumors formed from 4T1/FL-E362A 
cells. 
 In conclusion, the inhibitory effect of ADAMTS4 active site mutant 





Does ADAMTS4 play a role in human lung 
cancer?  
8.1 Overexpression of full-length ADAMTS4 did not affect in vivo A549 
tumor growth 
 Our results have demonstrated a dual role for ADAMTS4 in mouse 
melanoma (Section 3.2 and 3.3) and breast cancer (Section 7.1 and 7.2). The 
full-length protein is pro-tumorigenic dependent on the catalytic activity of the 
protein, while the ancillary regions of the protein are anti-tumorigenic. To 
determine if ADAMTS4 would function similarly in human cancers, human 
lung adenocarcinoma cell line A549 was chosen due to its low level of 
endogenous ADAMTS4 expression (Fig 3.3). 
8.1.1 Establishment of stable A549 clones overexpressing FL-WT  
 To investigate the roles of ADAMTS4 in human tumor progression, 
human A549 adenocarcinoma cells were chosen to create a xenograft tumor in 
Balb/c nu/nu mice.  
 Stable human FL-WT overexpressing A549 cell lines were created by 
transfecting plasmid FL-WT into A549 cells and stable clones were selected 
as described in section 3.2.1. Only one FL-WT expressing clone designated as 
A549/FL-WT was obtained.  In contrast, vector-transfected A549 colonies 
were pooled and designated as A549/TOPO and used as control cells.  
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 FL-WT expression in the conditioned medium was confirmed with 
Western blotting using anti-V5 tag antibody. As shown in Fig 8.1A, FL-WT 
expressed by stable cell line could be detected as a weak immature prodomain 
form at 100 kDa and a mature form at 75 kDa.  The expression level in this 
clone was very low. No corresponding signal was detected in A549/TOPO 
cells.  
 
Fig 8.1 - Selection of FL-WT-overexpressing A549 stable cell lines - A. 
Expression of FL-WT was detected by Western blotting using anti-V5 
antibody. The FL-WT protein was detected using the femto chemiluminescent 
substrate, 1000 times more sensitive than the pico substrate. B. In vitro 
growth rates were not changed in FL-WT overexpressing A549 stable cell line 
(A549/FL-WT) comparing to empty vector-transfected control cell line 
(A549/TOPO). 
 
 Further, to determine whether cell proliferation is influenced by the 
transfection process or overexpression of FL-WT, the in vitro growth kinetics 
of the stable cell lines (A549/TOPO and A549/FL-WT) were monitored as 
described in section 3.2.2. As shown in Fig. 8.1B, there was no significant 
difference in cellular proliferation of A549 cells between control stable cell 
line and FL-WT overexpressing stable cell line. This result indicated that the 
in vitro growth characteristics of these stable cell lines were not changed by 




8.1.2 Overexpression of ADAMTS4 full-length protein did not affect A549 
tumor growth in vivo  
 To investigate the role of ADAMTS4 in A549 tumor progression, 
mouse tumorigenesis assay was performed as described in section 3.2.3. 
 Tumor volume was measured every week after tumors became visible 
on day 7. As shown in Fig 8.2B, tumor volume did not increase in the early 
weeks in A549/ FL-WT tumors, but showed a mild increase after day 28. This 
volume increase is not significant comparing to control tumor. At the end of 
the experiments (35 days after tumor cell inoculation), tumors were harvested 
and carefully excised and weighed, it was found that tumor weight from FL-
WT overexpressing A549 cells did not change significantly compared to 





Fig 8.2 - Overexpression of FL-WT did not affect lung tumor growth in 
vivo - A. Tumor growth curve comparing A549/FL-WT with A549/TOPO. 
Tumor volume was measured weekly from 7 days post s.c inoculation in 
C57Bl/6J on day 0 (n=7). Plots represent the mean tumor size (± SEM). B. 
Tumor weights of mice injected with A549/FL-WT or A549/TOPO post 
sacrifice on day 35 (n=7). Plots represent the relative mean tumor weight (± 
SEM). **P<0.05. 
 
 This lack of any significant effect on tumor growth could be as a result 
of low expression levels of FL-WT in the stable cell line A549/FL-WT. It was 
noted that the stable clone used in this tumorigenesis assay expressed FL-WT 
ADAMTS4 protein at a level at least 1000 fold less than the same protein 
overexpressed in B16 or 4T1 tumor cells. The exogenous ADAMTS4 protein 
can only be detected using a more sensitive chemiluminescent-HRP substrate 
(femto substrate 1000x more sensitive than the pico substrate). Nevertheless, 
the trend of promoting tumor growth was apparent as tumor growth of FL-WT 







8.1.3 Investigating the mechanisms of FL-WT’s effects on A549 tumor 
growth 
 The contribution of tumor angiogenesis, proliferation and apoptosis 
was assessed to investigate the effects of FL-WT on A549 tumor growth. 
 To investigate whether there were any changes in tumor angiogenesis, 
blood vessel density of various tumors were evaluated. Immunofluorescence 
staining of tumor tissue sections with anti-CD31 antibody revealed no 
significant change in tumor vascularization in FL-WT overexpressing A549 
tumors compared with control tumors (Fig 8.3A, left panels, tumor vessels in 
red and B). 
 To find out whether tumor proliferation was affected, proliferation 
index was examined by immunostaining with an antibody to a novel 
proliferation marker PhosphoHistone H3 (pHH3). As shown in Fig. 8.3A 
middle panels and C, there was no significant difference in cell proliferation 
between control and FL-WT-overexpressing A549 tumors. 
 Tumor cell apoptosis was also analysed for any changes upon 
expression of FL-WT in A549 tumors by TUNEL staining. As shown in Fig. 
8.3A (right panels) and D, TUNEL staining results showed no difference in 
the number of apoptotic tumor cells (green dots) in FL-WT-overexpressing 





Fig 8.3 - FL-WT influence on A549 tumor angiogenesis, tumor cell 
proliferation and apoptosis - A. FL-WT did not influence tumor angiogenesis, 
tumor cell proliferation or apoptosis drastically. Immunofluorescence staining 
with anti-CD31 antibody (left panels), anti-Phospho-Histone H3 antibody (middle 
panels) and In-situ TUNEL staining (right panels) of tumor sections from 
A549/TOPO or A549/FL-WT tumors are shown. Scale bars represent 100μm for 
CD31 staining and 20 μm for Phospho-Histone H3 and TUNEL. B-D. 
Quantification of tumor blood vessel, tumor cell proliferation and tumor 
apoptosis. Comparison of the relative number of blood vessels, proliferating cells 
and apoptotic cells per field. Plots represent the relative mean vessel number, 
proliferating cell number and apoptotic cell number analyzed for 3 fields per 
section, 3 sections per tumor (± SEM).  
 
 In conclusion, these results demonstrated that the low FL-WT 
overexpression in A549 cells is not sufficient to cause dramatic changes in 
tumor angiogenesis, proliferation or apoptosis and hence affect tumor growth 
drastically. However, since the trend of increased tumor growth was observed 
in the final weeks it cannot be discounted that upon higher expression of 
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ADAMTS4 in the A549 tumors more dramatic increase in tumor growth or 
tumor angiogenesis will not be observed. 
8.2 ADAMTS4 active-site mutant inhibits A549 lung adenocarcinoma 
growth  
8.2.1 Establishment of stable clones overexpressing FL-E362A in A549 
lung adenocarcinoma cell line 
 To investigate whether the catalytic activity of the protein is important 
for the pro-tumorigenic effects of ADAMTS4 in human lung cancer tumor 
progression stable human ADAMTS4-mutant overexpressing A549 cell lines 
were used. Plasmid FL-E362A was transfected into A549 cells and stable 
clones were selected as described in section 3.2.1. Isolated colonies were 
expanded by subculture and analysed for the expression of FL-E362A. FL-
E362A expression in the conditioned medium was confirmed with Western 
blotting using anti-V5 tag antibody. As shown in Fig. 8.4A, FL-E362A 
expressed by stable cell line could be detected as the immature prodomain 
form at 100 kDa and the mature processed form at 75 kDa. Only one high 
expressing clone designated as A549/FL-E362A was obtained. In contrast, 
vector-transfected A549 colonies were pooled and designated as A549/TOPO 
and used as control cells. No corresponding signal was detected in 




Fig 8.4 - Selection of FL-E362A-overexpressing 4T1 stable cell lines - A. 
Expression of FL-E362A was detected by Western blotting using anti-V5 
antibody. B. In vitro growth rates were not changed in FL-E362A 
overexpressing A549 stable cell line (A549/FL-E362A) comparing to empty 
vector-transfected control cell line (A549/TOPO).  
 
 Further, to determine whether cell proliferation is influenced by the 
transfection process or overexpression of FL-E362A, the in vitro growth 
kinetics of the stable cell lines (A549/TOPO and A549/FL-E362A) were 
monitored as described in section 3.2.2. As shown in Fig. 8.4B, there was no 
significant difference in cellular proliferation of A549 cells between control 
stable cell line and FL-E362A overexpressing stable cell line. This result 
indicated that the in vitro growth characteristics of these stable cell lines were 
not changed by the increased expression of FL-E362A or by the transfection 
process. 
8.2.2 Overexpression of ADAMTS4 active site mutant inhibits tumor 
growth in vivo  
 To investigate whether the lung tumor promoting effect of ADAMTS4 
is dependent on the catalytic activity of the protein, mouse tumorigenesis 
assay was carried out as described in section 3.2.3. 
185 
 
 Tumor volume was measured every week after tumors became visible 
on day 7. As shown in Fig. 8.5A, tumor volume decreased dramatically in 
A549/FL-E362A. At the end of the experiments (35 days after tumor cell 
inoculation), tumors were harvested and carefully excised and weighed, it was 
found that tumor weight from FL-E362A-overexpressing A549 cells were 
reduced  by 50% compared to control (Fig. 8.5B). 
 
Fig 8.5 - Overexpression of FL-E362A inhibited lung tumor growth in 
vivo - A. Tumor growth curve comparing A549/FL-E362A with A549/TOPO. 
Tumor volume was measured weekly from 7 days post s.c inoculation in 
C57Bl/6J on day 0 (n=6). Plots represent the mean tumor size (± SEM). B. 
Tumor weights of mice injected with A549/FL-E362A or A549/TOPO post 
sacrifice on day 17 (n=6). Plots represent the relative mean tumor weight (± 
SEM). **P<0.05. 
 
8.2.3 ADAMTS4 FL-E362A suppresses lung tumor growth by inhibiting 
angiogenesis but not proliferation 
 The contribution of tumor angiogenesis and proliferation was assessed 
to investigate the mechanisms of FL-E362A’s lung tumor inhibitory effect. To 
investigate whether the diminished tumor growth in A549/FL-E362A was 
attributable to reduced tumor angiogenesis, blood vessel density of various 
tumors were evaluated. Immunofluorescence staining of tumor tissue sections 
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with anti-CD31 antibody revealed a 2-fold decrease in tumor vascularization 
in A549/FL-E362A overexpressing tumors compared with control tumors as 
seen by the average number of vessels per field calculated as described in 
section 3.2.4 (Fig. 8.6A left panels and B). This strongly suggests that 
continued presence of high level of FL-E362A in the tumor milieu inhibits 
tumor angiogenesis and hence tumor growth in mice. 
 
Fig 8.6 - FL-E362A influence on A549 tumor angiogenesis and tumor cell 
proliferation - A. FL-E362A inhibited tumor angiogenesis but not tumor cell 
proliferation. Immunofluorescence staining with anti-CD31 antibody (left 
panels) and anti-Phospho-Histone H3 antibody (middle panels) from 
A549/TOPO or A549/FL-WT tumors are shown. Scale bars represent 100μm 
for CD31 staining and 20 μm for Phospho-Histone H3. B and C. 
Quantification of tumor blood vessel and tumor cell proliferation respectively. 
Comparison of the relative number of blood vessels and proliferating cells per 
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field. Plots represent the relative mean vessel number and proliferating cell 
number analyzed for 3 fields per section, 3 sections per tumor (± SEM).  
 
 To find out whether the reduced growth in FL-E362A overexpressing 
lung tumors is a result of reduced tumor cell proliferation, tumor cell 
proliferation was examined by immunostaining with an antibody against novel 
proliferation marker PhosphoHistone H3 (pHH3). The average number of 
proliferating cells per microscopic field quantified as described in section 
3.2.4 showed that there was no significant difference of cell proliferation 
between control and FL-E362A overexpressing tumors (Fig 8.6A middle 
panels and C). 
8.2.4 ADAMTS4 FL-E362A suppresses lung tumor growth by inducing 
apoptosis of tumor cells, endothelial cells and macrophages 
 Tumor cell proliferation upon overexpression of FL-E362A was not 
affected in A549 lung tumors. Thus, to determine if tumor cell apoptosis was 
also a reason for tumor growth inhibition in addition to tumor angiogenesis, 
TUNEL staining was undertaken.  
 Double staining of different cell types was performed. Tumor sections 
were stained for endothelial cells (CD31), tumor cells (as detected by V5 
staining) and macrophages (F4/80) along with TUNEL to detect which of the 
cell types within the tumor were apoptotic. As shown in Fig 8.7A, left panels 
and B, compared to control, FL-E362A overexpressing tumors had three times 
more apoptotic blood vessels. However, the apoptotic cells were 
predominantly tumor cells as observed by the V5 and TUNEL double-stained 
cells (Fig 8.6A, middle panels and C). Besides these, more macrophages were 
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apoptotic in FL-E362A tumors compared to vector control (Fig 8.6A, right 
panels and D). 
 
Fig 8.7 - FL-E362A influence on apoptosis of tumor cells, endothelial cells 
and macrophages in A549 tumors - A. FL-E362A enhanced apoptosis of 
A549 tumor cells, endothelial cells and macrophages in A549 tumors. 
Representative immunofluorescence staining with anti-CD31 antibody plus 
TUNEL (left panels), anti-V5 plus TUNEL (middle panels) and F4/80 plus 
TUNEL (right panels) of tumor sections from A549/TOPO, A549/FL-WT or 
A549/FL-E362A tumors are shown. Scale bars represent 20 µM. CD31, V5 
and F4/80 are stained red and TUNEL staining is in green. Representative 
cells that are both TUNEL and cell marker positive are indicated by white 
arrows. B-D. Quantification of double positive cells. The number of apoptotic 
blood vessels (a vessel containing at least one apoptotic endothelial cell), 
tumor cells and macrophages per microscopic field were quantified. Bar 
graphs represent the number of apoptotic vessels, tumor cells and 
macrophages analyzed for 3 microscopy fields per section, 3 sections per 




 Taken together, ADAMTS4 FL-E362A suppressed lung tumor growth 
by inducing apoptosis of several cell types within the tumor microenvironment 
including tumor cells, endothelial cells and macrophages with tumor cells as 



















Elucidating the role of ADAMTS4 in metastasis 
9.1 Overexpression of full-length ADAMTS4 promotes B16 melanoma 
metastasis 
 Proteolytic enzymes such as matrix metalloproteases (MMPs) have 
been shown to be key enzymes during metastatic progression, primarily via 
their ability to degrade ECM and thus facilitating the movement of primary 
tumor cells to distant organ sites. We have shown that ADAMTS4 as a 
secreted protease promotes tumor growth via its catalytic activity. Thus 
ADAMTS4 might also be acting as a protease to cleave ECM components 
such as brevican versican etc, commonly found in tumor stroma to impact 
metastasis. 
 To determine its role in metastasis, we employed the B16 experimental 
metastasis model to test the effect of ADAMTS4 on melanoma metastasis. 
Experimental metastasis represents the extravasation step of blood-borne 
tumor cells into metastatic sites, distinct from spontaneous metastasis which is 
more true to the entire process of metastasis (Elkin and Vlodavsky 2001). 
Stable luciferase expressing B16F10 cells were chosen for this study in order 






9.1.1 Establishment of stable B16F10-Luc2 mouse melanoma cell line 
overexpressing FL-WT 
 To investigate the roles of ADAMTS4 in lung metastasis, mouse 
B16F10-Luc2 melanoma cells were chosen to test for experimental metastasis 
in C57Bl/6J mice. 
 Stable human FL-WT overexpressing B16F10-Luc2 cell lines were 
created by transfecting plasmid FL-WT into B16F10-Luc2 cells and stable 
clones were selected as described in section 3.2.1. Two FL-WT expressing 
clones designated as B16-Luc2/FL-WTa and B16-Luc2/FL-WTb were 
obtained.  In contrast, vector-transfected B16-Luc2 colonies were pooled and 
designated as B16-Luc2/TOPO and used as control cells. 
 FL-WT expression in the conditioned medium was confirmed with 
Western blotting using anti-V5 tag antibody. As shown in Fig 9.1A, FL-WT 
expressed by stable cell line could be detected as a weak immature prodomain 
form at 100 kDa and a mature form at 75 kDa.  B16-Luc2/FL-WTb showed 
higher FL-WT expression (B16-Luc2/FL-WT). No corresponding signal was 




Fig 9.1 - Selection of FL-WT-overexpressing B16F10-Luc2 stable cell lines 
- A. Expression of FL-WT was detected by Western blotting using anti-V5 
antibody. B. Immunostaining of B16 positive stable cell lines with anti-V5 
antibody. Secondary antibody used was anti-mouse IgG conjugated with Alexa 
fluor 568. FL-WT staining was shown as red fluorescence. Nucleus was 
stained blue by DAPI. 
  
 To further examine the homogeneity of established stable cell lines, 
immunostaining of B16-Luc2/FL-WTa and B16-Luc2/FL-WTb cells with 
anti-V5 antibody were performed. As shown in Fig. 9.1B specific staining was 
only observable in the cytoplasm of B16-Luc2/FL-WTa and B16-Luc2/FL-
WTb cells, but not B16-Luc2/TOPO. 
 Taken together, stable transfection of ADAMTS4 overexpression 
construct into B16F10-Luc2 cells resulted in enhanced ADAMTS4 expression 
in B16-Luc2/FL-WTa and B16/FL-WTb two stable cell lines with high purity. 
B16-Luc2/FL-WTb with the highest expression was chosen for studies and 





9.1.2 In vitro cell proliferation rates and luciferase expression were similar 
between FL-WT and vector overexpressing B16F10-Luc2 cell lines 
 To determine whether cell proliferation is influenced by the 
transfection process or overexpression of FL-WT, the in vitro growth kinetics 
of the stable cell lines (B16-Luc2/TOPO and B16-Luc2/FL-WT) were 
monitored as described in section 3.2.2. As shown in Fig. 9.2A, there was no 
significant difference in cellular proliferation of B16F10-Luc2 cells between 
control stable cell line and FL-WT overexpressing stable cell line. This result 
indicated that the in vitro growth characteristics of these stable cell lines were 
not changed by the increased expression of FL-WT or by the transfection 
process. 
 
Fig 9.2 - Growth kinetics and luciferase expression levels of B16-Luc2/FL-
WT stable cell line - A. In vitro growth rates were not changed in FL-WT 
overexpressing B16F10-Luc2 stable cell line (B16-Luc2/FL-WT) comparing to 
empty vector-transfected control cell line (B16-Luc2/TOPO). B. Luciferase 
activities were not changed between FL-WT overexpressing B16F10-Luc2 
stable cell line (B16-Luc2/FL-WT) and empty vector-transfected control cell 
line (B16-Luc2/TOPO). 
 
 Further, in order to determine whether overexpression of ADAMTS4 
affected the luciferase expression levels in the B16F10-Luc2 cells, luciferase 
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assay was performed. Luciferase activity was analyzed by measuring the 
amount of light produced upon addition of the substrate luciferin. As shown in 
Fig 9.2B, there was no significant different in the luciferase activity between 
the B16F10-Luc2 cells overexpressing the TOPO vector and FL-WT, 
suggesting that neither the transfection process nor the overexpression of the 
protein affected luciferase activity. Negative control B16F10 cells without any 
luciferase expression did not produce any light upon luciferin addition.  
9.1.3 Overexpression of full-length ADAMTS4 promoted B16 melanoma 
lung metastasis 
 To investigate whether ADAMTS4 has a role to play in lung 
metastasis of B16F10 melanoma cells, experimental metastasis assay was 
performed. 
 2.5 X 105 cells of B16-Luc2/FL-WT cells were injected into the tail 
vein of C57BL/6J mouse (n=7). The same number of B16-Luc2/TOPO cells 
was also injected into another set of mice at the same time. Since the cells 
injected express luciferase, in vivo non-invasive imaging of the fate of the 
tumor cells was possible.  Non-invasive imaging was done using the IVIS-
spectrum (Caliper Life Sciences, USA). Mice were injected with substrate 
luciferin intraperitoneally and the total counts/ second of emitted light was 
captured by the IVIS spectrum.  Luciferase signal from tumor cells in the lung 
started to become visible by day 6 (data not shown). The experiment was 
terminated at 2 weeks post injection. Final day IVIS images of mice with lung 
tumor signal were captured.  Mice were sacrificed and lungs harvested and 
preserved for histological observation. Metastatic foci on the surface of the 
lungs were counted under a stereomicroscope and images were taken. 
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 As shown in Fig 9.3B, mice injected with ADAMTS4 overexpressing 
B16-Luc2 cells had enhanced tumor lung metastasis compared to mice 
injected with control vector overexpressing tumor cells. Representative images 
of mice lungs with tumor nodules are shown in Fig 9.3A and the average 
numbers of surface metastatic foci per lung were plotted in Fig 9.3C.  Total 
counts/second emitted from a region of interest defined by the total lung area 
where light signals were visible are plotted in Fig 9.3D. Taken together, 
ADAMTS4 promotes B16 melanoma metastasis to lung. 
 
Fig 9.3 - ADAMTS4 FL-WT promotes lung metastasis - A. Representative 
macroscopic views of lung metastases  in B16-Luc2/TOPO and B16-Luc2/FL-
WT injected mice at 2 weeks after injection of 2.5 X 105 melanoma cells (n=7 
per group). Note that metastatic foci are seen as black nodules on the surface 
of the lungs. B. Average number of metastatic foci per lung in B16-
Luc2/TOPO and B16-Luc2/ FL-WT injected mice. Metastatic foci were 
counted by stereomicroscope. Bars represent mean + S.D **P<0.005. C. 
Representative images of luciferase signal at 2 weeks taken with IVIS 
spectrum at an exposure time of 3 minutes. Luciferin was injected 
intraperitoneally at 150 mg/kg and mice imaged 15 minutes post injection. D. 
Measured Bioluminescence reported as average total photon count emitted at 
2 weeks. Bars represent mean + S.D * P<0.05. 
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9.2 Overexpression of ADAMTS4 active-site mutant (E362A) inhibits B16 
melanoma metastasis 
9.2.1 Establishment of stable B16F10-Luc2 mouse melanoma cell line 
overexpressing FL-E362A 
 To investigate whether the ADAMTS4 lung metastatic activity is 
dependent on its catalytic activity, experimental tail vein metastasis assay was 
performed using B16F10-Luc2 cells overexpressing FL-E362A. 
 Stable human FL-E362A overexpressing B16F10-Luc2 cell lines were 
created by transfecting plasmid FL-E362A into B16F10-Luc2 cells and stable 
clones were selected as described in section 3.2.1. Two FL-E362A expressing 
clones designated as B16-Luc2/FL-E362Aa and B16-Luc2/FL-E362Ab were 
obtained.  In contrast, vector-transfected B16-Luc2 colonies were pooled and 
designated as B16-Luc2/TOPO and used as control cells.  
 FL-E362A expression in the conditioned medium was confirmed with 
Western blotting using anti-V5 tag antibody. As shown in Fig 9.4A, FL-
E362A expressed by stable cell line could be detected as a weak immature 
prodomain form at 100 kDa and a mature form at 75 kDa.  B16-Luc2/FL-
E362Ab showed higher FL-E362A expression. No corresponding signal was 




Fig 9.4 - Selection of FL-E362A-overexpressing B16F10-Luc2 stable cell 
lines - A. Expression of FL-E362A was detected by Western blotting using 
anti-V5 antibody. B. Immunostaining of B16 positive stable cell lines with 
anti-V5 antibody. Secondary antibody used was anti-mouse IgG conjugated 
with Alexa fluor 568. FL-E362A staining was shown as red fluorescence. 
Nucleus was stained blue by DAPI. 
  
 To further examine the homogeneity of established stable cell lines, 
immunostaining of B16-Luc2/FL-E362Aa and B16-Luc2/FL-E362Ab cells 
with anti-V5 antibody were performed. As shown in Fig. 9.4B specific 
staining was only observable in the cytoplasm of B16-Luc2/FL-E362Aa and 
B16-Luc2/FL-E362Ab cells, but not B16-Luc2/TOPO. 
 Taken together, stable transfection of ADAMTS4 overexpression 
construct into B16F10-Luc2 cells resulted in enhanced ADAMTS4 expression 
in B16-Luc2/FL-E362Aa and B16/FL-E362Ab two stable cell lines with high 
purity. B16-Luc2/FL-E362Ab with the highest expression was chosen for 





9.2.2 In vitro cell proliferation rates and luciferase expression were similar 
between FL-E362A and vector overexpressing B16F10-Luc2 cell lines 
 To determine whether cell proliferation is influenced by the 
transfection process or overexpression of FL-E362A, the in vitro growth 
kinetics of the stable cell lines (B16-Luc2/TOPO and B16-Luc2/FL-E362A) 
were monitored as described in section 3.2.2. As shown in Fig. 9.5A, there 
was no significant difference in cellular proliferation of B16F10-Luc2 cells 
between control stable cell line and FL-E362A overexpressing stable cell line. 
This result indicated that the in vitro growth characteristics of these stable cell 
lines were not changed by the increased expression of FL-E362A or by the 
transfection process. 
 
Fig 9.5 - Growth kinetics and luciferase expression levels of B16-Luc2/FL-
E362A stable cell line - A. In vitro growth rates were not changed in FL-
E362A overexpressing B16F10-Luc2 stable cell line (B16-Luc2/FL-E362A) 
comparing to empty vector-transfected control cell line (B16-Luc2/TOPO). B. 
Luciferase activities were not changed between FL-E362A overexpressing 
B16F10-Luc2 stable cell line (B16-Luc2/FL-E362A) and empty vector-
transfected control cell line (B16-Luc2/TOPO). 
 
 Further, in order to determine whether overexpression of ADAMTS4 
affected the luciferase expression levels in the B16F10-Luc2 cells, luciferase 
assay was performed. Luciferase activity was analyzed by measuring the 
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amount of light produced upon addition of the substrate luciferin. As shown in 
Fig 9.5B, there was no significant different in the luciferase activity between 
the B16F10-Luc2 cells overexpressing the TOPO vector and FL-E362A, 
suggesting that neither the transfection process nor the overexpression of the 
protein affected luciferase activity. Negative control B16F10 cells without any 
luciferase expression did not produce any light upon luciferin addition.  
9.2.3 Overexpression of ADAMTS4 active-site mutant inhibited B16 
melanoma lung metastasis 
 To investigate whether the enhanced lung metastatic effect observed in 
ADAMTS4 overexpressing B16 melanoma cells is due to its catalytic activity, 
experimental tail vein metastasis assay was performed using the B16F10-Luc2 
cells overexpressing FL-E362A. 
 2.5 X 105 cells of B16-Luc2/FL-E362Acells were injected into the tail 
vein of C57BL/6J mouse (n=7). The same number of B16-Luc2/TOPO cells 
was also injected into another set of mice at the same time. Lung metastasis 
was observed non-invasively as described in section 9.1.3.  
 As shown in Fig 9.6B, mice injected with FL-E362A overexpressing 
B16-Luc2 cells had reduced tumor lung metastasis compared to mice injected 
with vector control tumor cells. Representative images of mice lungs with 
tumor nodules are shown in Fig 9.6A and the average numbers of surface 
metastatic foci per lung were plotted in Fig 9.6C. Total counts/second emitted 
from a region of interest defined by the total lung area where light signals 
were visible are plotted in Fig 9.6D. Taken together, FL-E362A inhibits B16 





Fig 9.6 - ADAMTS4 FL-E362A inhibits lung metastasis - A. Representative 
macroscopic views of lung metastases  in B16-Luc2/TOPO and B16-Luc2/FL-
E362A injected mice at 2 weeks after injection of 2.5 X 105 melanoma cells 
(n=7 per group). Note that metastatic foci are seen as black nodules on the 
surface of the lungs. B. Average number of metastatic foci per lung in B16-
Luc2/TOPO and B16-Luc2/ FL-E362A injected mice. Metastatic foci were 
counted by stereomicroscope. Bars represent mean + S.D **P<0.005. C. 
Representative images of luciferase signal at 2 weeks taken with IVIS 
spectrum at an exposure time of 3 minutes. Luciferin was injected 
intraperitoneally at 150 mg/kg and mice imaged 15 minutes post injection. D. 
Measured Bioluminescence reported as average total photon count emitted at 











 ADAMTS4 as a member of the ADAMTS family, has been previously 
studied mainly for its role as an aggrecanase and shown to be important in the 
pathophysiology of osteoarthritis and rheumatoid arthritis. In recent years it 
emerged that ADAMTS4 is a proteoglycanase with many other substrates such 
as versican (in the blood vessel walls and tumor stroma), brevican (in the brain 
ECM) and other ECM components such as the SLRP family of proteoglycans, 
biglycan, fibromodulin etc. Many members of the ADAMTS family have been 
recently attributed to have roles in cancer and angiogenesis (Kumar, Rao et al. 
2012). Although, ADAMTS4 is expressed in several cancers, its role in cancer 
remains unknown. In this study, we demonstrated a new role for ADAMTS4 
in cancer and angiogenesis. 
10.1 The role of ADAMTS4 in cancer 
 ADAMTS4 is expressed in several cancers such as glioblastoma, 
breast cancer, head and neck cancer and Ewings sarcoma. In human 
glioblastoma, ADAMTS4 has been shown to be induced by TGF-β and high 
amounts were expressed both at the mRNA and protein levels (Held-Feindt, 
Paredes et al. 2006). ADAMTS4 has been shown to cleave brevican, with the 
cleavage products promoting increased invasion and contribute to glioma 
progression (Matthews, Gary et al. 2000; Viapiano, Hockfield et al. 2008). 
Malignant breast cancer also showed an upregulation of ADAMTS4 mRNA 
(Porter, Scott et al. 2004). In the case of Ewings sarcoma, a malignant bone 
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tumor, ADAMTS4 is recognised as a novel tumor marker (Minobe, Ono et al. 
2010). However, in head and neck cancer, ADAMTS4 was consistently 
downregulated in metastatic samples compared to primary tumor samples as 
well as their corresponding normal tissues (Demircan, Gunduz et al. 2009). 
Results from our lab also demonstrated strong expression of ADAMTS4 in 
both normal and human cancer tissues as well as in several human cancer cell 
lines (Fig 3.2, 3.3 and 3.4). Although expression studies revealed the presence 
of ADAMTS4 in several cancers, no study has explored the exact roles of this 
protein in cancer. In this work, we demonstrated for the first time a complex 
role for ADAMTS4 in cancer. 
 Our results demonstrate a pro-tumorigenic role for full-length 
ADAMTS4 in mouse melanoma. ADAMTS4 promoted in vivo tumor growth 
and this effect was dependent on the enzymatic activity of the protein (Fig 
3.7). Several metalloproteases such as members of the MMP family typically 
promote tumor growth via multiple mechanisms, central to all of them being 
their catalytic activity against various substrates (Egeblad and Werb 2002) 
ADAMTS1, the most closely related member to ADAMTS4 within the 
ADAMTS family also has been implicated with pro-tumorigenic roles wherein 
again the enzymatic activity of the protein plays a crucial role. For example, 
ADAMTS1 promoted mammary tumor growth via the accumulation of 
cleaved versican (Ricciardelli, Frewin et al. 2011). Another study using 
xenograft assays with fibrosarcoma cells showed that ADAMTS1 could 
promote tumor growth via induction of vascular mimicry (Casal, Torres-
Collado et al. 2010). ADAMTS1 was also shown to promote tumor 
development using a bronchial epithelial tumor cell line via the induction of 
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stromal reaction an in vivo, a phenomenon that did not occur with a 
catalytically inactive ADAMTS1 (Rocks, Paulissen et al. 2008). This 
underscores the relevance of ADAMTS4’s tumor promoting effect through its 
enzymatic activity. 
 Interestingly, when an active-site mutant of ADAMTS4 was tested for 
its effect on tumor growth, loss of enzymatic activity not only abolished the 
tumor promoting function of the protein, but also rendered the protein anti-
tumorigenic (Fig 3.15). This result suggested that tumor suppressive functions 
of ADAMTS4 could be harboured in the C-terminal ancillary regions of the 
protein. Systematic domain deletion studies of ADAMTS4 revealed that the 
C-terminal ancillary regions of the protein alone are anti-tumorigenic in vivo 
(Fig 5.2). Importantly, we also demonstrated that the single centrally located 
TSR domain was responsible for this anti-tumorigenic function as 
tumorigenesis studies using a recombinant construct lacking the TSR domain 
(C-S) lost the ability to inhibit tumor growth (Fig 5.5). Moreover, the TSR 
domain could also act independently to suppress tumor growth in vivo (Fig 
5.8). Several other members of the ADAMTS family have been recently 
discovered to have anti-tumorigenic functions acting via the TSR domain such 
as ADAMTS1 (Vázquez, Hastings et al. 1999), ADAMTS2 (Dubail, Kesteloot 
et al. 2010), ADAMTS5 (Kumar, Sharghi-Namini et al. 2012) and 
ADAMTS12 (Llamazares, Obaya et al. 2007). 
 Our results that the C-terminal ancillary region is anti-tumorigenic 
raised the question, whether these C-terminal ancillary regions exist in vivo as 
naturally cleaved fragments. ADAMTS4 has been previously shown to 
undergo autocatalytic cleavage or cleavage by MT1-MMP at its C-terminus to 
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generate two N-terminal fragments of 53 kDa and 40 kDa respectively 
(Flannery, Zeng et al. 2002; Gao, Plaas et al. 2004). However, no cleavage at 
the N-terminus has been reported so far. We demonstrated for the first time, 
novel C-terminal fragments generated by cleavage at the N-terminus of the 
protein in cultured mammalian cells. Mass spectrometric analyses revealed 
four C-terminal fragments (Table 6.1). In addition, we further determined the 
N-terminus of one of the bands (band -2) by N-terminal sequencing to be Leu-
Asp-Lys-Pro-Glu resulting in a cleaved fragment that comprises of a region 
encompassing disintegrin-like domain to spacer domain. This finding is very 
relevant since this fragment closely resembles the recombinant construct D-S, 
which was shown to be anti-tumorigenic in vivo (Fig 5.2). Thus it is 
conceivable that such C-terminal fragments exist in tissue. Accordingly, we 
observed a strong C-terminal fragment in human normal tissues and tumors 
with our C-terminal specific antibody (Fig 3.2).  
 Autocatalytic cleavage or cleavage by other proteases has often been 
observed to alter the enzymatic properties or functions of proteins. For 
example, MT1-MMP undergoes autocatalytic cleavage to release 
enzymatically inactive fragments thereby resulting in a self-destructive 
mechanism for control of pericellular proteolysis (Toth, Hernandez-Barrantes 
et al. 2002). On the other hand, in the case of MMP-2, a pro-tumorigenic 
molecule, autocatalytic cleavage at the C-terminus releases an anti-angiogenic 
peptide PEX, which has been shown to inhibit tumor growth (Brooks, Silletti 
et al. 1998). Even in the case of ADAMTS1 autocatalytic cleavage as well as 
MMP-mediated cleavage has been shown to release C-terminal fragments 
(Rodriguez-Manzaneque, Milchanowski et al. 2000; Liu, Xu et al. 2006). 
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ADAMTS1 C-terminal fragments containing TSR domains were shown to 
inhibit tumor growth in mice (Liu, Xu et al. 2006). Alteration of proteolytic 
activity has also been reported in the case of ADAMTS4 upon C-terminal 
truncation. Cleavage at the C-terminus resulted in enhanced aggracanase and 
versicanase activities for ADAMTS4 and also revealed promiscuous activity 
against its substrate aggrecan along with activity against new substrates such 
as fibromodulin and decorin (Gao, Westling et al. 2002; Kashiwagi, Enghild et 
al. 2004).  
 This raised the possibility that ADAMTS4 cleavage events could also 
influence its effects on tumor growth. Indeed, ADAMTS4 cleavage at the N-
terminus could release fragments which are anti-tumorigenic in contrast to the 
full-length protein which is pro-tumorigenic. In order to determine whether the 
naturally existing N-terminal 53 kDa fragment of ADAMTS4 retains its tumor 
promoting activity we tested the effect of overexpression of this fragment in 
mouse melanoma. Our results showed that, like the ADAMTS4 full-length 
protein, ADAMTS4 N-terminal 53 kDa fragment also promotes tumor growth 
in vivo (Fig 4.6). This is contrary to ADAMTS1 where both the N- and C-
terminal fragments demonstrated anti-tumorigenic functions (Liu, Xu et al. 
2006). In addition we also demonstrated that the tumor promoting activity of 
the N-terminal fragment is also dependent on its catalytic activity (Fig 4.11). 
Thus, cleavage of ADAMTS4 resulted in fragments with different functions. 
This suggested that the net influence of ADAMTS4 on tumor growth is 
probably a balance between the different kinds of fragments generated, in 
different tissues at different time points. 
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 It has frequently been observed that a molecule might have different 
functions in different kinds of tumors. For example, ADAMTS1 has been 
shown to promote tumor growth in a fibrosarcoma (HT-1080) model and a 
PyMT mammary cancer model (Casal, Torres-Collado et al. 2010; 
Ricciardelli, Frewin et al. 2011). On the other hand, using three different 
tumor cell lines, it has also been shown to have anti-tumorigenic functions 
(Obika, Ogawa et al. 2012). In order to test whether ADAMTS4 tumor 
promoting function is restricted to melanoma or is a common phenomenon, we 
tested the effect of overexpression of ADAMTS4 in another mouse model 4T1 
breast adenocarcinoma as well as in A549 human lung adenocarcinoma. Our 
results demonstrated that ADAMTS4 exhibited the same tumor promoting 
effect on the 4T1 breast adenocarcinoma tumor model. However, there was no 
significant effect on A549 lung adenocarcinoma model. This could be due to 
the low expression of ADAMTS4 in the A549 stable cell line. In both tumor 
models, ADAMTS4 active-site mutant caused anti-tumorigenic effects 
corroborating our previous findings in the case of the melanoma model (Figs 
7.2, 7.4, 8.2 and 8.5). 
It was noted that mouse to mouse variation in tumor growth was large 
between different experiments. It is likely, that this difference could result 
from the condition of the cells during culture, prior to performing the mouse 
tumorigenesis assays. However, before each mouse tumorigenesis experiment 
was performed, it was confirmed that the two stable cell lines being compared 
within the experiment has similar in vitro proliferation rates. No cross-
comparison between experiments was done. 
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 To sum up, ADAMTS4 promotes tumor growth in several cancer 
models in an enzyme-dependent manner. In addition, the C-terminal ancillary 
regions of the same protein exhibit contrary anti-tumorigenic functions via its 
TSR domain. Cleavage events within the ADAMTS4 protein result in 
fragments with opposing functions, which might influence the net behaviour 
of the protein on tumor progression. The anti-tumorigenic fragments could 
play a significant role under situations when (1) the substrate of ADAMTS4 is 
absent or at low abundance in a tumor milieu; (2) the abundance of the C-
terminal fragments are overwhelmingly dominant over the full-length protein 
or the catalytically active N-terminal truncates. 
10.2 The role of ADAMTS4 in angiogenesis 
 Tumor angiogenesis is an indispensable event during tumor 
progression and is a prerequisite during this process (Folkman 1971; Kerbel 
2008). Our results elucidating the role of ADAMTS4 in cancer progression 
revealed that ADAMTS4 promoted tumor growth via influencing tumor 
angiogenesis. 
 Overexpression of ADAMTS4 in B16 mouse melanoma cells 
promoted in vivo tumor growth (Fig 3.7). These effects on tumor growth were 
likely an indirect effect as overexpression of ADAMTS4 did not have any 
effect on in vitro proliferation rates of B16 melanoma cells (Fig 3.6). 
Immunohistochemistry of tumor sections from ADAMTS4 overexpressing 
B16 tumors revealed that ADAMTS4 promoted tumor angiogenesis as 
observed from the increased blood vessel marker CD31 staining (Fig 3.8). 
However, ADAMTS4 overexpression did not affect tumor cell proliferation or 
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tumor cell apoptosis in vivo (Fig 3.9 and 3.10). This suggests that the observed 
tumor promoting effects were most likely due to an indirect effect of enhanced 
tumor angiogenesis rather than a direct effect on proliferation of tumor cells. 
Several such examples of tumor promotion as a result of increase in tumor 
angiogenesis have been reported previously. For example, recently a cartilage 
derived secreted glycoprotein YKL-40 (human cartilage glycoprotein-39), was 
reported to promote tumor growth and angiogenesis, without affecting tumor 
cell proliferation directly (Shao, Hamel et al. 2009). ADAMTS1 also 
increased mammary tumor growth through promoting tumor angiogenesis 
with only a mild effect on tumor cell proliferation (Liu, Xu et al. 2006). 
 In contrast, overexpression of ADAMTS4 active-site mutant not only 
abolished its tumor promoting activity, it resulted in causing tumor growth 
inhibition via negatively influencing angiogenesis (Fig 3.15 and 3.17). This 
negative influence on tumor angiogenesis resulted in enhanced tumor cell 
apoptosis, although no effect on tumor cell proliferation was observed. Many 
other endogenous angiogenesis inhibitors have demonstrated similar anti-
tumorigenic effects via angiogenesis inhibition, however, without affecting 
tumor cell proliferation, for example, endostatin (O'Reilly, Boehm et al. 1997), 
angiostatin (O'Reilly, Holmgren et al. 1996) and thrombospondin-2 (Streit, 
Riccardi et al. 1999). 
 Since it appeared that ADAMTS4’s effects on tumor growth were 
mainly through its influence on tumor angiogenesis, we probed for 
angiogenesis signaling pathway proteins in B16 tumors overexpressing either 
the full-length ADAMTS4 protein or its active-site mutant. Our results 
demonstrated that ADAMTS4 differentially regulated several angiogenesis 
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signaling pathway proteins (Table 3.1 and Fig 3.18). Five of the proteins with 
contrasting changes were chosen for further validation by Western blot 
analysis (Fig 3.18). Exactly how ADAMTS4 influences these proteins is not 
known and would be an interesting point to clarify in future. Several 
possibilities exist such as downregulation at the mRNA or protein level or 
protein degradation.  
 Interestingly, pro-angiogenic proteins were found to be upregulated in 
the full-length overexpressing tumors, while the same proteins are 
downregulated or their expression are not changed in the ADAMTS4 mutant 
expressing tumors when each was compared to their respective control vector 
tumors. IGFBP-1 (Insulin-like growth factor binding protein-1) binds to 
Insulin growth factor and could act to enhance the growth promoting effects of 
IGFs (Jones and Clemmons 1995). IGFBP-1 has also been shown to play IGF-
independent functions, promoting cell adhesion and migration through the 
RGD integrin binding domain (Gleeson, Chakraborty et al. 2001). In addition, 
it has been hypothesized that IGFBP-1 via interactions with the ECM could 
provide a local reservoir of IGFs indirectly contributing to tumor growth 
(Rajaram, Baylink et al. 1997). Consistent, with its tumor promoting 
functions, IGFBP-1 was slightly upregulated in FL-WT overexpressing tumors 
but drastically dwonregulated in FL-E362A tumors (Fig 3.18). PlGF-2, 
another angiogenic protein was also found to be significantly upregulated in 
FL-WT overexpressing tumors and to a milder extent in FL-E362A tumors 
(Fig 3.18). PlGF-2 has been shown to promote vessel formation at the site of 
tumor neovascularization (Li, Sharpe et al. 2006). Studies also showed that it 
contributed to pathological angiogenesis by promoting endothelial cell 
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survival and maintaining vascular networks by vessel normalization and 
vascular remodelling (Cai, Ahmad et al. 2003; Hedlund, Hosaka et al. 2009). 
IL-1 alpha, another molecule that was found to be differentially regulated in 
the angiogenesis array upon ADAMTS4 overexpression has also been shown 
to promote tumor growth and angiogenesis (Salven, Hattori et al. 2002; 
Voronov, Shouval et al. 2003). 
 Contrastingly, known anti-angiogenic proteins such as DPPIV and IL-
10 were found to be upregulated in FL-E362A tumors whereas their 
expression was either unchanged or downregulated in FL-WT tumors when 
compared with respective vector controls. Both DPPIV and IL-10 have been 
shown to anti-tumorigenic especially in melanoma (Huang, Xie et al. 1996; 
Stecca, Nardo et al. 1997). While expression of DPPIV did not change in FL-
WT expressing tumors, expression of IL-10 was reduced drastically (Fig 
3.18). 
 Earlier we demonstrated that although cleavage at the N-terminus 
resulted in C-terminal fragments which have a completely different function 
from the full-length protein, the naturally existing abundant N-terminal 53 
kDa fragment N-p53 promoted tumor growth in an enzyme-dependent manner 
similar to the full-length protein (Figs 4.6 and 4.11). Recently a study by Hsu 
et al., reported that ADAMTS4 is expressed by cultured endothelial cells and 
recombinant ADAMTS4 fragment 213-685 (equivalent to N-p53) binds to 
VEGF and suppress VEGFR2 phosphorylation and in vitro endothelial cell 
tube formation (Hsu, Staton et al. 2012). Our in vitro studies with recombinant 
N-p53 also corroborated these results. Both N-terminal fragments of 
ADAMTS4, N-p53 and N-p40 could inhibit in vitro EC tube formation in a 
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dose dependent manner (Fig 4.1). Further N-p53 could induce EC apoptosis 
even in the presence of a pro-angiogenic factor VEGF (Fig 4.2) and inhibit 
VEGF-induced EC proliferation in a dose dependent manner (Fig 4.3). 
However, very surprisingly, immunohistochemistry studies with N-p53 
overexpressing tumors revealed that overexpression of N-p53 promoted tumor 
angiogenesis in an enzyme-dependent manner (Fig 4.8 and 4.13). The in vitro 
EC tube formation matrigel assay is a simple two-dimensional assay format 
(Madri and Pratt 1986). This assay does not allow us to entirely mimic the 
complex three-dimensional microenvironment of a tumor. Thus it is likely that 
this discrepancy between the in vitro and in vivo results was probably due to 
the influence of the complex tumor microenvironment and the availability of 
different substrates to digest. This is especially relevant because the effects of 
N-p53 on tumor angiogenesis were enzyme-dependent. For example, in the 
case of ADAMTS9, the anti-angiogenic activity of this protein was also 
dependent on its catalytic activity, although the precise substrates are as yet 
unknown (Koo, Coe et al. 2010). Thus identification of ADAMTS4 substrates 
in the tumor microenvironment is necessary. 
 The TSR domain has been well characterized for its role in 
angiogenesis and is present in several molecules including TSP-1 and TSP-2 
(Tucker 2004). It has been reported that the region responsible for the 
antiangiogenic properties of TSP-1 are confined to the second and third TSR 
(Iruela-Arispe, Vazquez et al. 1999). Many TSR containing proteins besides 
the Thrombospondins have been shown to be anti-angiogenic such as BAI-1 
(Nishimori, Shiratsuchi et al. 1997) and several members of the ADAMTS 
family (ADAMTS1, -2, -5, -8, -9, and -12) (Kumar, Rao et al. 2012). 
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ADAMTS4 contains a single central TSR domain and previous studies have 
shown that peptides from the ADAMTS4 TSR are anti-angiogenic 
(Karagiannis and Popel 2007). This is also corroborated by our mouse 
tumorigenesis studies which showed that the tumor inhibitory activity of the 
mutant ADAMTS4 protein resides in the C-terminal ancillary regions of the 
protein, particularly the TSR domain was shown to be responsible for this 
function (Figs 5.2, 5.5 and 5.8).  Similar to the mutant ADAMTS4 protein, the 
inhibitory effect on tumor growth was shown to be a consequence of tumor 
angiogenesis suppression even in the case of the C-terminal ancillary regions 
(Fig 5.3). Overexpression of the recombinant constructs D-S and T-S resulted 
in potent suppression of tumor angiogenesis and as a result enhanced tumor 
apoptosis without affecting tumor cell proliferation (Fig 5.3). Importantly, the 
TSR domain was shown to be responsible for this anti-angiogenic response as 
the recombinant construct C-S lacking the TSR domain failed to inhibit tumor 
angiogenesis and as a result did not inhibit tumor growth (Fig 5.6). The TSR 
domain could also act independently to inhibit tumor angiogenesis and induce 
tumor cell apoptosis (Fig 5.8). 
The vessel numbers, apoptotic and proliferating tumor cell numbers 
between different experiments displayed considerable differences. These 
differences could be because of the randomness in these processes. 
Comparative analysis of pairwise tumors injected into the flanks of the same 
mice would have given a more reliable and accurate understanding of the 





 Taken together, although in vitro studies might have indicated an anti-
angiogenic role for ADAMTS4, both the full-length protein, as well as the N-
terminal fragment (N-p53) influenced tumor angiogenesis positively. 
However, the C-terminal ancillary regions of the protein containing the TSR 
domain and the ADAMTS4 TSR domain itself inhibited tumor angiogenesis, 
consistent with other TSR containing proteins. Thus it seems that despite 
containing the TSR domain, the full-length protein promoted tumor 
angiogenesis in an enzyme dependent manner. This suggested that the 
cleavage events resulting in different ADAMTS4 fragments would determine 
the net influence on tumor angiogenesis. In addition, ADAMTS4 was also 
shown to differentially regulate several angiogenesis signaling pathway 
proteins. However, the precise mechanisms of ADAMTS4’s effects on these 
proteins are not known yet and need to be further investigated. 
10.3 The role of ADAMTS4 in metastasis 
 The angiogenic switch, as previously noted, is central to the process of 
cancer progression. The new blood vessels that fuel the primary tumor also 
provide a conduit for the dissemination of these tumor cells to distant 
metastatic sites (Folkman 2002). Several pro-angiogenic factors have been 
known to also promote metastasis, for example tumor growth, lung 
colonization, and spontaneous metastasis were controlled by the rate of 
angiogenesis and hence by the angiogenic factors promoting the angiogenesis 
(Rofstad and Halsor 2000). Several angiogenic factors such as VEGF, IL-8, 
PD-ECGF and bFGF were shown to cause spontaneous metastasis in mouse 
melanoma xenograft models (Rofstad and Halsor 2000). In prostate cancer 
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cells, constitutive gene expression of pro-angiogenic factors correlated with 
metastatic potential (Aalinkeel, Nair et al. 2004). 
 Consistent with this, we demonstrated that overexpression of 
ADAMTS4 in B16F10 melanoma cells, promoted lung metastases (Fig 9.3). 
In another report, ADAMTS4 expression was found to be upregulated in 
human glioblastoma, where it could possibly contribute to invasion via the 
cleavage of brain ECM protein brevican, often found to be upregulated in 
glioblastoma (Matthews, Gary et al. 2000; Held-Feindt, Paredes et al. 2006). 
Another ECM protein which is highly upregulated in the tumor stroma of 
several cancers is versican (Ricciardelli, Sakko et al. 2009). Local 
accumulation of versican fragments by ADAMTS cleavage promoted glioma 
cell migration and adhesion (Arslan, Bosserhoff et al. 2007). In addition, a 
preliminary study also reports that cleaved versican expression and higher 
ADAMTS4 levels are observed in malignant prostate glands compared to 
normal glands (Ricciardelli, Sakko et al. 2009). The precise substrates of 
ADAMTS4 that are involved in its role in melanoma tumor promotion are not 
known yet and need to be investigated. Versican has emerged as an important 
ECM protein in melanoma tumor progression, where it is differentially 
expressed (Touab, Villena et al. 2002; Gambichler, Kreuter et al. 2008). It is 
possible that versican degradation by ADAMTS4 could be a reason for its pro-
tumorigenic effects. 
 Other ADAMTS family members have also been shown to promote 
metastasis. For example, ADAMTS1 sheddase activity results in the release of 
membrane bound growth factors from the surface of tumor cells that facilitate 
invasion and bone metastasis of breast cancer (Lu, Wang et al. 2009). Work by 
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Liu et al., has demonstrated that overexpression of full-length ADAMTS1 
promoted pulmonary metastasis of breast cancer cells. However surprisingly, 
the N- and C-terminal fragments that contain TSRs were anti-metastatic (Liu, 
Xu et al. 2006). The N- and C-terminal fragments of ADAMTS4 were earlier 
shown to differentially affect tumor growth (Fig 4.6 and 5.2). It would be 
interesting to know how the ADAMTS4 fragments influence metastasis. 
 Interestingly, ADAMTS4 active-site mutant inhibited B16F10 lung 
metastasis (Fig 9.6). This suggested that probably the C-terminal ancillary 
regions of the protein could negatively influence metastasis. It has been 
recognized that endogenous inhibitors of angiogenesis maintain metastasis in a 
non-proliferating quiescent state (Kirsch, Schackert et al. 2000). For example, 
systemic gene delivery of angiostatin, endostatin and TIMP-2 resulted in 
inhibition of metastasis in MMTVneu transgenic mice (Sacco, Cato et al. 
2001). Several endogenous angiogenesis inhibitors have been shown to inhibit 
metastasis such as arresten (Colorado, Torre et al. 2000) and endostatin 
(O'Reilly, Boehm et al. 1997). Among the TSR containing angiogenesis 
inhibitors, TSP-1 and TSP-2 have been reported to inhibit metastasis via their 
influence on angiogenesis (Weinstat-Saslow, Zabrenetzky et al. 1994; 
Tokunaga, Nakamura et al. 1999). ADAMTS1 cleaved fragments as well as 
the enzyme inactive mutant inhibited breast cancer metastasis, suggesting that 
the loss of catalytic activity together with the presence of the TSR domain 
likely rendered the protein anti-metastatic (Liu, Xu et al. 2006). Additionally, 
ADAMTS1 was also linked to an anti-metastatic role in liver metastasis, 
through enhanced cleavage of TSP-1, resulting in the release of the anti-
angiogenic TSR regions (Lee, Koch et al. 2010). Thus it is conceivable that in 
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the case of ADAMTS4, the loss of catalytic activity together with the presence 
of the TSR domain could render the mutant protein anti-metastatic. It also 
suggested that any C-terminal cleavage fragments generated could also have a 
potential anti-metastatic role, although this needs to be investigated. 
 Taken together, ADAMTS4 promoted B16F10 lung metastasis in an 
enzyme-dependent manner. It is probable that ADAMTS4 could cleave ECM 
proteins in the tumor stroma such as versican, thus enhancing tumor cell 
invasion and metastasis. The loss of catalytic activity rendered the protein 
anti-metastatic, probably due to the indirect anti-angiogenic influence of the 
C-terminal ancillary regions, particularly the TSR domain, which led to 
metastasis inhibition. 
10.4 Conclusion 
 In this study, we present the first experimental evidence indicating a 
complex role for ADAMTS4 in cancer and angiogenesis. ADAMTS4 or its 
fragments were shown to be important for tumor progression and metastasis. 
 Catalytically-active ADAMTS4 (full-length or proteolytic fragment) 
promoted melanoma growth in mice. In contrast, catalytically-inactive 
isoforms suppressed melanoma growth. Structure-function mapping revealed 
that the single TSR domain is essential and sufficient for the anti-tumorigenic 
activity displayed by the catalytically inactive ADAMTS4 isoforms. We also 
confirmed that ADAMTS4 effects on tumor growth are not restricted to a 
particular cancer. Tumorigenesis studies in two different cancer models - 4T1 
mouse breast cancer and A549 human lung cancer also demonstrated similar 
effects of ADAMTS4 on cancer and tumor angiogenesis. 
217 
 
 ADAMTS4’s effects on tumor growth in mice were attributed to the 
influence of the protein on tumor angiogenesis.  The pro-tumorigenic 
functions of the full-length protein were found to be as a result of enhanced 
tumor angiogenesis. Tumor growth suppression induced by the mutant protein 
or the C-terminal ancillary regions were as a result of inhibition of tumor 
angiogenesis accompanied by a significant increase in tumor cell apoptosis 
while tumor cell proliferation was not affected. The contrasting functions 
towards tumor growth in mice by the wild-type protease and its catalytically-
inactive mutant correlated with their contrasting influences on angiogenesis 
signaling pathway molecules in B16 melanoma in mice. 
 Significantly, we identified novel catalytically-inactive isoforms 
containing only the C-terminal ancillary domains, co-existing with the 
catalytically-active isoforms in cultured human cells, and also most likely in 
tissues and cancers. This suggested that the complex role for ADAMTS4 in 
cancer will be dependent on functional balance of pro-tumorigenic and anti-
tumorigenic isoforms likely acting as an important parameter in determining 
the net influence of this metalloprotease on tumor growth in vivo. 
 Finally, as a metalloprotease, ADAMTS4’s influence on B16 
melanoma pulmonary metastasis was tested. We found that ADAMTS4 
promoted lung metastasis in an enzyme-dependent manner, as the loss of 
catalytic activity rendered the protein anti-metastatic. The precise mechanisms 
for ADAMTS4 influence on invasion and metastatic progression could be a 




10.5 Current status of ADAMTS family in cancer and angiogenesis 
Several ADAMTS family members have been recently shown to be 
involved in cancer and/or angiogenesis since 2009. The current list of 
ADAMTSs involved in angiogenesis includes ADAMTS1, -2, -4, -5, -8, -9, -
12 and -13, of which some have been implicated wth pro-angiogenic roles in 
addition to anti-angiogeneic functions (Table 1.4) and Fig 10.1. For all the 
ADAMTSs involved in angiogenesis the mechanisms of action through which 
they mediate angiogenesis is not the same. Two common themes emerge; one 
is the importance of the catalytic activity. The other is the involvement of the 














Table 10.1 - ADAMTS in angiogenesis 




Role in Angiogenesis 
ADAMTS1 Yes (Pro-angiogenic) 
(Fu, Nagy et al. 2011)  
Yes (Anti-angiogenic) 
(Iruela-Arispe, Carpizo 
et al. 2003) 
No (Anti-angiogenic) 




(Liu, Xu et al. 
2006) 
Anti-angiogenic  
- Suppresses EC proliferation in a cell-specific, dose dependent manner (Vázquez, 
Hastings et al. 1999; Iruela-Arispe, Carpizo et al. 2003)  
- Disrupts growth factor induced angiogenesis in vivo in a CAM model and 
matriplug assay (Vázquez, Hastings et al. 1999) 
- Suppresses tumor angiogenesis in T47D human breast carcinoma  (Iruela-Arispe, 
Carpizo et al. 2003) 
- Regulates angiogenesis in ischemic myocardium (Nakamura, Hirohata et al. 2004) 
- Suppresses tumor angiogenesis in HT-1080, DU145 and CHO-K1 tumors (Obika, 
Ogawa et al. 2012) 
- Alters blood vessel morphology in prostate tumors (Gustavsson, Tesan et al. 2010)  
- Induced by VEGF in ECs and ischemia induced retinal neovascularization (Xu, 
Yu et al. 2006) 
 
Pro-angiogenic 
- Induction of ADAMTS1 to degrade basement membrane versican in VEGF-
induced pathological angiogenesis. (Fu, Nagy et al. 2011) 
- Promotes tumor angiogenesis in TA3 mammary carcinoma and Lewis lung 
carcinoma (Liu, Xu et al. 2006) 









 Role in Angiogenesis 
ADAMTS2 No (Anti-angiogenic) 





Kesteloot et al. 
2010)  
 Anti-angiogenic 
- Suppressed VEGF-stimulated EC proliferation in a cell-specific manner, induces 
apoptosis and inhibits capillary network formation of HUVEC (Dubail, Kesteloot 
et al. 2010) 
- Increased blood vessels in vivo in a CAM model in ADAMTS2 knockout mice 
(Dubail, Kesteloot et al. 2010) 
- Suppressed tumor angiogenesis in ADAMTS2 overexpressing tumors (Dubail, 





(Rao, Ke et al. 2013) 
Yes (Anti-
angiogenic) 
(Hsu, Staton et 
al. 2012; Rao, 
Ke et al. 2013) 
Anti-angiogenic 
- Anti-angiogenic peptide from ADAMTS4 TSR suppresses EC proliferation and 
VEGF-induced HUVEC migration (Hsu, Staton et al. 2012) 
- Truncated ADAMTS4 fragment inhibits HuDMEC differentiation and migration 
in a scratch wound healing assay (Hsu, Staton et al. 2012) 
- ADAMTS4 C-terminal ancillary regions inhibit tumor angiogenesis  
 
Pro-angiogenic 
- Full-length ADAMTS4 promotes tumor angiogenesis  
 
ADAMTS5 No (Anti-angiogenic) 
(Kumar, Sharghi-





et al. 2012) 
Anti-angiogenic 










Role in Angiogenesis 
ADAMTS8 Not known Yes (Anti-
angiogenic) 
(Vázquez, 
Hastings et al. 
1999) 
Anti-angiogenic 
- Inhibits EC proliferation in a cell-specific reversible manner in vitro (Vázquez, 
Hastings et al. 1999) 
- Disrupts growth factor induced angiogenesis in vivo in a CAM model and 
matriplug assay (Vázquez, Hastings et al. 1999) 
 
ADAMTS9 Yes (Anti-angiogenic) 
(Koo, Coe et al. 2010) 
No (Anti-
angiogenic) 
(Koo, Coe et al. 
2010) 
Anti-angiogenic 
- Knockdown of ADAMTS9 in cultured ECs suppresses in vitro capillary network 
formation and migration (Koo, Coe et al. 2010) 
- Increased corneal neovascularization and tumor vascularization in Adamts9+/- 
mice compared to the wild type mice (Koo, Coe et al. 2010) 
- Suppresses oesophageal and nasopharyngeal carcinoma angiogenesis (Lo, Lung et 
al. 2010) 
 
ADAMTS12 No (Anti-angiogenic) 
(El Hour, Moncada-




Obaya et al. 
2007) 
Anti-angiogenic 
- Inhibits capillary network formation by BAE-1 cells in 3D collagen gels 
(Llamazares, Obaya et al. 2007) 
- Adamts12-/- mice showed increased sprout density in both ex vivo and in vivo 












Role in Angiogenesis 
ADAMTS13 Not known Yes (Anti-
angiogenic) 
(Lee, Rodansky 
et al. 2012) 
Anti-angiogenic 
- ADAMTS13 inhibits VEGF-mediated angiogenesis - mediated HUVEC 




- Full-length ADAMTS13 promoted HUVEC tube formation, induces EC 
proliferation and migration in vitro (Lee, Rodansky et al. 2012) 
 
ADAMTS15 Not known Not known Not known 
 








ADAMTS family members that have been implicated in cancer 
include ADAMTS1, 2, 4, 5, 8, 9, 12, 13, 15 and 18. Many of these have been 
shown to be also involved in angiogenesis. However, not all ADAMTS 
members regulate cancer through angiogenesis. Direct impact on tumor cells 
without the involvement of angiogenesis is also an important mechanism for 
ADAMTS members to regulate cancer. Recent reviews have extensively 
documented the role of ADAMTSs in cancer (Rocks, Paulissen et al. 2008; 
Wagstaff, Kelwick et al. 2011; Kumar, Rao et al. 2012). 
 
Fig 10.1 - ADAMTS in angiogenesis and cancer: current status - Many 
ADAMTS members have been shown to regulate angiogenesis and/or cancer. 
Most of ADAMTS family members have been shown to inhibit angiogenesis 
(ADAMTS1, 2, 5, 8, 9, 12 and 18), while some (ADAMTS4, 13) have been 
shown to promote. ADAMTS also regulate cancer via both angiogenesis-
dependent as well as independent mechanisms. Some are known to promote 
tumor progression (ADAMTS1, 4, 5), while others act as tumor suppressors 
(ADAMTS2, 8, 9, 12, 13, 15, and 18). (Adapted from Kumar et al, Cancers., 







10.6 Future perspectives 
 Although this work demonstrated a convincing role for ADAMTS4 in 
cancer and angiogenesis, with the full-length protein promoting tumor growth 
in several cancer models, and the C-terminal ancillary region fragments 
inhibiting tumor growth and angiogenesis, several questions remain to be 
answered. 
10.6.1 How would a tumor behave in Adamts4-/- knockout mice? 
 Although, overexpression of ADAMTS4 in tumor cells revealed its 
pro-tumorigenic role in mouse melanoma, the contribution of endogenous host 
stromal cell derived ADAMTS4 to tumor progression is not known. 
 In order to clarify this, Adamts4-/- knockout mice will be employed in 
tumorigenesis assays. It has been shown previously that Adamts4 knockout 
mice are phenotypically normal (Glasson, Askew et al. 2004; Glasson, Askew 
et al. 2005; Stanton, Rogerson et al. 2005). Thus it is possible that 
ADAMTS4’s effects on tumor growth are only apparent under pathological 
conditions. Our lab has obtained the Adamts4-/- knockout mice from Dr 
Satoshi Hirohata (Okayama University, Japan) of the strain B6.129P2-
Adamts4tm1Dgen/J. These mice have been backcrossed at least five generations 
with C57Bl/6 mice. 
 Mouse tumorigenesis assays will be performed to determine whether 
enhanced expression of ADAMTS4 in tumor cells is solely responsible for the 
tumor promoting effect by comparing the effect on tumor growth in an 
ADAMTS4 negative microenvironment. In addition, investigation of whether 
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endogenous stromal levels of ADAMTS4 could directly affect tumor growth 
by comparing the extent of B16 tumorigenesis between ADAMTS4 wildtype 
and knockout mice will also be undertaken. 
10.6.2 Identification of ADAMTS4 substrates in tumor 
microenvironment 
 Our results showed that ADAMTS4 effects on tumor growth were 
enzyme-dependent. Thus it is likely that ADAMTS4 facilitates in tumor 
progression and metastasis via cleavage of ECM proteins in the tumor 
microenvironment. 
 In order to determine the possible ECM substrates that could 
potentially be involved in ADAMTS4 effects on tumor progression, 
immunohistochemical and Western blot studies will be undertaken to probe 
for specific ECM proteins in ADAMTS4 overexpressing tumor stroma. 
Neoepitope specific antibodies are available for some known ECM proteins 
such as versican and brevican which have been reported to be abundant in 
tumor stroma. These will be employed to check for specific cleavage by 
ADAMTS4 and correlated to with the observed tumor growth response. 
 
10.6.3 Characterization of how ADAMTS4 influences angiogenesis 
signaling pathway proteins 
 ADAMTS4 was shown to promote tumor angiogenesis in vivo, via 
differentially affecting several angiogenesis signaling pathway proteins. 
Although increased protein expression of pro-angiogenic molecules or 
suppression of anti-angiogenic molecules was noted, it is not yet clear how 
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ADAMTS4 influences these molecules, whether it is via sheddase activity, or 
control of expression at the transcriptional or translational level. 
 In order to elucidate the mechanism through which ADAMTS4 
affects the proteins of angiogenesis signaling pathways, in vitro studies will 
be undertaken to analyse for changes in expression at mRNA or protein 
levels of these proteins, upon ADAMTS4 overexpression in tumor cells. Any 
potential sheddase activity will be analysed by cotransfecting ADAMTS4 
with pro-angiogenic molecules and probing for the specific cleavage 
fragments generated. 
10.6.4 Identification of ADAMTS4 receptors on ECs 
 ADAMTS4 effects on tumor growth were attributed mainly to its 
effects on tumor angiogenesis, especially the TSR domain was shown to be 
important for this effect. Heparan sulphate proteoglycans on the surface of 
ECs act as coreceptors for several pro-angiogenic growth factors (Iozzo and 
San Antonio 2001). ADAMTS4 has been known to bind to GAG chains in 
the ECM through TSR domain and C-terminal spacers (Tortorella, Pratta et 
al. 2000; Flannery, Zeng et al. 2002) . In addition, integrins have also been 
shown to be low affinity receptors for several ECM proteins (Akimov, 
Krylov et al. 2000; Weigel-Kelley, Yoder et al. 2003). Thus it is possible that 
ADAMTS4 could act through HSPGs or via integrins in modulating tumor 
angiogenesis. 
 In order to determine the ADAMTS4 receptors in ECs, the 
ADAMTS4 TSR domain will be incubated with ECs membrane extract and 
proteins interacting with His-tagged ADAMTS4 TSR can be isolated through 
a pull-down assay. Proteins that bind to TSR will then be subjected to SDS-
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PAGE and protein bands will be analyzed and identified by Mass 
Spectrometry. Identified ADAMTS4 receptor candidates can be validated 
using co-immunoprecipitation or ELISA experiments. After receptor 
identification, antibody blocking or siRNA approaches will be used to 
determine the functional significance of these receptors in ADAMTS4-
mediated angiogenic effects. 
10.6.5 Elucidation of the role of ADAMTS4 fragments in metastasis 
 ADAMTS4 full-length promoted lung metastasis while the active-site 
mutant inhibited metastasis (Fig 9.3 and 9.6). In the case of ADAMTS1, full-
length protein promoted lung metastasis, while the fragments displayed anti-
metastatic activity (Liu, Xu et al. 2006). Thus it would be interesting to 
determine the effects of ADAMTS4 fragments on metastasis. 
 In order to determine the effects of ADAMTS4 on lung metastasis of 
B16 melanoma cells, recombinant constructs representing the ADAMTS4 C-
terminal fragments such as N-p53, D-S and T-S will be tested in experimental 
tail vein metastasis assays. In addition, the exact mechanisms through which 
ADAMTS4 exerts its metastatic effects is not known yet and will be explored. 
 
10.6.6. Would ADAMTS4 be a useful protein for developing human 
cancer drugs? 
The ADAMTS4 protein lacking the enzymatic activity, the C-terminal 
ancillary regions of the protein and especially the TSR domain were found to 
be anti-angiogenic and anti-tumorigenic in this study. This indicates that 
ADAMTS4 could have potential in being developed as a cancer drug. It is 
often noted that large protein drugs have significant problems with regards to 
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targeted delivery. This is primarily due to the requirement to maintain a 
precise higher order structure that could impact biological activity of the 
protein in vivo (Lu, Yang et al. 2006).  
In the case of ADAMTS4 therefore, peptide derivatives that could 
efficiently block angiogenesis are a better option for drug development. 
Previously, an anti-angiogenic peptide from ADAMTS4 TSR, called 
adamatostatin-4 has been tested in in vitro assays (Karagiannis and Popel 
2007). Peptides like these could be tested for efficacy in inhibiting 
angiogenesis and sourced for drug development. 
Another possibility is utilising gene therapy to deliver ADAMTS4 C-
terminal fragments that have been shown to negatively influence cancer. 
Several viral and non-viral vectors are available for targeted delivery. Several 
of these methods have been successfully employed in the case of endogenous 
angiogenesis inhibitors such as endostatin, angiostatin etc. for targeted 
suppression of cancers (Tandle, Blazer et al. 2004). Thus, direct injection of 
naked ADAMTS4 fragment DNA or DNA complexed with liposomes could 
be exploited for direct delivery into tumors. In addition, viral vector delivery 
can also be explored although safety concerns exist. 
Several studies have shown that combination therapy with other anti-
angiogenic agents have been more successful in the past. Combining agents 
that target different pathways along with chemotherapy and radiation have 
yielded improved anti-tumor effects and long-term metastatic suppression 
(Scappaticci 2002; Abdollahi, Lipson et al. 2003). Thus, combining 
ADAMTS4 delivery either as peptides or fragments along with other anti-
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